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ABSTRACT 
 
 Iodide transport is necessary for the synthesis of thyroid hormones following 
accumulation in the follicular lumen out of thyroid cells, via channels unknown with 
the exception of pendrin.   
 According to our hypothesis, TMEM16A could be the main molecular identity of the 
channel mediating iodide efflux in the thyroid gland. TMEM16A is the prior 
candidate for calcium-activated chloride conductance (CaCC). TMEM16A belongs to 
the TMEM16/anoctamin family comprising ten members (TMEM16A-K). Higher 
affinity of TMEM16A for iodide and predicted expression in the thyroid gland 
suggest its mediation of iodide efflux. 
 The aim of this project was to identify the role of TMEM16A in iodide transport in 
the thyroid gland, by characterizing its molecular expression and functional 
properties.  
 We demonstrated that TMEM16F, H, K transcripts are expressed in FRTL-5 thyroid 
cells, as well as TMEM16A, which is TSH-independent. Tumor tissue from human 
thyroid maintains TMEM16A expression.  
 Functional in vivo experiments in FRTL-5, stably expressing YFP-H148Q/I152L 
fluorescent protein as a biosensor, showed that iodide efflux is stimulated by agonists 
of purinergic receptors with an order of potency of ATP>UTP>ADP (compatible with 
an involvement of P2Y purinergic receptors), and by agonists of adrenergic receptors 
(epinephrine, norepinephrine and phenylephrine). Iodide efflux was blocked by α-
receptor antagonists prazosin and phentolamine, consistent with a role of α1 
adrenergic receptors. Iodide efflux was specifically dependent on calcium mobilized 
from intracellular compartments and induced by the calcium ionophore ionomycin. 
CaCC blockers suppressed ionomycin-/ATP-/epinephrine-stimulated iodide efflux. 
   Heterologous expression of TMEM16A in CHO K1 cells induced calcium-activated 
iodide fluxes. 
 All these results support the hypothesis of the involvement of TMEM16A in calcium-
dependent iodide efflux induced by receptor agonists in thyroid cells. TMEM16A 
may represent a new pharmacological target for thyroid cancer therapy, since its 
blockade may enhance the retention of radioiodide by tumour cells enhancing the 
efficacy of radioablative therapy. 
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CHAPTER   1 
 
INTRODUCTION 
 
 
1.1  THYROID GLAND 
 
 
1.1.1 STRUCTURAL AND MORPHOLOGICAL CHARACTERISTICS 
 
 Thyroid gland is an endocrine gland specialized in synthesis, storage and secretion of 
hormones essential for regulation of metabolism and for thermogenesis. 
 It is localized at under- hyoid region of neck, on the front surface of trachea. Thyroid 
gland contacts laterally sternocleidomastoid muscle and carotid arteries, rear-recurrent 
laryngeal nerve, trachea and esophagus. Above thyroid gland there is larynx. 
 Thyroid gland consists of two side lobes joined in the midline by a thin portion of 
tissue, isthmus. Like all endocrine glands, thyroid is richly vascularised, in particular 
branches of internal carotid artery: two superior thyroid arteries. Each lobe has a 
length of about 4 cm and a width of about 1-2 cm. In adults, normal thyroid gland 
weighs between 15 and 25 grams. Its size, however, may be different according to 
individual, environmental, nutritional factors. 
 Secretory epithelial cells produce thyroid peptide hormones T3 (tri-iodothyronine) 
and T4 (tetra-iodothyronine or thyroxin), calcitonin. These cells are classified into two 
types, follicular and parafollicular. Follicular cells (thyrocytes) are organized as a 
single layer of cubic hollow structures called follicles (50-500 uM in diameter), 
representing unity of structure and function of thyroid gland (Fig.1.1). Thyroid gland 
is the only body follicular gland. Thyrocytes synthesize, accumulate and secrete 
thyroid hormones. In fact, it is enclosed in follicular lumen thyroid colloid, a protein 
matrix which acts as a deposit of T3 and T4 thyroid hormones, secreted by thyrocytes 
in response to hormonal stimuli, as the glycoprotein thyroglobulin (TG).  
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Fig. 1.1 Anatomy and follicular structure of human thyroid gland. (pyroenergen.com) 
 
Thyroid gland is the only body gland to accumulate hormones outside the cells that 
synthesize them. Due to their active secretion of protein molecules, thyrocytes are 
characterized by a large number of mitochondria and a rough endoplasmic reticulum 
of considerable size. 
 Thyrocytes parafollicular cells ("clear" or "C") are among follicular thyrocytes and in 
interfollicular interstitium. Parafollicular cells are not organized into defined 
structures such as follicles, but scattered in small groups. These cells secrete 
calcitonin hormone, which helps body metabolism of calcium, in antagonism with 
parathyroid hormone secreted by dark chief cells of parathyroid glands. The latter are 
in contact with rear side lobes of thyroid gland. Calcitonin inhibits the release of 
minerals from bones causing hypocalcaemia and ipophosphoremia, whereas PTH 
promotes their release causing hypercalcaemia and hyperphosphatemia. 
 Hormones T3 and T4 produce rather wide-ranging effects by interacting with several 
districts of organism: they increase basal metabolic rate, oxygen consumption and 
thermogenesis, stimulate metabolism of carbohydrates and lipids, accelerate 
metabolism of cholesterol, decrease liver glycogen levels. 
 Hormones T3 and T4 also play a role in growth and development of organism not 
only in general, since they stimulate protein synthesis, proliferation and cell 
differentiation, but also, particularly, in  cardiovascular parameters such as frequency, 
heartbeat, myocardial contractility and vasodilatation. 
 Thyroid hormones triiodothyronine (T3) and thyroxin (T4) are the only endogenous 
molecules to contain iodine element, on which thyroid gland depends for its proper 
function. In fact,  thyroxin contains two molecules of tyrosine and four iodine atoms 
while  triiodothyronine two molecules of tyrosine and three atoms of iodine.Through 
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bloodstream, dietary iodine is transported into thyroid follicular cells as iodide anion. 
In this manner thyroid hormones can be synthesized. 
 
 
 
1.1.2 INNERVATION  
 
 Innervation of thyroid gland is supplied by cervical sympathetic and vagus nerve, 
mainly through superior inferior laryngeal nerve (recurrent), responsible for 
phonation. 
 Superior laryngeal nerves have an internal branch, which is distributed in supraglottic 
laryngeal mucosa and in the two faces of epiglottis, and an external branch, which 
innervates cricothyroidal muscle and is distributed in subglottic and laryngeal mucosa 
up to laryngeal ventricle of Morgagni mucosa. Lesion of external branch of superior 
laryngeal nerve causes paralysis of cricothyroidal muscle and consequently loss of 
ipsilateral true vocal cord tension, which leads to resulting dysphonia (voice 
impairment). 
 Laryngeal nerves below, known as "recurrent" (because of their course that embraces 
arch of aorta to the left and the right subclavian artery), are the main nerves, with 
phonatory function, because innervate all the muscles endolaryngeal that determine 
vocal cords motility. 
 Experimental evidences showed thyroid innervations and signalling pathways for 
thyroid hormone synthesis in details.  
 Cholinergic nerve fibers take contacts with follicle cells and cholinergic mediators 
enhance cGMP accumulation in human normal thyroid gland. A muscarinic receptor 
antagonist, atropine, blocked this activity, effect that suggested involvement of 
parasympathetic nervous system  in regulation of human thyroid function (Van Sande 
et al., 1980) 
 In a cell model, FRTL-5 thyroid cells, a muscarinic receptor was found to inhibit 
phospholipase C activity. Carbachol, a cholinergic agonist, decreases the steady-state 
iodide content, an effect correlated with iodination of thyroglobulin and with thyroid 
hormone synthesis. Carbachol potentiated thyrotropin-induced stimulation of adenylyl 
cyclase enzyme, without alteration of cAMP  basal levels (Di Girolamo et al., 1991). 
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 Histochemistry and cytospectrofluorometry studies in calf thyroid cells revealed that 
sympathetic nerve fibres, located around vessels as a network and close to thyroid 
follicles as single fibres, contained norepinephrine. 
 Mast cells, located around follicles and vessels, contain histamine and dopamine and 
the latter was found also in parafollicular cells. Numerous acetylcholine-containing 
nerve fibres were found around vessels and between follicles. 
 Isolated thyroid cells, exposed to several amines, showed a increase in iodine uptake 
and organification stimulated by norepinephrine and dopamine. Also epinephrine, 
isoproterenol, and S-hydroxytryptamine produced responses with the same entity. 
Phentolamine, an  adrenergic blocking agent, blocked iodine organification. Thyroid 
hormone synthesis was suggested to be regulated with contribution of norepinephrine 
released from intrathyroidal sympathetic terminals and of dopamine released from 
intrathyroidal mast cells (Melander et al.,  1973)  
 Comparison between fetuses, young (20-45), and elderly (greater than 60) euthyroid 
people with thyroid cancer or hyperparathyroidism, revealed a reduction in the 
number of interfollicular adrenergic nerve terminals and lower norepinephrine 
concentration with increasing age, suggesting functional role of catecholamines in 
thyroid gland (Melander et al., 1978). 
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1.1.3 CATECHOLAMINES 
 
 Structure of catecholamines consists of a catechol (1-2 dihydroxy-benzene), and an 
amino group (fig. 1.2). Central nervous system, sympathetic nerve endings and 
cromaffin cells of adrenal medulla synthesize adrenaline/epinephrine, 
noradrenaline/norepinephrine and dopamine from tyrosine aminoacid.  
 Many cells possess adrenergic receptors, and binding of an agonist will generally 
cause a sympathetic (or sympathomimetic) response (e.g. fight-or-flight response).  
For instance, heart rate will increase and pupils will dilate, energy will be mobilized, 
and blood flow diverted from other non-essential organs to skeletal muscle. 
  Adrenergic receptors are classified into 2 types,  and , divided into 5 subtypes: 
 α1 and α2, with different affinity to antagonists;  
 β1, with equal affinity for epinephrine and norepinephrine; 
 β2, with greater affinity for epinephrine than norepinephrine;  
 β3.  
 Dopaminergic receptors are classified into 2  types, D1 and D2, divided into 5 
subtypes: 
 D1 and D5; 
 D2, D3, D4. 
Adrenergic α1 receptors are coupled to Gq proteins; when activated, hydrolysis of 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) leads to formation of 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG). IP3 induces Ca
2+
 release from 
intracellular stores increase Ca
2+
 influx across plasma membrane. Ca
2+-
dependent 
protein kinase activated may mediate free Ca
2+
 effects. DAG actives protein kinase C. 
 Adrenergic α2 receptors are coupled to Gi proteins, when activated lead to inhibition 
of adenylate cyclase with  consequent intracellular cAMP decrease. 
 β receptor activation induces adenylate cyclase activation with intracellular cAMP 
increase. Final effect is activation of glycogen phosphorylase.  
 Adrenergic receptors can undergo slower or faster desensitization after exposure to 
catecholamines or sympathetic mimetics drugs. Receptors can be phosphorylated by 
protein kinase GRK and increase their affinity for β-arrestins, once bound to them are 
no longer able to activate G protein. 
Isoproterenol is the main  β-adrenergic agonist. 
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Among α-adrenergic antagonists there are: 
 phentolamine, competitive antagonists against α1 α2 adrenergic receptors and 
inhibitor of serotonin-dependent responses; phentolamine can be agonist on 
muscarinic receptors and histamine H1 and H2 receptors; 
 prazosin, highly selective for α1-adrenergic receptors, 1000 fold more than α2-
adrenergic receptors. 
The most important β-antagonist is propranolol, non-selective antagonist against all 
subtypes of β receptors. 
 
 
 
 
 
Fig. 1.2 Structure of catecholamines scientific-training.it 
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1.1.4  EFFECT OF CATECHOLAMINES ON THYROID GLAND 
 
 Catecholaminergic system functional role in thyroid gland was examined in several 
studies.  
 Thyrotropin increases number of adrenergic 1- receptors by inducing their 
biosynthesis, a cAMP-mediated effect (Corda et al, 1985). Adrenergic 1- receptors 
on FRTL-5 thyroid cells have been functionally linked to iodide efflux into follicular 
lumen and to thyroglobulin iodination and, subsequently, thyroid hormone synthesis; 
adrenergic 1-receptor signal was mediated by Ca
2+
 rather than by cAMP, with 
involvement of arachidonic acid intermediates. Specifically, this studies employed 
norepinephrine. (Corda et al, 1985). According to other studies, biosynthesis of 
adrenergic α1- receptors in FRTL-5 cells depends on TSH action, which induces a 
signaling mechanism cAMP dependent, since binding of radioactive prazosin, -
adrenergic agonist, was dependent on TSH concentration in culture medium  (Rope 
and Khon, 1985).  
 
 
1. 2 IODIDE TRANSPORT 
 
 According to studies carried out so far, molecular responsible for transport from 
basolateral to apical membrane of thyrocytes, within the follicular lumen, are mainly 
two proteins:  Sodium Iodide symporter (NIS) (Rodriguez, 2002) and pendrin 
(Royaux, 2000) (fig. 1.3). 
 NIS transporter is able to accumulate iodide within thyrocytes up to 30-40 fold 
compared to plasma compartment (nM), taking it at concentrations of the order of 
mM (Carrasco, 1993). Transport is active: iodide transport against electrochemical 
gradient is allowed by transport of sodium according to gradient concentration 
maintained from Na
+
/ K
+
 ATPase pump with consume of ATP. In this manner, iodide 
can be transported from interstitial fluid to thyrocyte cytoplasm. 
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Fig. 1.3 NIS (Sodium Iodide Symporter, Dohán et al., 2003) 
 
 
 Iodide is then transported into follicular lumen through apical membrane by means of 
pendrin, an anion exchanger which carries  iodide and chloride into thyroid gland, in a 
passive manner, according to concentration gradient (Soleimani, 2001, Scott, 2000). 
 Once in follicular lumen, iodide undergoes a oxidation process with tyrosine residues 
to form MIT (monoiodiotyrosine) and DIT (diiodiotyrosine) ("organification", since  
iodine is incorporated into an organic compound, the iodinated thyroglobulin) . At the 
interface between apical membrane and follicular lumen there are the enzymes that 
allow organification process of iodide to be accumulated in colloid, with more details 
a NADPH tireossidasi (ThOX), which generates peroxide (H2O2), substrate of  thyroid 
peroxidase (TPO). Thyroglobulin, a protein found in most of the colloid, provides 
tyrosine residues that undergo iodination to form thyroid hormones, it acts as 
"scaffolding" for their synthesis. Thyroglobulin also allows their accumulation after 
synthesis. 
 Thyroglobulin monoiodiotyrosine and diiodiotyrosine, formed by oxidation of iodide, 
together constitute triiodiotyrosine (T3) and tetraiodiotyrosine or thyroxin (T4) via an 
ether bond (Cahman, 1977, Virion, 1981). Thyroglobulin may contain from four to 
eight molecules of hormones. 
 Thyroid hormones are released as a result of external stimuli, in particular, TSH 
(Thyroid-Stimulating Hormone), to activate processes described below. 
Thyroglobulin related to T3 and T4 hormones is internalized by endocytosis, 
hydrolyzed in fagolisosomes, so hormones can be released. Thyroglobulin undergoes 
a process of recycling being re-transported into colloid or degraded, hormones are 
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secreted into bloodstream with a mechanism still not well defined or metabolised by 
microsomal iodotyrosine dehalogenase, to recover as much as possible iodine not 
secreted. 
 
 Iodide metabolism, synthesis and release of thyroid hormones are possible thanks to 
follicular organization and thyroid follicular cell polarization in basolateral and apical 
area, each with its own proteins properly placed and not free to move laterally, also 
thanks to presence of tight junctions between cells; the latter, moreover, allow the 
maintenance of iodide concentration gradient between the inside and the outside of 
follicle and retention of luminal content which otherwise would diffuse. 
 
 TSH is the main regulator of thyroid hormones T3 and T4. Control occurs via 
hypothalamic-pituitary-thyroid axes. TRH hormone (thyrotropin releasing hormone) 
is secreted by hypothalamus, reaches anterior pituitary where it stimulates TSH 
release (thyroid stimulating hormone or thyrotropin) from thyrotropic cells.   TSH, 
thus synthesized and poured into bloodstream, acts on a specific membrane receptor 
(the TSHR, TSH receptor, coupled to a stimulatory G protein), which undergoes a 
conformational change activates stimulatory G protein resulting in the increase AMP 
levels of 3'-5 'cyclic (cAMP) intracellular, which leads to activation of a cAMP-
dependent protein kinase (PKA). Finally process leads to activation of thyrocyte, 
which internalises cells by phagocytosis of colloid. Phagosomes, once formed, fuse 
with lysosomes, which split the bond between thyroglobulin and thyroid hormones, 
then released into  bloodstream via basolateral membrane . 
 T4 is secreted about 20% more than in T3 in the bloodstream. Hormones released 
from thyroglobulin but not secreted are deiodinated from iodothyrosine dehalogenase 
to allow all of iodide to be reabsorbed and recycled. 
 TSH, through activation of these processes, stimulates  thyroid gland to synthesize 
thyroid hormones and increase its volume. 
 Elevated levels of T4 and T3 inhibit the secretion of TRH and TSH, with a negative 
feedback mechanism. Drugs that inhibit T4 and T3 synthesis increase  TSH circulating 
levels, which stimulates  thyroid gland hyperplasia (goiter). 
 Thyroid hormone release can also be stimulated indirectly through blood vessels by 
nerve fibers of  cervical sympathetic ganglia. 
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 As with all components contained in the plasma, thyroid hormone molecules free and 
reversibly bounds with plasma transport proteins, thyroxine binding globulin (or 
TBG) and transthyretin. 
 The main form of thyroid hormones is T3. In peripheral districts most of  free T4, in 
fact, is deiodinated and converted into T3, which binds on  nuclear receptors of 
thyroid hormones in the target cells, with an affinity ten fold higher compared to T4.   
A hormone-receptor complex is created, thus, which translocates to nucleus and 
regulates transcription of target genes by binding to specific thyroid hormone 
response elements (TRE), contained in them. The effects exerted are manifold, in 
general, body metabolism speed increase, catabolism of carbohydrates and lipids and 
protein synthesis stimulation. 
 
 
 Thyroid gland is among the most responsive organs of the body: in response to 
specific stimuli that increase cell metabolism, such as occurs during puberty or 
pregnancy, there is increased physiologically volume and activity of the gland, 
transitional epithelial hyperplasia (follicular cells become tall and columnar and 
thyroglobulin is reabsorbed). Stimulus cessation produces the reverse process: 
glandular epithelium is flattened, cuboidal, and resumes colloid accumulation in the 
follicular lumen. 
 
 According to studies carried out so far, molecular mediators for iodide transport from 
basolateral to apical membrane of thyrocytes within follicular lumen, are mainly two 
proteins: Sodium Iodide Symporter (NIS) (Rodriguez, 2002) and pendrin (Royaux, 
2000) . 
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 Synthesis of thyroid hormones requires iodide uptake by thyroid follicular cells 
across basolateral membrane and, after passing through the cell, ion efflux into 
follicular lumen through apical membrane. The mechanisms that mediate iodide 
transport through thyroid cells basolateral membrane are well known (Dohan et al., 
2003). Less it is known about the mechanism iodide efflux across apical membrane, 
efflux which is dependent on continuous iodide uptake, to maintain the high ion 
intracellular concentration. Carriers certainly involved in iodide transport in the 
thyroid gland are NIS and pendrin. 
 
 
1.2.1 NIS 
 
 NIS (Na
+
/ I
-
 symporter) is a membrane intrinsic glycoprotein that actively 
cotransports two ions and a sodium iodide ion. NIS belongs to solute transporters 
SLC5A family (Bizhanova and Kopp, 2009), and represents the member number 5, 
and is encoded by SLC5A5 gene (solute carrier family 5), located on chromosome 19 
(19p12-13.2) and contains 15 exons and 14 introns (Smanik et al., 1997). All 
members of this family of proteins exploit the electrochemical gradient of sodium as a 
driving force for anion transport across plasma membrane (Reizer et al., 1994). NIS 
has a high affinity for iodide and is able to also carry other ions (Eskandari et al., 
1997). 
 
1.2.1.1  Molecular characterization 
 
 Molecular characterization of NIS protein started in 1996, when cDNA encoding rat 
NIS was isolated by cloning of expression in oocytes of Xenopus laevis (Dai et al., 
1996). Subsequently, it was also cloned human cDNA by RT-PCR (Reverse 
Transcriptase - Polymerase Chain Reaction), taking advantage of homology with rat 
NIS (Smanik et al., 1996). Human protein contains 643 amino acid residues, while rat 
618; amino acid sequence identity between the two proteins is 84% (Smanik et al., 
1997; Dai et al., 1996). 
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 According to currently accepted structural model, NIS contains thirteen 
transmembrane domains and has the amino-terminal end located outside the cell, 
while the carboxy-terminal end is located in the cytosol (Dohan et al., 2003) .Mature 
protein weighs about 87 kDa and has three asparagine residues that are glycosylation 
sites (Dohan et al., 2003). Glycosylation does not seem to be required for stability, 
activity or correct location of  NIS on plasma membrane (Levy et al., 1998). 
 
 
 
 
 TSH is the main regulator of thyrocyte proliferation and differentiation and functions, 
including  iodide uptake (Vassart and Dumont, 1992). Then, TSH stimulates iodide 
accumulation in thyroid gland, regulating positively NIS expression, both at protein 
level and at mRNA level, via activation of cyclic AMP pathway (cAMP) (Weiss et al., 
1984a). This has been demonstrated by in vitro studies on a highly differentiated cell 
line of rat thyroid gland (FRTL-5) (Weiss et al., 1984a) and on primary cultures of 
human thyroid gland (Saito et al., 1997), but also through studies on animals in vivo. 
In fact, hypophysectomised rats showed greatly reduced levels of protein expression 
of NIS and a single injection of TSH has led to recovery of normal expression levels 
(Levy et al., 1997).  Moreover, rats fed a diet low in iodine or treated with 6-propyl-2-
thiouracil, an agent capable of blocking iodide organification, have a high 
concentration of TSH, which correlates with an increase in NIS protein expression in 
thyroid gland (Bizhanova and Kopp, 2009).  FRTL-5 cells, grown in medium TSH-
free, have decreased intracellular concentration of cAMP and impaired ability to 
transport iodide; when  TSH is provided to cells again, increases expression of NIS 
mRNA and protein, and subsequently also iodide uptake (Weiss et al., 1984a). TSH 
not only regulates NIS transcription and biosynthesis but, through post-translational 
mechanisms, it also stimulates its activity and expression on thyrocyte basolateral 
membrane (Riedel et al, 2001). In FRTL-5 cells deprived of TSH,  NIS half-life  is 
reduced from five to three days and the protein translocates from plasma membrane to 
intracellular compartments (Riedel et al, 2001). Intracellular distribution regulation of 
NIS have been only partially elucidated. 
 Iodide itself regulates its accumulation in thyroid gland. In 1948, Wolff and Chaikoff 
reported that high doses of iodide (beyond a critical threshold) block process of 
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organification in thyroid gland of rats in vivo (Wolff and Chaikoff, 1948). This 
phenomenon is known as Wolff-Chaikoff’s acute effect and is a reversible process, 
since once organification resumes, serum iodide concentration decreases. In fact, this 
effect, rather than depending on plasma iodide concentration, depends on 
intracellular: it has been demonstrated, in fact, that the acute effect is deleted by 
inhibitors of NIS (Raben, 1949). Mechanisms underlying the effect of Wolff-Chaikoff 
are very complex and affecting regulation of several genes and proteins. In particular, 
high iodide concentrations influence NIS expression and activity, determining in vivo 
and in vitro a reduction mRNA and protein levels, and not through post-translational 
mechanisms (such as the increase in the turnover of the protein) (Eng et al., 1999; Eng 
et al., 2001). 
 Finally, NIS expression is deleted, at transcriptional level, from the follicular 
thyroglobulin (in fact, when this protein accumulates in follicular lumen, it is induced 
by  reduction of iodide uptake in vivo) (Koichi et al., 1999) .  
 
1.2.1.2   Inhibitors 
 
 Thiocyanate (SCN
-
) and perchlorate (ClO4
-
) are two major anions able to inhibit 
iodide accumulation in the thyroid gland, by competing with iodide for interaction 
with NIS (Carrasco, 1993; Wolff, 1964). Perchlorate is between 10 and 100 foldmore 
potent than thiocyanate (Dohan et al., 2003) and has been used in the treatment of 
hyperthyroidism (pathological condition caused by an excessive synthesis of thyroid 
hormones) for a long time, despite the severe side effects. Perchlorate is also used to 
detect defects in iodide organification (Baschieri et al., 1963). Some studies claim that 
perchlorate is simply a NIS inhibitor (Eskandari et al, 1997), but, in more recent 
publications, it was demonstrated that is actively transported by NIS and is, therefore, 
one of its substrate (Dohan et al., 2007). Sodium and perchlorate transport mediated 
by NIS is electroneutral (1 Na
+
: 1 ClO4
-
), while iodide transport is electrogenic (2 
Na
+
: 1 I
-
), then NIS is capable of carrying different substrates with different 
stoichiometry (Dohan et al., 2007). Perchlorate, a widely used pollutant, is transported 
by NIS in breast milk, with great risk to infant health (Dohan et al., 2007). 
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1.2.1.3 NIS gene mutations  
 
 Biallelic mutations in gene encoding NIS is responsible for a rare congenital defect in 
iodide transport (or ITD, Iodide Transport Defect), autosomal recessive and 
characterized by reduced or absent iodide uptake in the thyroid gland, hypothyroidism 
(i.e. clinical condition characterized by insufficient thyroid hormone synthesis), goiter 
and low ratio of iodide concentration in saliva and plasma (Dohan et al., 2003; Wolff, 
1983). Congenital hypothyroidism has deleterious and irreversible effects on 
developing babies and, if untreated, results in cretinism (hypothyroidism and 
associated disease characterized by altered development of skeletal and central 
nervous system, with severe mental retardation, low stature and coarse facial 
features). Absence or deficiency of functional NIS molecules reduces iodide uptake 
from thyrocytes and thyroid hormone synthesis, resulting in increased levels of 
circulating TSH and induction of morphological and biochemical processes that result 
in development of goiter. In most cases, heterozygous subjects are euthyroid and have 
normal size of the gland, and then a single healthy copy of gene encoding NIS is 
however sufficient to ensure a normal transport of iodide in thyroid follicular cells. So 
far, twelve NIS mutations were identified causing the ITD and some have been well 
characterized. 
 
 
 
 
 
 
 
 
 
 Thanks to NIS transporter, the thyroid gland is able to accumulate radioiodide, and 
this property is essential for diagnosis and treatment of thyroid disorders, such as 
neoplastic diseases, whose therapy is generally radioiodide administration, which, 
being a radioactive isotope, is toxic for the cells able to pick it up, such as tumor cells 
of thyroid origin. 
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1.2.2. APICAL IODIDE TRANSPORT:  PENDRIN 
 
1.2.2.1 Expression and function 
 
 Among the proteins expressed in apical membrane of thyrocytes, pendrin is one of 
most studied. It is involved in iodide efflux. The encoding gene is SLC26A4 (first 
called PDS Pendred Syndrome, a disease which is responsible of), a member of 
family of "multifunctional anion exchangers" SLC26A (Mount and Romero, 2004). It 
is located on chromosome 7 (7q31) and consists of 21 exons (Kopp et al., 2008). 
 Encoded protein consists of 780 amino acids, is 86 kDa, has 11 or 12 transmembrane 
domains and is highly hydrophobic. Both the amino-terminal segment and the 
carboxy-terminal are located within the cytosol (Kopp et al., 2008). 
 Initially it was believed to be a sulphate transporter, given its similarity with this 
family of transporters. It has been shown, however, that pendrin is a iodide-
independent sodium transporter (Scott et al., 1999). 
In patients with Pendred’s syndrome, have not been shown alterations of sulphate 
transport in thyroid tissue (Kraiem, 1999). 
 Pendrin has the function of transporting iodide, entered in cytoplasm of thyrocyte by 
means of NIS, towards follicular lumen. One of the evidence that confirm is its ability 
to carry it only if concentrated more than 1 mM, as observed in CHO cells and COS-7 
transfected with SLC26A4cDNA.                                      
 This feautre of pendrin is characteristic of a channel, rather than a transporter. 
Several studies have shown that pendrin was involved in iodide efflux. Most effective 
approach has been the use of a dual-chamber culture system: NIS and pendrin were 
made to express in polarized cells MDCK (Madin-Darby canine kidney epithelial), 
grown at the interface of a semi-permeable cell culture double chamber; pendrin could 
allow concentration of iodide from one compartment to another, while in cells 
expressing only NIS, with high intracellular iodide concentration, this phenomenon 
was not observed (Yoshida, 2004). 
 Cells expressing only pendrin showed, however, lower levels of intracellular iodide 
compared to not transfected cells, but higher levels in apical chamber. (Gillam et al., 
 
20 
 
2004). Results of this type are in favour of hypothesis that sees pendrin involved in 
iodide transport across the apical membrane of thyroid follicular cells. 
 It has been shown  property of pendrin to be exchanger chloride/ base in different cell 
types, for example chloride/ format, if it is expressed in Xenopus laevis oocytes (Scott 
DA., Karniski LP., 2000), or carrier of bicarbonate, hydroxide ion formed cells and 
human embryonic kidney (Soleimani, 2001). It should be noted, however, that 
expression of exogenous transporters and ionic channels can lead to  alteration of  
features: for example  chloride and iodide transport  seemed competitive in oocytes of 
Xenopus laevis and Sf9 (Scott et al., 1999) but was not confirmed in other studies. 
 Pendrin would be a transporter of chloride, bicarbonate and iodide (Yoshida et al., 
2002), in particular a exchanger chloride/ iodide, according to electrophysiological 
studies (Rillema, Melissa, 2003). Through pendrin, chloride and iodide would enter 
thyrocyte and emerge towards follicular lumen. Both the ions would activate 
transport. Chloride reabsorption in thyrocyte would play a role similar to that covered 
in cells of other tissues: maintaining the "tone" phone (volume) of water distribution 
and concentrations of elements in the follicle. 
 SLC26A4 transcript is present in the thyroid gland and in the kidney (Northern blot 
experiments) and in the fetal cochlea (experiments screening of a cDNA library). 
 Pendrin is present on apical membrane of epithelial cells of the thick ascending of 
Henle's loop and the distal convoluted tubule (immunohistochemical experiments) but 
200 fold less than in the thyroid gland(Lacroix et al., 2001), and with heterogeneous 
expression, both qualitatively and quantitatively. 
 Pendrin is also expressed in several other districts of nephron: was detected in 
cortical collecting ducts (Soleimani, 2001), especially in intercalated cells, which 
regulate excretion of acid/ base transporting bicarbonate. Knock-out mice for 
SLC26A4 have cortical collecting ducts lack the capability to secrete bicarbonate. An 
earlier study (Scott et al., 1999) had shown, among other things, that pendrin 
expressed in oocytes of Xenopus laevis, has transport properties similar to those of the 
exchanger chloride/ format, which absorbs 60% of the chloride filtrate and is localized 
to the apical membrane of proximal tubule cells. 
In the inner ear, pendrin has similar functions: the endolymph present therein has a 
low sodium concentration, but potassium and chloride high concentrations compared 
to plasma and perilymph, gradients guaranteed by transporters expressed by the 
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surrounding cells. Since gene mutationsof these transporters are associated with forms 
of deafness, it is clear their involvement in homeostasis of electrolyte composition of 
the inner ear as an essential factor for normal hearing function. 
 Pendrin is also expressed in placental syncytiotrophoblast and in lactating mammary 
gland (immunohistochemistry experiments) (Rillema et Hill, 2003). 
 
1.2.2.1   Regulation 
 
NIS and TPO (thyroid peroxidase) genes are more sensitive to stimulation by TSH 
induced with respect to SLC26A4 gene, however, even if levels of TSH and TG 
(thyroglobulin) show a regulatory function: pendrin expression would be induced by 
low levels of TG (Bidart et al., 2000), antagonist of stimulating effect of TSH on other 
genes: NIS and TSHR are less expressed with high levels of TG. Regulation is 
complex: according to an accepted model, TG inhibits NIS expression in a follicle 
with a lumen rich in TG accumulated, thereby reducing iodide uptake. Functional 
pendrin would carry all the iodide already concentrated within the cell into follicular 
lumen, despite low level of SLC26A4transcription in the situation described. In this 
follicle, TSH would promote reabsorption and degradation of follicular TG and 
secretion of T3/T4 in the blood stream. The concentration of TG would decrease as 
the reabsorption of follicle and degradation in lysosomes of newly synthesized TG 
was higher than TG. A lower concentration of follicular TG would then re-challenge 
NIS, TG, pendrin expression (Kohn, 2001). 
 Recent studies, however, showed that TG, however, causes an increase in 
transcriptional gene activity (Kopp et al., 2008), in contrast with what previously 
found and with its function as a suppressor of thyroid-specific expression. 
Against this hypothesis, however, TSH accelerates iodide apical efflux into follicular 
lumen (Weiss et al., 1984b; Nilsson et al., 1990), both in rat thyroid cells than in the 
pig. TSH stimulates the metabolic pathway of PKA (protein kinases A), leading to, in 
thyroid cells, regulation of pendrin, primarily regulated by pituitary hormone: 
phosphorylation of pendrin leads to increase in its membrane translocation, recruited 
from endosomal pool (Royaux et al., 2000). 
 TTF1 transcription factor specific for thyroid cells appears to be involved in positive 
regulation of the activity of pendrin gene promoter, while does not seem that iodide, 
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at least in vitro, can regulate gene expression of pendrin gene (Suzuki and Kohn, 
2006) . 
 
1.2.2.3. Pendred’s syndrome 
  
 Pendred’s syndrome is an autosomal recessive disorder caused by mutation biallelic 
(homozygous or heterozygous compound) of gene encoding pendrin. The main 
feature is the association between sensor-neural hearing loss (bilateral) and goiter, 
with highly variable phenotype. Name "pendrin" derivers from the researcher, 
Vaughan Pendred, who first described this syndrome between endemic goiter and 
deafness family in 1896, a century before the responsible gene was identified (Kopp, 
1999) . 
 Hypothyroidism is usually subclinical and present in 30-40% of cases, while most of 
the patients is euthyroid (with or without goiter), especially with adequate supply of 
iodine in diet. Among syndromic deafnesses is the most common form and represents 
10% of hereditary deafness (Fraser, 1965). Inner ear is presented morphologically 
altered, a feature probably also due to alteration of ionic transport associated with the 
syndrome, in particular water and solutes flow, which would lead to the expansion of 
cochlea and loss of its functional architecture. 
 Despite pendrin plays an important role in chloride transport in the nephron, 
Pendred’s syndrome does not involve renal alterations at clinical level, probably due 
to presence of multiple and compensating transport systems. 
 In thyroid tissue of patients, iodide is not completely organified, presumably to lower 
transport of iodide in thyroid colloid through the pendrin, thyroid hormone 
biosynthesis may therefore undergo various consequences (Royaux et al., 2001). Most 
of the numerous gene mutations are missense; known mutations are almost 150 (Kopp 
et al., 2008) predominantly missense mutations (a few are nonsense or inside the 
intron); protein undergoes some alteration in translocation to plasma membrane, 
probably due to an abnormal folding, finally remaining in endoplasmic reticulum 
(Taylor et al., 2002; Rotman-Pikielny et al., 2002). This retention (Endoplasmatic 
Reticulim Storage Disorders, ESRD) has been confirmed by functional studies of 
localization of mutated and wild type protein with tags (GFP, Green Fluorescent 
Protein) in HeLa cells (Taylor er al., 2002) . 
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 Despite the numerous studies that have confirmed its role in iodide transport, pendrin 
seems not to be essential for apical iodide transport of in the thyroid gland (efflux into 
follicular lumen): carriers of mutations in SLC26A4 gene do not always develop 
goiter (Kopp et al. , 2008), while studies in knock-out mice for pendrin showed no 
thyroid abnormalities (Everett et al., 2001). With greater probability, iodide flows 
through thyrocyte apical membrane according to concentration gradient, by means of 
different channels permeable anionic iodide, such as the pendrin (Wolff, 2005) . 
 
 
1.2.3. OTHER CHANNELS IN  THYROID GLAND 
 
 There are also other channels permeable to iodide anion expressed in thyrocytes, 
CFTR and ClC-5, their function is still controversial as far as it regards iodide 
transport in thyroid gland, maybe involvement in apical transport. 
 
1.2.3.1 CFTR 
 
 CFTR (Transmembrane Conductance Regulator in Cystic Fibrosis) is a chloride 
channel expressed in epithelial cells of various organs and tissues, in the apical 
membrane, e.g. in thyroid gland (Devuyst et al., 1997), respiratory tract, pancreas , 
intestine, testes, and sweat glands (only in the latter, transporter is responsible for 
chlorine absorption and its secretion, as occurs in other organs) (Verkman et Galietta, 
2009) . This channel allows and regulates the transepithelial transport of water and 
solutes and is mainly responsible for epithelial chloride (Cl
-
) permeability. CFTR can 
carry, in addition to chloride, also other anions, such as iodide and nitrate, for which, 
however, permeability is smaller. Gene encoding CFTR, identified in 1989 and 
located on chromosome 7, is mutated in cystic fibrosis, deadly genetic disease and 
more common in Caucasians. This is an inherited autosomal recessive and the main 
events are chronic and recurrent lung infections and pancreatic exocrine insufficiency. 
  CFTR is an integral membrane protein which consists of 1480 amino acid residues. 
Has twelve transmembrane segments, which are grouped to form two domains 
(MSD1 and MSD2, Membrane-Spanning Domain) (Figure) and constitute the channel 
pore. It also has two binding domains to nucleotides (NBD1 and NBD2, Nucleotide 
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Binding Domain) to which ATP molecules bind, separated by a large regulatory 
domain polar (R domain), which is phosphorylated at multiple sites (Figure). cAMP-
dependent phosphorylation results in channel activation (Figure), therefore, its activity 
is stimulated by agents that elevate intracellular levels of cAMP, such as 
phosphodiesterase inhibitors, enzyme that degrades cAMP, and activators of the 
enzyme adenylate cyclase (including forskolin) which catalyzes synthesis of cAMP 
from ATP.  CFTR is a member of ABC transporter superfamily (ATP-Binding 
Cassette): channel activation requires, in addition to phosphorylation, binding and 
hydrolysis of ATP (Figure), which determines conformational changes required for 
channel opening control and ion transport according to concentration gradient across 
the plasma membrane. 
 
 
CFTR expression in human thyroid gland has been demonstrated both for mRNA with 
RT-PCR, and for protein, with Western blot performed on membrane extracts 
(Devuyst et al., 1997). Immunohistochemical studies also showed that 64% of 
follicular thyroid tests are positive for CFTR, but that, for each follicle, only 16% of 
thyrocytes is labelled with anti-CFTR (Devuyst et al., 1997) . High heterogeneity of 
follicular cell population in CFTR expression seems to reflect the different state of 
cell metabolism: follicular cells expressing CFTR are those particularly active in the 
secretion or reabsorption of thyroglobulin (Devuyst et al., 1997) . 
 Role of CFTR in many secretory epithelia is still unclear. With regard to the thyroid 
gland, it is believed that CFTR may directly or indirectly influence iodide efflux into 
follicular epithelium because subclinical hypothyroidism was found in patients with 
cystic fibrosis (De Luca et al., 1982). As in many other secretory epithelia, fluid 
secretion into thyroid follicle lumen appears to be driven, at least in part, by the 
transport of Cl
-
 mediated by a cAMP-activated channel (Armstrong et al., 1992), 
whose molecular identity, however, has not yet been characterized. So if it were 
shown that this channel is CFTR, subclinical hypothyroidism in patients with cystic 
fibrosis could be explained by presence of slight alterations in secretion or absorption 
of colloid (Devuyst et al., 1992) . 
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1.2.3.2  CLC-5 
 
 ClC-5 is a chloride channel voltage-dependent, belonging to ClC protein family. It is 
expressed predominantly in the kidney and is responsible for electrogenic exchange of 
ions H
+
/ Cl
-
 (Scheel et al., 2005): chloride influence is coupled to outflow of protons 
with a stoichiometry of 2Cl
-
: 1H
+
. It is expressed in intracellular compartment and its 
function is to facilitate endosome acidification: in fact, it is necessary to maintain 
electroneutrality during electrogenic pumping of H
+
 ions into organelle lumen, 
mediated by vacuolar ATPase, with consumption of ATP (Günther et al., 1998) 
(Figure). Mutations in CLCN5 gene, encoding ClC-5, are responsible for Dent's 
disease, a rare X-linked disease, characterized by proteinuria and kidney stones, due 
to alteration of receptor-mediated endocytosis mechanisms in apical proximal tubule 
of the nephron ( Piwon et al., 2000). 
 One study showed that ClC-5 is expressed in mouse thyroid, where mRNA levels are 
about 40% of kidney levels and protein was immunolocalized on thyrocyte apical pole 
(Van den Hove et al., 2006). Using knockout mice ClC-5, channel loss was 
demonstrated not to inhibit apical endocytosis (as occurs in the kidney) of 
thyroglobulin labeled with 
125
I, but induces euthyroid goitre (with normal levels of 
TSH and T4 in the serum) to due to slowing iodide efflux apical and organification, 
associated to pendrin expression decrease, with mRNA and protein levels reduced by 
60% (Van den Hove et al., 2006) . In light of these data, three hypotheses have been 
advanced about ClC-5 role in the thyroid gland and interaction with pendrin: the 
channel may act as an alternative apical iodide channel, although it has greater affinity 
for chloride, could be involved in recycling of chloride in follicular lumen, to support 
the antiport mediated by I
-
/Cl
-
 pendrin, finally, could act indirectly, by modulating 
pendrin gene expression. However, regardless of exact action mechanism, these data 
suggest importance of ClC-5 in chlorine and iodine homeostasis in the thyroid gland. 
 
 
1.3 MALIGNANT TUMOURS OF THYROID GLAND 
 
 Thyroid cancers are rare tumours and represent, in fact, only about 1% of all 
malignancies. Thyroid cancers primarily affect adults and females and can be 
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hereditary or sporadic. Among the predisposing environmental factors, the main is 
represented by exposure to ionizing radiation. 
 There are four main subtypes of thyroid carcinoma: three well-differentiated, i.e. 
papillary, follicular and medullary, and a highly undifferentiated anaplastic . In most 
cases these are well-differentiated carcinomas,  most common is papillary carcinoma, 
which represents about 80% of all cases of thyroid cancer, followed by the follicular 
(about 15% of cases) and bone marrow ( about 5%). Anaplastic carcinoma is very 
rare. All carcinomas of thyroid follicular epithelium originate with the exception of 
medullary carcinoma, which is derived from the C cells. 
 Papillary carcinomas arise at any age, but especially between 20 and 40 years, and 
are more frequently associated with previous exposure to radiation. Microscopic 
examination of fine needle aspiration biopsies shows papillae, even branched, which 
possess a stalk fibrovascular covered by one or more layers of cuboidal epithelial 
cells. Prognosis is generally very good, with a 10-year survival rate of 95% (Dohan et 
al., 2003). 
 Follicular carcinomas appear later in life compared to papillary carcinomas (40-50 
years) and have a high prevalence in areas with endemic goiter by iodine deficiency. 
Follicular carcinomas are constituted by small follicles containing colloid, which 
resemble a normal thyroid. In some cases, follicular differentiation is less evident: 
there are sheets of cells without colloid. Prognosis depends on tumour extent at the 
time of diagnosis: the minimally invasive follicular carcinoma is characterized by a 
10-year survival greater than 90%. 
 A variant of papillary and follicular carcinomas is represented by oncocytic tumour, 
in which neoplastic cells are characterized by an aberrant mitochondrial mass increase 
of the cell, responsible for appearance of swollen cells ("oncocytic" term is derived 
from the Greek word onkoustai, which means swell) (Gasparre et al., 2010). 
 Anaplastic thyroid carcinoma is an undifferentiated tumour, with rapid growth and, 
unlike differentiated thyroid carcinoma is highly aggressive and lethal, with a 
mortality rate of almost 100%. It may arise de novo or derive from the 
dedifferentiation of a well-differentiated carcinoma, accumulation of genetic 
mutations, such as loss of p53. It strikes at an older age than other thyroid cancers 
(around 65 years) . 
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1.3.1  RADIOIODIDE IN CANCER THERAPY 
 
For more than sixty years, most of the cases of thyroid carcinoma is treated with total 
thyroidectomy and subsequent administration of therapeutic doses of radioactive 
iodine, in particular for elimination of possible micrometastases (which are also able 
to uptake it). Radioiodide is used not only in therapeutic phase, to destroy the 
neoplastic cells primitives and/ or metastatic, but also to perform scintigraphic 
imaging in diagnosis. This is a technique that has been very successful in significantly 
improving prognosis of patients with thyroid cancer because it is characterized by 
specific cytotoxicity to cells of the thyroid, with minimal side effects. 
 A key role both in physiology in the pathogenesis of thyroid cancer is done by the 
NIS, responsible for the accumulation of iodide, and therefore also of radioiodide in 
thyroid follicular cells. Efficacy of therapy with radioiodide is reduced when in 
tumour cells of thyroid gland NIS expression is suppressed and insufficient, for 
example because of cellular dedifferentiation increase or TSH receptor expression 
decrease (Spitzweg and Morris, 2002). “Hot” thyroid nodules are intensely stained 
with scintigraphy, because these nodules accumulate radioiodide and have increased 
expression of NIS, the “cold”, instead, express low levels of NIS and radioiodide 
uptaken slightly. Most of thyroid carcinomas, even those differentiated, behave as 
cold hypofunctional nodules  and many studies have shown that in these tumours 
levels of expression NIS, both as mRNA and as a protein, are much lower, in some 
cases absent, compared to normal thyroid tissue. In contrast to these data, some 
studies have found high levels of NIS expression in a high percentage (up to 70%) of 
tumour samples analyzed (Saito et al., 1998; Dohan et al., 2001): in these tumours 
NIS was localized both on plasma membrane (in a non-polarized) that in intracellular 
compartments, suggesting that malignant transformation may result in alteration of 
NIS correct positioning or retention mechanisms in plasma membrane. 
 Although most of thyroid tumours and their metastases respond effectively to the 
ablation, about 30% of patients with malignant thyroid tumours are resistant to this 
therapy. To increase effectiveness of radiotherapy in patients with 
131
I-resistant, 
strategies should be carried out to restore a sufficient NIS activity in primary tumour 
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and metastasis by stimulating transporter expression or promoting its correct 
localization in plasma membrane. 
 Decreased expression and/ or functionality of NIS only partly explain low capacity of 
radioiodide uptake generally observed in thyroid tumour tissue. A role is played also 
by iodide efflux channels, which promote the escape of the radioactive isotope 
accumulated through NIS and cause failure of therapy with radioiodide. Another 
strategy to increase the effectiveness of therapy with 
131
I, therefore, could be the 
inhibition of activity of outflow channels. Lithium carbonate, used for the treatment of 
mood disorders, potentiates 
131
I therapy due to its inhibitory effect on iodide release 
by neoplastic cells (Koong et al., 1999). 
 Since NIS is expressed physiologically even in extrathyroidal tissues, radioiodide 
could be used for diagnosis and treatment of these tumours. For example, with regard 
to breast cancer, NIS is expressed in epithelial cells of mammary gland tumour (both 
in plasma membrane nda inside the cells) in more than 80% of cases, while in the 
healthy gland only during terminal stage of pregnancy and during lactation (Tazebay 
et al., 2000). Applicability of radioiodide therapy in breast carcinomas represent a 
major breakthrough in treatment of malignant cancer more deadly in women. 
In the light of its potential diagnostic and therapeutic and thanks to gene therapy, NIS 
expression may be induced in tumour cells non-thyroidal, in order to make even the 
primitive tumours not susceptible to destruction of thyroid gland with radioiodide 
(Spitzweg et al. 2002). Several attempts of gene transfer were performed on human 
and mouse cell lines of various tumours, demonstrating induction of iodide 
accumulation and cytotoxic effect of selective radioiodide accumulation (Boland et 
al., 2000; Mandell et al., 1999 ). In vivo studies have yielded good results: human 
tumour xenografts in nude mice and expressing NIS are able to accumulate 
radioiodide (Boland et al., 2000). Demonstrated ability of NIS gene transfer to induce 
activity of iodide uptake in tumour cells, therapeutic efficacy remains to be confirmed 
in vivo. Spitzweg et al., 2000, showed an average reduction of more than 90% of 
tumour volume by NIS expression in a prostate tumour line xeno-grafted in nude 
mice. Results obtained so far are very promising but remain to be solved typical 
problems of gene therapy, in particular identification of transduction systems more 
efficient and safer, allowing a systemic administration of vector and a tumour-specific 
regulation of gene expression. 
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1.4 CHLORIDE TRANSPORT 
 
 Between anions with high physiological relevance, chloride, iodide, bicarbonate and 
thiocyanate pseudohalide can be numbered. Chloride (Cl
-
) is involved in processes as 
fluid epithelial secretion and cell volume regulation, iodide (I
-
) in thyroid hormone 
synthesis, bicarbonate (HCO3
-
) in pH regulation, thiocyanate (SCN
-
) in epithelial 
sterility. Homeostasis depends also on proper anion flow, activity in which numerous 
transporters and channels are involved, more or less specific for each anion. 
 
1.4.1  CHLORIDE CHANNELS 
 
 Cl
-
 channels are expressed in epithelial tissues mostly, where exert functions such as 
cell volume regulation and fluid secretion. Cl
-
 channels are fundamental also in neuro-
excitation and in smooth muscle contraction and involved in endosomal, lysosomal 
and Golgi acidification (Jentsch et al., 2002).  
 Cl
-
 channels allow flow of chloride but also other halides in a less specific manner, 
such as bicarbonate (HCO3
-
)and thiocyanate (SCN
-
) (Verkman et al., 2009). 
 Many mutations were found and characterized in genes codifying for Cl
-
 channels; 
some of these can determine diseases such as cystic fibrosis (mortal genetic disease 
most diffused among Caucasian), macular degeneration, kidney lithiasis,  renal loss of 
salt and hyperekplexia. 
 Defective  transport can provoke disorders such as secretory diarrhea, polycystic 
kidney disease, osteoporosis and hypertension, whose therapy is based on Cl
-
  
channels modulators, some already employed, some others screened in preclinical and 
clinical studies. 
 Cl
-
  channels are divided into five categories: 
 Volume-regulated chloride channels;  
 CFTR (Cystic Fibrosis Transmembrane Conductance Regulator), activated by 
cAMP-dependent phosphorylation and binding of ATP to nucleotide-binding-
domain (NBD); 
 ClC (Voltage-gated Chloride), depending on membrane potential variations; 
one of these, ClC-1, is involved in Cl
-
  conductance and repolarization after 
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action potential in skeletal muscle and some mutations of it were associated 
with myotonia; 
 GABA/Gly receptors, ligand-dependent Cl- channels (GABA and glycin-
activated), situated in brain inhibitory synapses (GABA receptors, bound also 
by benzodiazepines and barbiturates, modulator used as drugs currently) and 
spinal cord especially (glycin receptors, activated also by β-alanine and 
taurine, responsible of neuronal hyperpolarization and consequent lasting 
inhibition);  GABA/Gly receptor mutations were associated with epilepsy and  
hyperekplexia respectively;   
 CaCC (Calcium-activated Chloride Channel), Cl- channels activated by high 
intracellular Ca
2+
 concentrations, whose molecular identity and activation 
mechanism are unknown so far. 
 
 
 
 
 
 
 
 
 
1.4.2  CALCIUM-ACTIVATED CHLORIDE CHANNELS 
 
 CaCC function is mediated by calcium-activated chloride channels, highly expressed 
in mammalian cells, where exert a role in many physiological processes such as fluid 
transepithelial secretion, fertilization of the egg cell, smooth muscle contraction, heart 
muscle and neuron excitation, visual and olfactory signal transduction (Hartzell et al., 
2005). 
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 CaCC shared features are mediated stimulation, slow and reversible activation after  
membrane depolarization and a typical anion permeability order:  NO3
-
 > I
-
 > Br
-
 > 
Cl
-
 > F
-
. So far, molecular identity of this conductance is unclear; protein involved 
could be Cl- channels or Cl- channels components/regulators. Among CaCC 
candidates, two protein families were considered mainly: bestrofins and anoctamins. 
Studies on bestrofins revealed some discordances, such as lack of detectable effects in 
bestrofin-1 knock-out mice in calcium-activated chloride currents and in tissues which 
express it (retinal pigment epithelium mostly) and generation of currents with features 
different from classical CaCC, when expressed exogenously. Anoctamins remains the 
most likely CaCC candidate, especially because of anoctamin-1/TMEM16A 
biophysical and pharmacological properties coherent with CaCC (Kunzelmann et al., 
2009). 
 Sensory, chemical or electrical stimuli can activate transduction pathway leading to  
CaCC activation: Gq protein coupled receptors stimulate phospholipase C enzyme for 
inositol 1,4,5-triphosphate (IP3) synthesis, which mediates intracellular signalling 
(Yang et al., 2008). 
 
 
  
 Intracellular calcium concentration increase can be provoked by IP3 level increase, 
which leads to cytoplasmic calcium release from intracellular stores, and by calcium 
influx from extracellular compartment via  voltage-gated Ca
2+ 
 channels. Intracellular 
calcium increase causes membrane depolarization via CaCC activations and 
hyperpolarization of Ca2+ dependent potassium (K+) channels (fig.   ). Transduction 
pathway leads to CaCC activation by Ca2+ direct action, i.e. in salivary glands 
epithelium, or involves Ca2+-calmodulin-dependent kinase type II (CaMKII)  i.e. in 
intestine epithelium (fig.    ). CaCC can be activated by ATP through its binding to 
P2Y2 purinergic receptor, and carbachol, agonist active on acetylcholine muscarinic 
receptors. Also Ca2+ ionophores as ionomycin can active CaCC increasing membrane 
permeability to Ca2+ . 
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1.4.3 ANOCTAMINS 
 
 
1.4.3.1 General features 
 
 Anoctamin family consists of ten members in mammalians known so far, called 
ANO/TMEM16 (ANO1-10, TMEM16A-K). These proteins are highly evolutionarily 
conserved: particularly, their predicted structure is characterized by eight 
transmembrane domains and both carboxy- and amino-terminals in cytosol (fig.  ). 
Anoctamin name results from fusion between “anion”, because anoctamins are 
involved in anion transport, and “oct” because of their eight transmembrane domains. 
Between TMEM16A and TMEM16B sequence identity is close to 60% but less for 
the other members, up to 20-30% for TMEM16F, G, H, J, K (Galietta, 2009). 
Sequence homology arrives to almost 90% for transmembrane domains. A very 
interesting property is their little homology with other ionic channels families, that 
places them in a new family. 
 
 
 Anoctamins have a characteristic expression pattern in tissues, and every tissue 
expresses its own anoctamin set. Anoctamins 1, 5, 6, 7, 8, 9, 10 are expressed in 
epithelial tissues mostly, anoctamins 2, 3, 4 in nervous system. Their exogenous 
expression was considered in several studies: one of these (Schreiber et al., 2009) 
found that all anoctamins are localized in plasmatic membrane when expressed in 
FRT cell line (from rat normal thyroid epithelium, not expressing thyroid 
differentiation markers but highly polarized). 
 As far as it regards functional role, anoctamins are little known; TMEM16A, 
TMEM16B function is known (calcium-activated chloride channel or CaCC); also 
TMEM16H and TMEM16F have CaCC activity (the latter, in particular, is included 
in “scramblase complex” of platelets, Suzuki J, Nagata S., 2011). Likely also other 
members of family are involved in anion transport, since they share sequence 
homology, with functional properties still to be defined. 
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1.4.3.1 Anoctamin-1/ TMEM16A 
 
 Anoctamin-1/TMEM16A gene is located on q-arm of human 11 chromosome. It was 
cloned by mouse retina originally. Human protein shares high homology with mouse 
ortholog (91%). TMEM16A exerts a role in CaCC activity in epithelium and smooth 
muscle contraction.  Its properties and predicted expression in virtually all tissues, as 
CaCC, suggested it could be a potential candidate. 
  
 CaCC activity was known and studied for a long time but its molecular identity not 
so clear. Recently three different independent laboratories identify TMEM16A as 
CaCC molecular mediator with their own strategy: 
 
 search for transmembrane proteins with multiple transmembrane domains and 
isoforms without any known function in data-banks (Young et al., 2008);   
 genomic functional studies after an experimental evidence: interleukin-4 (IL-
4) increased calcium-activated chloride secretion in human bronchial epithelial 
cells, then IL-4 up-regulated genes codifying orphan membrane protein were 
identified with expression mRNA microarray (Caputo et al., 2008); 
 expression cloning with amphibian Axolotl oocytes, without CaCC 
endogenous activity (Schroeder et al., 2008). 
 
 Besides, silencing provoked blockade of a typical CaCC-dependent function, salivary 
glands secretion inhibition in vivo (Yang et al., 2008). 
 TMEM16A-knock-out neonatal mice dead, likely because of high tracheomalacia, 
and show electrolytic cell transport defects similar to cystic fibrosis, such as strongly 
reduced CaCC in airways, mucus accumulation in lumen and reduced ciliary motility 
(Rock et al., 2008; Rock et al., 2009).  
 Taken together, all these evidences strongly support hypothesis on TMEM16A as a 
CaCC, fundamental in airway epithelium physiology. Likely high mortality of knock-
out mice could be due to a functional default in multiple organs, since TMEM16A is 
highly expressed in secretory epithelial tissues as pancreas, prostate, salivary glands, 
thyroid, colon (Schreiber et al., 2009). Tracheal cartilage anomalies are not known but 
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could be due to loss of normal tissue architecture, provoked by mucus accumulation 
and other effects of TMEM16A lack (Rock et al.,  2008). 
 A notable evidence is a CaCC residual activity in TMEM16A knock-out mice, which 
suggests involvement of other proteins, putatively other members of anoctamin 
family, in CaCC. 
 Differential maturation of anoctamin-1 transcript leads to various isoforms due to 
presence or absence of four segments (Caputo et al., 2008): 
 
 “a” segment, consisting of 116 aminoacid residues, localized at amino-
terminus; 
 “b” segment, consisting of 22 aminoacid residues, localized before of first 
transmembrane domain; 
 “c” and “d” segment, consisting of 4 and 26 aminoacid residues respectively, 
localized inside the first intracellular loop, that connects the second 
transmembrane domain to the third . 
 
  
 
 TMEM16A(abcd), complete protein including all four peptide segments, consists of 
1008 aminoacid residues. TMEM16A(0), is the basic isoform and consists of 840 
aminoacid residues, can transport anions but without voltage-dependent activation 
(Ferrera et al., 2010 ). 
 According with recent hypothesis, process of alternative splicing could regulate 
channel biophysical and pharmacological properties, as voltage-dependence and 
calcium sensitivity.  
 Some predictions suggest presence of a pore forming structure: region between the 
fifth and the sixth transmembrane segment should form a re-entrant loop in plasmatic 
membrane, not completely extracellular. This feature was showed by a mutational 
study, through identification of three highly conserved charged residues, whose 
mutations provoked alterations in protein ionic properties.  
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 So far, is not clear calcium-dependent activation of TMEM16A, which does not 
contain domains with direct binding sites for calcium or calmodulin (such as E-F hand 
domain and others). This fact suggests existence of non canonical domains or sites for 
other mediator, such as PKA, PKC e CaMK kinases, whose consensus sequence were 
found in TMEM16A cytosolic region (Kunzelmann et al., 2009).  
 Among TMEM16A inhibitors can be numbered niflumic acid, acid 5-nitro-2-(3-
fenilpropilamino) benzoic acid (or NPPB) or other classic CaCC inhibitors (Hartzell 
et al., 2005), active at uM concentrations. 
 Anoctamin-1 stimulates the highest basal anionic conductance, ATP-dependent rapid 
activation among tested anoctamins, and, notably, can be activated by ionomycin in 
contrast to other members (Schreiber et al., 2009). 
 High cytosolic calcium concentrations are required for anoctamin-1 (EC50 = 0.7 µM), 
that is inhibited by extracellular calcium removal. Anoctamin-1 activity is maximum 
with 10uM intracellular calcium but inhibited by higher concentrations. 
 Anoctamin-1 appears to be activated by an increase of intracellular Ca
2+
 (Galietta, 
2009), but exact mechanism is not know yet, as with other CACC. Certain 
assumptions are activation mediated by calmodulin and Ca
2+
-dependent 
phosphorylation (Galietta, 2009). 
 A likely mechanism of activation is given by presence of ATP extracellular receptor 
agonist P2, which not only produces an increase in IP3 and a robust mobilization of 
Ca
2+ 
from intracellular stores, but also promotes calcium influx, arachidonic acid 
(AA) release  and I
- 
efflux FRTL-5 cells (Smallridge and Gist, 1994). 
 Recently, a study showed the possible mechanism of TMEM16A and bestrofin-1 (a 
Ca
2+
-activated Cl
-
/ I
- 
channel) operation, following intracellular Ca
2+
- increase due to 
ATP binding to its receptor P2Y ( Kunzelmann et al., 2009). Resulting stimulation of 
G protein (Gq/11) and of phospholipase C (PLC) increases the IP3, inducing Ca
2+
 
release from endoplasmic reticulum stores and bestrofin-1 activation, which in turn 
facilitates the release ( Figure ). Bestrofin-1 activity is regulated by PP2A and PKA2 
kinases. Intracellular calcium release stimulates TMEM16A activation (Kunzelmann 
et al., 2009). 
 Furthermore, CACC activity was studied in CFPAC cells and CFBE41o-1-(cell line 
of human tracheal epithelium, homozygous for ΔF508 CFTR mutation) transfected 
with the siRNA specific, with a Yellow Fluorescent Protein(YFP)-based assay halide-
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sensitive (Caputo et al., 2008). The cells were stimulated with UTP (Figure ) in order 
to produce intracellular calcium increase; fluorescence decrease was caused by a high 
influx of I
-
 through CACC. Cells transfected with siRNA against TMEM16A mRNA 
showed a 60% reduction of the influence of iodide Ca
2+
-dependent compared to cells 
treated with siRNA control or against other targets (Caputo et al., 2008). 
 In some studies (Caputo et al., 2008; Hartzell et al., 2009), it was demonstrated that 
flow-dependent anion ANO1 is highly sensitive to NFA and NPPB, which typically 
inhibit CACC, but is not affected by inhibitors such as CFTRinh-172 and DPC. 
Two recent studies (Namkung et al., 2010th; Namkung et al., 2010b) have identified 
other inhibitors of ANO1 as tannic acid (TA), a compound belonging polyphenol  
family, contained in a wide range of natural products, such as green tea and red wine.  
By means of electrophysiological analysis (short-circuit analysis) in FRT cells, it was 
demonstrated that tannic acid (100μM) inhibits (selective) to 95% of TMEM16A Cl-
conductance of stimulated by ionomycin (ionophore that increases Ca
2+ 
permeability 
of membranes) which, at the same concentration, has only a slight effect on CFTR Cl
-
conductance (Namkung et al., 2010b). 
 
 Since its involvement in many processes, TMEM16A and the other anoctamins could 
be employed as a new class of pharmacological targets for several human diseases, 
i.e. to compensate chloride defective transport in cystic fibrosis, and to regulate 
smooth muscle contraction in asthma, hypertension and gastrointestinal motility 
disorders. 
 An interesting evidence of anoctamin-1 is its increased expression in several human  
tumours, as gastrointestinal stromal tumour (or GIST). TMEM16 is called also DOG1 
because “Discovered On GIST” (Espinosa et al., 2008). TMEM16A shows higher 
expression in many epithelial tumours, in fact another name is ORAOV2 (ORAl 
cancer OVerexpressed 2). 
 Anoctamin-1 is located inside a chromosomal region containing several oncogenes, 
as cyclin D1, this could explain its increased expression in cancer cells. So far, 
TMEM16A was used as a tumour biomarker, i.e. in human coloncarcinoma and could 
be still used, not only for diagnosis and follow-up, but also for as a target of therapy, 
if chloride conductance were showed to be connected with tumourigenesis. 
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1.4.3.2   Anoctamin-2/ TMEM16B 
 
 Anoctamin-2/TMEM16B is expressed on plasmatic membrane of nervous and 
epithelial cells, as eye cells, where its transcript has the highest expression (Schreiber 
et al., 2009). TMEM16B seems to show a CaCC activity in sensorial transduction, i.e. 
in ciliated olfactory cells (Stephan et al., 2009) and in photoreceptors (Stöhr et al., 
2009). As TMEM16A, also TMEM16B was expressed in a heterologous system to 
discover its effects, Axolotl oocytes (Schroeder et al., 2008) and HEK (Human 
Embryonic Kidney) cell lines (Pifferi et al., 2009). TMEM16B resulted to produce 
CaCC activity but with some properties, such as more rapid membrane 
depolarization-dependent activation, less calcium sensitivity, anion permeability 
order, SCN
- 
> I
- 
> NO
3- 
> Br
- 
> Cl
-
 , less membrane potential-dependent calcium 
affinity (property different from TMEM16A (Galietta, 2009). Comparative studies of 
these two anoctamins could lead to understanding structure-function relationships 
with more details for the whole family. 
 Mouse anoctamin-2 is expressed in neural tube and dorsal root ganglia during 
nervous system development (Harfe and Rock, 2008). 
 Among related diseases, it is notable founding of deletions of von Willebrand e 
TMEM16B genes, located on p-arm of  chromosome 12 in some patients with von 
Willebrand type 3 disease, which provokes impaired coagulation  (Schneppenheim et 
al., 2007); one TMEM16B polymorphism related to panic disorder was found in a 
genome –wide scan study (Otowa et al., 2009). 
 
1.4.3.3   Anoctamin-3/ TMEM16C 
 
 Also anoctamin-3/TMEM16C is expressed mostly in nervous system, in cerebral and 
cerebellar cells (Schreiber et al., 2009). Human TMEM16C is located on p-arm of 11 
chromosome. So far, no physiological information have been described about this 
protein. 
 
1.4.3.4   Anoctamin -4/ TMEM16D 
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 Anoctamin-4/TMEM16D is codified by a gene localized on q-arm of  chromosome 
12. Mouse protein is expressed in nervous tissue, particularly in spinal cord and 
brainstem (Schreiber et al., 2009). Rat TMEM16D mRNA was found in pulmonary 
artery smooth muscle cells at low levels (Manoury et al., 2010). So far, no 
physiological information have been described neither about this protein. 
 
1.4.3.5   Anoctamin-5/ TMEM16E 
 
 Anoctamin-5/TMEM16E is codified by a gene localized on q-arm of  chromosome 
11, codified protein consists of 913 aminoacid residues (Katoh and Katoh, 2004a). 
Mouse protein showed an epithelial expression (thyroid particularly), in skeleton 
muscle, in cartilage and nervous system (Schreiber et al., 2009). Another name is 
GDD1 because its gene is mutated in “GnathoDiaphyseal Dysplasia” in a rare human 
genetic disease likely with impaired bone calcification (Tsutsumi et al., 2004). Protein 
seemed  to be involved in embryonic/ fetal development of mouse skeletal muscle 
system (Mizuta et al., 2007). Its heterologous expression in FRT cell line led to a 
small CaCC (Schreiber et al., 2009). 
 
 
 
 
1.4.3.6   Anoctamin -6/TMEM16F 
 
 
 Anoctamin-6/TMEM16F is codified by a gene localized on q-arm of chromosome 12.  
Its expression was found ubiquitously, especially in epithelium (Schreiber et al., 
2009), but also in embryonic stem cells and foetal liver (Katoh and Katoh, 2004a) and 
in smooth muscle cells of rat pulmonary arteries (Manoury et al., 2010). Heterologous 
expression in FRT cell line revealed ATP-stimulated chloride conductance, coherent 
with CaCC activity, with patch-clamp technique (Schreiber et al., 2009). In FRT cells 
also its endogenous expression was found, likely responsible for their small chloride 
conductance. High intracellular calcium concentration is requested for its activation, 
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as observed with TMEM16A, but is not influenced by niflumic acid (Schreiber et al., 
2009). 
 As far as it regards relates diseases, TMEM16F gene mutations were found in Scott’s 
syndrome (one patient), characterized by loss of calcium-dependent 
phosphatidylserine membrane exposition by activated platelets and consequent 
impaired procoagulant activity (formation of scramblase complex) (Suzuki et al., 
2010).  
 Human chronic myeloid leukemia and intestinal cancer showed TMEM16F 
expression (Katoh and Katoh, 2004a). 
 TMEM16F was confirmed to provoke phospholipid scrambling in platelets (Suzuki J, 
Nagata S., 2011). 
 
1.4.3.7   Anoctamin -7/TMEM16G 
 
 Anoctamin-7/ TMEM16G is codified by a gene localized on q-arm of  chromosome 
2and contains 25 exons (Katoh and Katoh, 2004b). Codified protein consists of 932 
aminoacid residues and shows two isoforms, ANO7S, short, and ANO7L, long. Its 
expression was found especially in epithelial tissues in mice, such as stomach 
(Schreiber et al., 2009).  
 Heterologous expression in FRT cell line revealed CaCC activity (Schreiber et al., 
2009).  
 Another name is NGEP (New Gene Expressed in Prostate), because of its expression 
in both normal and tumour human prostate (Bera et al., 2004). 
 
  
 
1.4.3.8   Anoctamin-8/TMEM16H 
 
 Human anoctamin-8/TMEM16H is codified by a gene localized on p-arm of  
chromosome 19 and contains 18 exons; presence or absence of intron 17, due to 
alternative splicing of its transcript, leads to expression of two isoforms (Katoh and 
Katoh, 2004b). Between the fifth and the sixth transmembrane domain there is a 
longer region and rich in negative charges due to an additional segment containing 20 
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glutamate and aspartate residues, carboxy-terminus is rich in prolines (Galietta, 2009),  
features that make TMEM16H different from other anoctamins.  
 Endogenous expression in FRT cell line produced a small ATP-stimulated CaCC 
activity (Schreiber et al., 2009). 
 Its expression was found in stem embryonic cells and foetal brain (Katoh and Katoh, 
2005).  
 
1.4.3.9   Anoctamin-9/TMEM16J 
 
 Human anoctamin-9/ TMEM16J is codified by a gene localized on p-arm of  
chromosome 11. 
 Heterologous expression in FRT cell line blocked both basal chloride conductance 
and CaCC activity and, interestingly, inhibited anoctamin-1 activity when co-
expressed (Schreiber et al., 2009). 
 Its expression was found mostly in mouse epithelial tissues such as thyroid, and 
cartilage (Schreiber et al., 2009). 
 
1.4.3.10   Anoctamin-10/TMEM16K 
 
Human anoctamin-10/ TMEM16K is codified by a gene localized on p-arm of  
chromosome 3. 
 Endogenous expression in FRT cell line produced CaCC , showed with patch-
clamping studies and blocked basal anoctamin-6 chloride conductance and 
TMEM16A  CaCC activity when co-expressed (Schreiber et al., 2009). 
 Niflumic acid slightly inhibited anoctamin-10 currents and CaCC activation required 
cytosolic calcium concentration smaller than anoctamins -1 and -6 (EC50% = 0.2 
µM).  
 Anoctamin-10 gene mutations were found in patients carrying autosomal recessive 
cerebellar ataxia (Vermeer et al., 2010). 
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1.5 FLUORESCENT BIOSENSORS 
 
 Current methods used for study of cellular iodide transport are numerous; among 
these, radiotracers can monitor ion flows across cell membranes and 
electrophysiological techniques can measure ionic currents induced by iodide. 
Fluorescent indicators of halide (iodide and chloride) can also be used for this 
purpose. Among these, chemical compounds such as quinolinium (Galietta et al., 
2001) have, however, some disadvantages, i.e. require pre-incubation and washing of 
cells, have an imperfect cell retention and it is not possible to identify their specific 
subcellular localization (Galietta et al., 2001). 
 Troubles described were solved with fluorescent indicators halide sensitive, derived 
from green fluorescent protein (GFP) (Mansoura et al., 1999), endogenously 
expressed in Aequorea victoria jellyfish (Figure ) , pH but not halide-sensitive.  
 
 
 
 
 These intracellular chloride and iodide biosensors, GFP variants, can be stably 
expressed by cells, do not require pre-loading or washing in cells, are perfectly held 
inside cells and have better optical properties and photostability compared to chemical 
indicators (Jayaraman et al. , 2000). 
 The EYFP (Enhanced Yellow Fluorescent Protein) variant contains four different 
amino acid substitutions that shift the fluorescence from green (509 nm) to yellow-
green (527 nm). Although EYFP’s fluorescence excitation maximum is 513 nm, it can 
be efficiently excited at 488 nm, the standard laser line for an argon-ion laser. 
GFP variant YFP (Yellow Fluorescent Protein) has four point mutations (S65G, 
V68L, S72A, T203Y) and excitation spectra and emission shifted towards the red 
compared to GFP (Mansoura et al., 1999;  Elsliger et al. , 1999) . 
 
Cells expressing YFP coding sequence show fluorescence distributed in cytoplasm 
and nucleus in a uniform manner. 
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 YFP fluorescence is pH sensitive can bind halides and pseudohalides (Elsliger et al., 
1999; Wachter and Remington, 1999). Process takes place provoking pKa changes 
(Galietta et al., 2001b ) (-log10Ka), where Ka is acid dissociation constant, index of 
dissociation degree of an acid. If  pKa of YFP chromophore undergoes changes, 
absorption of radiation capability can be mutated (Galietta et al., 2001b). Higher  
halide concentration leads to pKa increase and YFP fluorescence decrease, while 
increased pH (with chromophore deprotonation and pKa reduction), leads to 
fluorescence increase. These changes in YFP fluorescence, in response to changes of 
halide concentration or pH, occur within a few milliseconds. 
 YFP has a binding site distinct halide, but near the chromophore, which is formed by 
three adjacent amino acids: glycine 65 (serine in GFP), tyrosine 66, glycine 67 
(Wachter et al., 2000. 
 
 YFP-H148Q variant is characterized by substitution of histidine residue in position 
148 with a glutamine. Compared to YFP has a rather low chloride sensitivity, with a 
Kd bigger than 100 mM (at that concentration of chloride, YFP fluorescence is 
reduced by 50%) (Galietta et al., 2001b). This form of YFP has a wider cavity at the 
level of chromophore, structure that explains its high affinity for an ion voluminous as 
I
-
, with a Kd of 21 mM (Galietta et al., 2001b; Wachter et al., 2000).  
 Randomly changing the six hydrophobic residues close to halide binding site, to 
change polarity and/ or size of this site, YFP-H148Q variants were obtained and 
selected with increased affinity for iodide and chloride, respectively YFP -I152L (Kd 
for I
-
: 2 mM) and YFP-V163S (Kd for Cl
-
: 40 mM) (Galietta et al., 2001b). These 
YFP mutants exhibit a specific sequence of sensitivity to anions: for YFP-I152L I
-
 > 
NO
3-
 > Br
-
 > Cl
-
, for YFP-V163S Cl
-
 > NO
3-
 > I
-
 > Br
-
 (Galietta et al., 2001b ) (Fig.  ).  
Probably, difference is caused by environment: halide binding pocket resulted more 
hydrophilic in YFP-V163S by mutation of valine in position 163 with a serine 
(chloride binds more strongly to the nearby water molecules) (Galietta et al ., 2001b). 
 YFP-V163S is ideal for measuring Cl
-
 concentration in subcellular organelles, in 
which Cl
-
 concentration is approximately 25-40 mM, and then close to its Kd for Cl
-
(Galietta et al., 2001b). 
 YFP-I152L is suitable for studies on the cellular transport of I-, in particular in 
thyroid gland, which uses iodide for thyroid hormones synthesis. 
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CHAPTER   2 
 
AIM 
 
The aim of this project is the identification of new channels involved in iodide efflux 
in thyroid follicular cells. According to the working hypothesis of the project, 
TMEM16A, a Ca
2+
-activated chloride channel (CaCC) which regulates chloride 
homeostasis, could also play a role in the transport of iodide
 
in thyroid gland. Thus, 
the aim of the research is the characterization of TMEM16A expression and function 
in the thyroid gland. 
 
Specific aims: 
 
 Determination of TMEM16A mRNA expression in thyroid cells (human 
normal or tumor thyroid gland and normal rat thyroid FRTL-5 cells) 
 
 Identification of splicing TMEM16A mRNA isoforms expressed in FRTL-5 
cells 
 
 Identification of members of anoctamin family mRNA expressed in FRTL-5 
cells  
 
 Functional analysis of TMEM16A in FRTL-5 cells, verifying that its activity 
is compatible with described features, such as Ca
2+
 dependence and purine 
nucleotide-mediated activation (such as ATP), membrane voltage-dependence 
(induced by depolarization)  
 
 Molecular analysis of TMEM16A mRNA and functional analysis of iodide 
efflux in a recombinant system 
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 Functional analysis of iodide efflux properties in FRTL-5 cells, evaluating the 
effect of intracellular Ca
2+
, depolarization, agonists/antagonists of purinergic 
receptors, specific CaCC inhibitors  
 
 
 Molecular analysis of TMEM16A mRNA and functional analysis of iodide 
efflux in FRTL-5 cells, evaluating the effects of TMEM16A RNA silencing  
 
 Molecular analysis of hTMEM16A protein in a recombinant system using a 
proteomic approach 
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CHAPTER   3 
 
MATERIALS AND METHODS 
 
3.1 CELL CULTURE 
3.1.1 FRTL-5 CELLS 
 The FRTL-5 cell line is derived from normal thyroid epithelium of Fisher strain 
albino rat (Fig 3.1). FRTL-5 cells grow in adhesion to substrate, are not polarized but 
are highly differentiated with expression of thyroid specific markers such as NIS, 
pendrin, TSH receptor, TPO, and TG. FRTL-5 cells are used as the cell model of 
choice for studies on the thyroid gland. 
 
 
Fig. 3.1 FRTL-5 cells. Image acquired under transmitted light, 20X objective, Zeiss Axiovert 200 
microscope. 
 
 
 
 
 
46 
 
3.1.2 FRTL-5 CELLS WITH YFP-H148Q/I152L STABLE EXPRESSION 
 Analysis of iodide fluxes in FRTL-5 cells requires the expression of a suitable 
biosensor. Stable clones of FRTL-5 expressing YFP-H148Q/I152L were previously 
developed in our laboratory (details in section 3.2.8) (fig. 3.2). 
 
Fig. 3.2. Left: pcDNA3.1-YFP H148Q/I152L plasmid (Invitrogen®). Right: Fluorescence image of 
FRTL-5 cells stably expressing YFP H148Q/I152L.  
 
 
3.1.3 CULTURE MEDIUM 
 FRTL-5 cells were cultured in 6H5 Coon’s medium (Sigma-Aldrich®), specifically 
designed for the culture of differentiated thyroid cells (Ambesi-Impiombato et al., 
1980). Cells were plated and maintained in T25 and T75 flasks, at constant temperature 
and CO2 (37°C and 5% CO2 in incubator).  
 When FRTL-5 were needed to suppress NIS transporter expression, were grown in  
TSH-free COON’S medium, also called 5H5, for at least one week. 
 F-12 COON’S MODIFICATION medium powder (Sigma-Aldrich®) was dissolved 
in milliQ water under continuous stirring. NaHCO3 30mM was added as a buffer 
agent. Medium pH was adjusted up to 7,3 with 1M HCl. Under sterility conditions the 
following additions were made: 
 serum NCS 5% (Newborn calf serum, Sigma-Aldrich®); 
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 penicillin 100 U/ml (Euroclone®); 
 streptomycin 100 µg/ml (Euroclone®); 
 apotransferrin 5 µg/ml (Sigma-Aldrich®); 
 hydrocortison 10 nM (Sigma-Aldrich®); 
 somatostatin 10 ng/ml (Sigma-Aldrich®); 
 GHL (glycine-L-histidine-L-lysine acetate) 10 ng/ml (Sigma-
Aldrich
®
); 
 TSH 1 mU/ml (Sigma-Aldrich®); 
 insulin 1 µg/ml (Sigma-Aldrich®); 
 Sterilization was made with filtration (Millipore
®
 0,22 um filters), it usually brought 
medium pH up to 7.4.  
 
3.1.4  FRTL-5 PASSAGE 
 Culture medium was changed almost every 2-3 days. FRTL-5 cells were passed when 
they reached 70%-80% confluence. Cells were washed with Ca2+-free PBS  and 
incubated with CTC mix for 30’: 
 50 U/ml collagenase (Sigma-Aldrich®);  
 500 U/ml trypsine (Sigma-Aldrich®); 
 2% chicken serum  dialysed in HBSS (Hanks’ buffered salt solution Ca2+ and 
Mg
2+
 free). 
This detachment medium has been specifically designed for FRTL-5 cells (Ambesi...). 
In particular, collagenase is included to facilitate digestion of the extracellular matrix 
synthesized by thyroid cells. Chicken serum  (which is devoid of trypsin inhibitory 
activity) is used to maintain viability during cell detachment. Cells were resuspended 
in 6H5 medium, so serum contained could block protease effects, and centrifuged at 
300 g for 5’. After removal of supernatant, FRTL-5 were resuspended in 6H5 medium 
and plated with an usual dilution 1:4.  
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3.1.5 CELL FREEZING AND THAWING  
 FRTL-5 were washed with Ca
2+
-free PBS and detached with CTC mix, centrifuged at 
300 g for 5’ and counted with Burker’s chamber. 
 Cells (1×10
6
 cells/ml) were cryopreserved in a solution containing 6H5 medium 
(50%)  and NCS (40%), and DMSO (10%). using freezing containers (Mr. Frosty 
Nalgene
®
) containing isopropanol at -80°C to allow a slow and successful freezing (1 
°C/min).   For long-term preservation, cryovials were maintained in liquid nitrogen. 
 Thawing was performed by rapidly immersing vials in a 37°C bath. After cleaning 
the vial with 70% ethanol in deionized water, cell suspension was transferred into 
tubes with 20ml COON’S medium and centrifuged to remove DMSO, toxic at RT. 
Pellet was resuspended in 5ml 6H5 medium and plated into T25  flasks. 
 
3.1.6 FRTL-5 CULTURE FOR FUNCTIONAL STUDIES 
 Functional experiments required growth of FRTL-5 cells on round 25mm diameter 
coverslips.  Coverslips were first cleaned by soaking overnight in 70% ethanol and 
1% HCl, and sterilized by UV  in 6-well plates.  FRTL-5 cells were plated at a density 
of 0,8×10
5
 cells/well and grown for 1 week before in vivo functional experiments.  
 
3.1.7 CHO CELL LINES 
 CHO cell lines are from a biopsy of an ovary of an adult Chinese hamster. CHO K1 
cell line used in our studies was a subclone from the parental CHO cell line (Fig 3.3).  
These cells grow in a monolayer. 
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Fig. 3.3 CHO K1 cells. Image acquired under transmitted light with an FluoView 1000 confocal 
microscope, 20X objective (Olympus, Tokyo, Japan). 
 
3.1.8 CHO CELLS  WITH YFP-H148Q/I152L AND hNIS STABLE EXPRESSION 
 Analysis of iodide efflux in CHO K1 cells required expression of a suitable 
biosensor. Thus, stable clones of CHO K1 expressing YFP-H148Q/I152L and hNIS 
proteins were obtained in our laboratory previously (details in section 3.2.8), suitable 
for functional in vivo experiments on iodide flow (fig.3.4). 
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Fig. 3.4. Left: pcDNA3hNIS Zeo (Invitrogen®) with MCS region. Right: CHO K1 cells stably 
expressing YFP H148Q/I152L. Image acquired with inverted optical microscope Zeiss™ 
Axiovert 200, through an oil immersion 40X objective. YFP fluorescence was observed at these 
wavelength (λ):  excitation 500 ± 12.5 nm and emission 545 ± 17.5 nm; specific filters set used was 
XF104-2, OMEGA® optical.  
 
 
 
 
3.1.9 CULTURE MEDIUM 
 CHO K1 cells required proline in their medium for growth, so proline-containing 
HAM’s nutrient mixture F12 medium or DMEM-F12 1:1 mixture (Sigma-Aldrich®) 
were used. Cells were plated and maintained in T25 ,T75 flasks or 100mm dishes, at 
constant temperature and CO2 (37°C and 5% CO2 in incubator).  
 Under sterility conditions the following additions were made: 
 serum FBS 10% (Fetal bovine serum, Sigma-Aldrich®); 
 penicilline 100 U/ml (Euroclone®); 
 streptomicine 100 µg/ml (Euroclone®); 
 
3.1.10  CHO PASSAGE 
 Culture medium was changed almost every 2-3 days. CHO K1 cells were passed 
when they reached 90% confluence. Old medium was removed and 3 washes with 
Ca
2+
-free PBS were made, to eliminate FBS residues, containing trypsin inhibitors.     
for some minutes cells were incubated in PBS: 
 KCl 2,7 mM; 
 KH2PO4 1,8 mM; 
 NaCl 137 mM; 
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 Na2HPO4 1 mM; 
Containing: 
 0.25% (w/V) trypsin 
 0.04% (w/V) EDTA (Sigma-Aldrich®), bivalent ion chelating agent, involved 
in intercellular junctions. 
 Cells were resuspended in F12 medium, so serum contained could block protease 
effects, and centrifuged at 300 g for 5’. After removal of supernatant, CHO K1 were 
resuspended in F12 medium and plated with an usual dilution 1:20/1:50, depending 
on experiments.  
3.1.11 CELL FREEZING AND THAWING  
 CHO K1 were washed with Ca
2+
-free PBS and detached with trypsin solution, 
centrifuged at 300 g for 5’ and counted with Burker’s chamber. 
 Cell pellet was resuspended in a solution containing FBS (90%), then cryopreserving 
agent DMSO (10%) was added after, to avoid its toxic effects as much as possible. 
Next steps were the same as FRTL-5.  
 Thawing was performed immersing vials in a 37°C bath (rapidly, for 1’). After 
cleaning vial with 70% ethanol in deionized water, cell suspension was transferred 
into tubes with 20ml F12 medium and centrifuged to remove DMSO, toxic at RT. 
Pellet was resuspended in 5ml F12 medium and plated into T75  flasks or 100mm 
dishes. 
 
3.1.12 CHO CULTURE FOR FUNCTIONAL AND PROTEIN STUDIES 
 For functional experiments CHO K1 were grown in 6 well plate with coverslips as 
described before.  
 For proteomic experiments CHO K1 cells were plated on 100mm Petri dishes (4,5 
10
5
 cells/dish) and grown for 2-3 days up to 95% confluence before performing every 
assay. 
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3.2 MOLECULAR ANALYSIS 
Exogenous expression was induced with cDNA transfection. Anoctamin transcripts 
were detected by RT-PCR, Real Time RT-PCR (quantitative). Transcript silencing 
was performed by small-RNA-interference (siRNA). TMEM16A-EYFP fusion 
protein were obtained by expression cloning. Protein was analyzed with proteomic 
assays and detected by fluorescence staining or Western Blot. 
 
3.2.1 CELL OR TISSUE COLLECTION 
 Cells were detached as previously described, resuspended in PBS and centrifuged at 
300 g for 5’(3X), with a final wash in microtubes at 600g. After removal of the 
supernatant, pellets were kept at -80°C. Tissue samples were collected from biopsies 
and kept at -80°C or in liquid nitrogen. Before extraction, cell pellets were thawed, 
tissue samples were homogenized with a specific pestle and chopped on ice. 
3.2.2 RNA EXTRACTION 
 Total RNA from cells or tissues was extracted with TRIZOL® (SIGMA) or TRI 
REAGENT® (Ambion) according to manufacturer's instructions. The method is a 
modification of the phenol chloroform method, developed by Chomczynski and 
Sacchi , 1987 which isolates aqueous phase containing RNA . 
 
3.2.3 DNASE TREATMENT 
To remove contaminant genomic DNA which could cause nonspecific signals in RT-
PCR, extracted RNA was processed with DNAse I enzyme. After extraction, RNA 
samples were diluted in: 
 reaction buffer; 
 DNasi I (Applied Biosystems®) 0.1 U/µl.  
After 15’ incubation, DNAse  was inactivated with stop solution for 10’ at 70°C.  
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3.2.4 RNA QUANTIFICATION 
 RNA was quantified spectrophotometrically, by measuring RNA absorbance at 260 
nm wavelength (value of maximum absorbance) according to the Lambert-Beer law: 
260 nm absorbance ∙ dilution factor ∙ 40 µg/ml.  
 Sample purity was checked according to the ratio between signals at  260/280 nm 
(proteins have maximum absorbance at 280 nm) and at 260/230 nm (solvents such as 
ethanol have maximum absorbance at 230 nm).  
RNA quality was checked by electrophoretical migration on 1% agarose gel. 
3.2.5 RETROTRANSCRIPTION (RT) 
 RNA-complementary DNA (cDNA) was obtained by retrotranscription, catalyzed by 
a recombinant reverse transcriptase, with RNA-dependent DNA-polymerase activity. 
Random hexamers were usually employed as primers for cDNA synthesis.  
 Reagents (Applied Biosystems®): 
 RT TaqMan 10x buffer; 
 MgCl2 5.5 mM; 
 dNTP mix (deoxyribonucleoside triphosphate), 125 µM each; 
 RNase inhibitor 0.4 U/µl; 
 random hexamers 2.5 µM; 
 MultiScribe Reverse Transcriptase, recombinant enzyme from Moloney 
Mouse Leukemia Virus ) 1.25 U/µl;   
 milliQ water up to proper reaction volume. 
Usually 1 ug RNA/25 ul reaction volume was used. 
 To check the cDNA purity of samples, two samples/ experimental set were processed 
without enzyme in order to check for contaminant genomic DNA residues (RT- 
samples).  
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 To remove intramolecular pairings, RNA was denatured at 60°C for 10’. 
 RT reaction steps: 
 25°C 10’ priming; 
  48°C 30’ enzyme binding and elongation; 
  95°C 5’ enzyme inactivation; 
cDNA samples were stored at -20°C, RNA samples at -80°C. 
3.2.6 RT-PCR 
 PCR (Polymerase Chain Reaction) was used to amplify DNA sequences in vitro. We 
used RT-PCR (cDNA as input DNA). 
 RT-PCR reagent mix (Applied Biosystems®): 
 10x reaction buffer; 
 MgCl2 (2, 3, 4 or 5.5 mM, depending on primers used);  
 dNTP mix with 
o dATP 200 µM; 
o dGTP 200 µM; 
o dCTP 200 µM; 
o dUTP 400 µM; 
 forward primer 200 nM; 
 reverse primer 200 nM; 
 AmpliTaq Gold DNA polymerase 0.025 U/µl;  
 uracil-N-glycosylase (UNG) 0.01 U/µl; 
 milliQ water up to proper reaction volume 
 UNG  enzyme removes uracil residues from DNA, to prevent carry-over 
contamination due to DNA from previous reactions (uracil-containing). Contaminant 
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DNA is degraded by UNG at 50°C (PCR first step). UNG is inactivated at 95°C  
before amplification.  
 Usually 1 ul cDNA/25 ul reaction volume was used. 
 PCR reaction steps: 
 50°C 2’ UNG reaction; 
 95°C 10’ cDNA melting and UNG inactivation; 
 35 cycles 
o 95°C 15” DNA melting; 
o 60°C, 62°C o 64°C 30” (annealing temperature, depending on primers used)  
o 72°C 30” elongation 
 72°C 7’ final elongation. 
 
 
 
 Final conditions used were: 
 
TMEM16A 2/3 mM 60°C 
TMEM16C 3 mM 60°C 
TMEM16D 5.5 mM 60°C 
TMEM16E 3 mM 60°C 
TMEM16F 2/3 mM 60°C 
TMEM16G 3 mM 64°C 
TMEM16H 3 mM / 4 mM 60°C / 64°C 
TMEM16K all 60°C 
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 For the other primers the final conditions used were 5.5 mM Mg
2+
Cl
-
 and 60°C 
annealing temperature.  
  
 3.2.6.1 PRIMERS 
 human GAPDH (housekeeping gene): 
o Forward primer: 5’-CTCTCTGCTCCTCCTGTTCGAC-3’ 
o Reverse primer: 5’-TGAGCGATGTGGCTCGGCT-3’ 
o 69 bp amplicon  
 human β-actin II (housekeeping gene): 
o Forward primer: 5’-CCTGGCACCCAGCACAAT-3’ 
o Reverse primer: 5’-GGGCCGGACTCGTCATACT-3’ 
o 144 bp amplicon  
 rat β-actin (housekeeping gene): 
o Forward primer: 5’-CGCCGGTCCACACCCGCCAC-3’ 
o Reverse primer: 5’-CCGCGAAGCCGGCCTTGCACA-3’ 
o 96 bp amplicon  
 human NIS: 
o Forward primer: 5’-TACGTGGCTTGCCGCACAGAGAAG-3’ 
o Reverse primer: 5’-CATGACGATGCCACAGCAGGC-3’ 
o 105 bp amplicon  
 rat NIS: 
o Forward primer: 5’-TATGTCGCCTGCCACACAGAG-3’ 
o Reverse primer: 5’-CATGACAATGCCACAGCAAG-3’ 
o 105 bp amplicon  
 human TMEM16A: 
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o Forward primer: 5’-TGAAACTGAAGATGCCGACGAAGAA-3’ 
o Reverse primer: 5’-CTTTGGGCTGGATGGGATCTGTGAT-3’ 
o 111 bp amplicon  
 rat TMEM16A (QRT-PCR): 
o Forward primer: 5’-ACAACATCACCATGTGTCCT-3’ 
o Reverse primer: 5’-AGCCCAGAGGGCCATAAACAC-3’ 
o 140 bp amplicon  
 rat TMEM16A “a” segment: 
o Forward primer: 5’-CACAAGAGAGCCTCGGGTAG-3’ 
o Reverse primer: 5’-ATCTTCACAAACCCGACACC-3’ 
o 267 bp amplicon  
 rat TMEM16A “b” segment: 
o Forward primer: 5’-CAAAACCCGGAGCACAATAG-3’ 
o Reverse primer: 5’-CAGGAGTTTCCTGTCGTTGA-3’ 
o 241/175 bp amplicon  
 rat TMEM16A “c” segment: 
o Forward primer: 5’-CTCTGGGCTGCCACCTTC-3’ 
o Reverse primer: 5’-TGGCTTCATACTCTGCTCTGG-3’ 
o 130/118 bp amplicon  
 rat TMEM16A “d” segment: 
o Forward primer: 5’-TCCCAGAGCAGAGTATGAAGC-3’ 
o Reverse primer: 5’-AGATGGGGAGGAGTTCATGG-3’ 
o 305/230 bp amplicon  
 rat TMEM16A: 
o Forward primer: 5’-TCCAAAGACTTCTGGGCTGT-3’ 
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o Reverse primer: 5’-TACTCGTAGCTGGGGACTGG-3’ 
o 305 bp amplicon  
 rat TMEM16B: 
o Forward primer: 5’-CCAGGGAAGCAGAGTTCTTG-3’ 
o Reverse primer: 5’-TGTTGTTGGCTCGAGAACAG-3’ 
o 297 bp amplicon  
 rat TMEM16C: 
o Forward primer: 5’-TCGGACTGCTACACTGGCCCT-3’ 
o Reverse primer: 5’-CAGCGTGCCCAGCGCTCATA-3’ 
o 290 bp amplicon  
 rat TMEM16D: 
o Forward primer: 5’-TGGCTTCGAGGGCCAAGGACA-3’ 
o Reverse primer: 5’-TGAGGCGGGTCCCGGTAGTC-3’ 
o 319 bp amplicon  
 rat TMEM16E: 
o Forward primer: 5’-ACGGCCAAAGTACCCACCCCT-3’ 
o Reverse primer: 5’-ACTGGCCATCATGGAGCGGG-3’ 
o 293 bp amplicon  
 rat TMEM16F: 
o Forward primer: 5’-AGCCATCCTGGCCGTGGTGA-3’ 
o Reverse primer: 5’-GCCCGGGTGGGTTTCGGAAG-3’ 
o 304 bp amplicon  
 rat TMEM16G: 
o Forward primer: 5’-TGGCGCCGCTTTTTGCCCTA-3’ 
o Reverse primer: 5’-GCAAGTGCGGTTGTGTGCCG-3’ 
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o 302 bp amplicon  
 rat TMEM16H: 
o Forward primer: 5’-AAGTTCGCCACCACCGCCAC-3’ 
o Reverse primer: 5’-TGATGCCTCGTGCAGCCAGC-3’ 
o 324 bp amplicon  
 rat TMEM16J: 
o Forward primer: 5’-GGCTGGCCTGTGGAAGCTGG-3’ 
o Reverse primer: 5’-GCCAACAGGGGTGCGAGTGG-3’ 
o 327 bp amplicon  
 rat TMEM16K: 
o Forward primer: 5’-GGCTACCCGCAGGCCAAATTG-3’ 
o Reverse primer: 5’-CCCACACGAACAGGTAGTAGGGC-3’ 
o 280 bp amplicon  
 Primers for the anoctamin family and TMEM16A/ANO1 isoforms have been 
published (Manoury et al., 2010). Other primers were designed with PRIMER 
BLAST software, taking sequences published on the NCBI database as  reference 
(http://www.ncbi.nlm.nih.gov). Sequences were aligned with BLAST software 
(http://www.ncbi.nlm.nih.gov/BLAST) to check for any predicted pairing with non 
specific sequences or to test cross-pairings. 
 For each primer couple, reactions were optimized by testing different conditions such 
as Mg
2+
 concentration and annealing temperature.  
 
3.2.7 REAL TIME PCR (QUANTITATIVE, QRT-PCR) 
 Levels of transcript expression were quantified with quantitative RT-PCR, also called 
Real Time PCR, since amplicon signals can be detected and followed “real time”.  
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This technique allows absolute or relative quantification of cDNA expression, 
compared to a reference gene.  
 SYBR Green I was used as a probe, whose fluorescence at 530nm increases more 
than 200 fold when bound to the DNA minor groove. Fluorescence is proportional to 
DNA copy number synthesized during amplification reaction, according to cDNA 
input concentration. 
 Since SYBR Green I is a non specific probe a melting curve was obtained at the end 
of the reaction, in order to detect any signal due to non specific amplicon (i.e. primer 
dimers). The double strand DNA melting temperature (Tm), specific for each 
amplicon, is determined by gradually increasing the temperature above the primer 
Tm. Fluorescence is rapidly quenched at the melting point, since the probe is not able 
to bind DNA.   Detection of overlapped melting peaks is good purity index, whereas 
different peaks indicate nonspecific amplicons.  
 QRT-PCR was performed in accordance with manufacturer's instructions (Applied 
Biosystems®), with a specific kit.  
 Reaction mix: 
 Fast SYBR® Green Master Mix; 
 forward primer 0.5 µM; 
 reverse primer 0.5 µM; 
 milliQ water up to proper reaction volume 
 Usually 2 ul cDNA/20 ul reaction volume was used. 
 QRT-PCR stages:  
 95°C 20” cDNA denaturation; 
 40 cycles: 
o 95°C 3” cDNA denaturation; 
o 60°C 30” annealing and elongation 
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 The threshold cycle is the number of cycles necessary to reach a fluorescence signal 
significantly higher than background, at the beginning of the exponential phase of 
amplification. At this stage DNA is quantified, since the fluorescence signal is not 
influenced by other reagents, which are limiting in the plateau phase, but is directly 
proportional to the number (n) of cycles. By convention the CT value is defined as 10 
times standard deviation of the fluorescence signal during the first 15 cycles. 
 Analysis was performed using 7500 Fast Real-Time PCR System software (Applied 
Biosystems®). Average Ct between duplicate samples  was calculated. 
 The threshold cycle comparison method was employed for analysis (Livak and 
Schmittgen, 2001), to determine gene differences in expression of control samples 
(calibrator) and treated samples.  Differences among input cDNA quantity or quality 
were corrected with a comparison between the target gene and a reference 
housekeeping gene (normalizer), whose expression is stable under different 
conditions.  
 Threshold cycle (CT) indicates the fractional cycle number at which the XN,q amount 
of amplified target reaches a fixed threshold (Livak and Schmittgen, 2001).  
According to this method (∆∆CT or Fit Point), target gene ∆CT was calculated both 
in control sample, ∆CT (C), and in treated sample, (∆CT (T): 
∆CT target gene = CT target gene – CT normaliser gene. 
 Then ∆∆CT was calculated for every sample: ∆∆CT (T) = ∆CT (T) - ∆CT (C). 
Finally, target gene expression levels in treated samples compared to control was 
calculated with the following function: 2
-∆∆CT (T)
. 
 To check the applicability of this method it was first necessary to calculate and 
compare primer efficiencies, since, according to the ∆∆CT method, amplification 
primer efficiency must be the same and maximum (E = 1). Calibration curves were 
performed with different input DNA concentrations (serial dilutions) amplified in the 
same reaction.  Calibration curves were obtained by linear regression of CP (crossing 
point) values depending on input cDNA concentration, using GraphPad software.  
 Efficiency was calculated with the following formula: E = 10-1/slope – 1 (Pfaffl.,  
When calibration curve slope is -3.3, efficiency is maximum. 
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 According with this analysis primer efficiencies were not significantly different and 
close to 1 (fig. 3.5 ) . Therefore, the ∆∆CT method could be used.   
 
Fig. 3.5. Calibration curves for QRT-PCR primers: TMEM16A, NIS,  actin. Correlation 
coefficients (r
2
) and angular coefficients (slope) of each curve are shown. Ct: Cycle-threshold, 
DNA input concentration ug/ul in logarithmic scale.   
 
 
 PCR products were observed with electrophoretical migration on 2% agarose gel. 
Solution used was Tris Borate EDTA (TBE):  
 1.09 % (w/V) Tris-amino-metano base;  
 0.557 % (w/V) boric acid; 
 0.074 % (w/V) EDTA bisodium as bivalent ion chelating agent 
to inhibit nuclease activity. 
 Gel staining was performed with 0.5 μg/ml ethidium bromide, whose fluorescence is 
20 fold more when bound to double strand DNA. Emitted light was detected with a 
UV transilluminator.  
 The loading buffer for samples contained: 
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 bromophenol blue 
 glycerol  
Electrophoretical run was done at 150 V. 
   
   
3.2.8 TRANSFECTION 
 Exogenous genetic material can be targeted into cells in different ways. The present 
study used transfection, a system which uses artificial constructs to deliver a 
DNA/RNA to eukaryotic cells and allow its expression.  
 Transient transfection was used to induce target cDNA expression and to knock-
down target mRNA expression, in order to determine their functional effect on iodide 
transport in cells studied. 
 Selection of stable clones after transfection was used to obtain cell models that are 
homogeneous and suitable for continuous functional assays on iodide transport.    
 When necessary, empty vectors were used as a control in transient transfection. 
 Employed in vitro transfection techniques: 
a) Lipofection (with Lipofectamine 2000®, Invitrogen), for DNA transient/stable 
expression or RNA interfering delivery; 
b) Polifection (with PEI, polyethyleneimine, Sigma), for DNA transient 
expression; 
c) Superfect (Quiagen®), for RNA interfering delivery; 
d) Peptide-based system (with N-TER™, Sigma), for RNA interfering delivery. 
a) Lipofection uses cationic lipids, which contain positively charged head group and 
one or two hydrocarbon chains. Lipid groups mediate entry of construct into cells,  
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charged head groups regulate interaction between lipid and phosphate backbone of the 
nucleic acid, producing DNA condensation. A neutral co-lipid or helper lipid is often 
inserted to form a unilamellar liposomal structure with a positive surface charge in 
water. Positively charged head group can also help the interaction of nucleic acids and 
cell membrane, so that liposome and nucleic acids (“transfection complex”) can fuse 
with the negatively charged cell membrane. The transfection complex is then thought 
to undergo endocytosis: a membrane bound/intracellular vesicle includes liposome 
and nucleic acid. Once inside the cell, the complex avoids the endosomal pathway, 
and enters the nucleus.  
Plasmids used:  
 
 pcDNA3 hNIS (S. Jhiang, Ohio State University)   
 pcDNA3.1 YFP-H148Q/I152L (L. J. V. Galietta, Laboratory of Molecular 
Genetics, Istituto Giannina Gaslini, Genova)  
 pcDNA3.1 hTMEM16A (L. J. V. Galietta, Laboratory of Molecular Genetics, 
Istituto Giannina Gaslini, Genova)  
  Cells were typically grown in 6 well plates and were transfected when 90% 
confluence was reached. 
 To obtain stable clones expressing YFP-H148Q/I152L, FRTL-5 were grown in 24 
well-plates and transfected with pcDNA3.1-YFPH148Q/I152L (0.8ug/well). 
Lipofectamine 2000 (Invitrogen ®) was used as transfection agent, with 4ul liposome: 
ug DNA ratio (Rhoden et al. 2007). FRTL-5 cell clones with stable YFP expression 
(FRTL-5 YFPH148Q/I152L, fig. 3.2, right) were selected by proliferation in an 
medium containing antibiotic (G418 or Geneticin, 500 ug/ml) for two-three weeks, 
followed by limit dilutions of survived cells to obtain clonal populations (Rhoden et 
al., 2007). 
 To obtain stable clones expressing YFPH148Q/I152L and hNIS, CHO K1 were 
grown in 6 well-plates and transfected with pcDNA3.1-YFPH148Q/I152L (2 ug/ 
well) and pcDNA3.1/Zeo-hNIS (2 ug / well) with Lipofectamine 2000 (Invitrogen ®)  
(ratio: 4μl Lipofectamine: 2μg DNA). Initially CHO-K1 cells were transfected with 
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pcDNA3.1-YFPH148Q/I152L, then underwent several rounds of selection with G418 
antibiotic (200-400 ug/ ml). YFPH148Q/I152L expression was monitored by 
fluorescence microscopy. A cell population with high stable fluorescence was used 
for subsequent transfection with pcDNA3.1/Zeo-hNIS. After the second transfection, 
cells were maintained in culture medium with G418 100 ug/ ml, to maintain selection 
for pcDNA3.1-YFP-H148Q/I152L, and Zeocina 100 ug/ ml to select the cells 
transfected with pcDNA3.1/ Zeo-hNIS. Selected cells were plated in 96-well plates at 
a limiting dilution to obtain a single cell/well. Clonal populations expressing both 
YFPH148Q/I152L and hNIS were obtained and tested for functional studies on iodide 
uptake. 
 TMEM16A expression was induced with ratio 3μl Lipofectamine 2000: 1μg DNA, 
according to manufacturer’s instructions. Particularly, stably expressing YFP-
H148Q/I152L and hNIS CHO-K1 cells were transfected to induce transient 
expression of human TMEM16A, with pcDNA3.1-hTMEM16A (2μg/ well 6WP), 
and Lipofectamine 2000, with ratio 4 ul Lipofectamine: 2 ug DNA.  
b) Polyfection methods are based on cationic polymers. Polyethyleneimine (PEI) was 
the second polymeric transfection agent discovered (Vancha et al., 2004), after poly-l-
lysine. Its secondary amines can condense DNA into positively charged particles, 
which can interact with anionic cell surface residues and undergo endocytosis. Inside 
the cell, amines are protonated,  counter-ion influx and the osmotic potential is 
lowered, leading to osmotic swelling and consequent release of polymer-DNA 
complexes (polyplex) from vesicles into the cytoplasm. DNA can diffuse to the 
nucleus if polyplex becomes less condensed (Rudolph et al., 2000; Akinc et al., 2004).  
 For proteomic experiments CHO K1 cells were passed 1-2 days before transfection at 
4,5 *10
5
 /100mm dish. The ratio of PEI nanoparticles (Sigma®): DNA was 3ul: 1ug.  
 Transfection was performed according to manufacturer’s instruction, exposing cells 
to construct overnight. 
Plasmids used:  
 
 pEYFP-N1 (Dr. Diego Alvarez De La Rosa Rodríguez, Pharmacology Unit, 
Canary University Hospital, La Laguna University, Tenerife) 
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 pEYFP-N1-hTMEM16A  
 pcDNA3.1-neo hTMEM16A (L. J. V. Galietta, Laboratory of Molecular 
Genetics, Istituto Giannina Gaslini, Genova)  
c) SuperFect Transfection Reagent is a specifically designed activated dendrimer . 
SuperFect Reagent architecture is spherical, and contains branches radiating from a 
central core with terminal charged amino groups. SuperFect Reagent optimizes entry 
of DNA into the cell assemblying DNA into compact structures. SuperFect–DNA 
complexes are positively-charged, therefore capable of binding to negatively charged 
receptors (i.e, sialylated membrane glycoproteins) on surface of eukaryotic cells. 
After its access into cytosol, SuperFect Reagent buffers lysosome after its fusion  with  
endosome, inhibiting pH-dependent lysosomal nucleases and stabilizing SuperFect–
DNA complexes.  
 The protocol is described in section 3.2.9. 
d) N-TER™ (Sigma) Nanoparticle siRNA Transfection System is a peptide-based 
system. N-TER Peptide can bind siRNAs non-covalently, forming a nanoparticle, 
which can interact with cell membrane surface lipids. The complex can diffuse 
through cell membrane and deliver siRNA directly to the cytoplasm, avoiding 
endosomal pathway and consequent likely degradation of compartmentalization. 
 This system was designed specifically to deliver siRNAs into cells and induce RNA 
interference. 
The protocol is described in section 3.2.9. 
3.2.9 SMALL INTERFERENCE RNA (siRNA) 
 RNA interference (RNAi) is a cytosolic RNA-dependent mechanism of silencing 
produced by double strand RNA molecules (dsRNA). dsRNA are exogenous in 
human cells and recognized by Dicer enzyme (Lewin, 2004). In vitro this enzyme was 
demonstrated to cut dsRNA with a ATP-dependent process, producing breaks in each 
3’ –end and, accordingly, small RNA molecules, “siRNA” (short interfering RNA) of 
21-23 bps, with short 3’ends protruding 2 bps (Lewin, 2004).  
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 A more successful system is delivery of synthetic siRNA specific for target mRNA 
into cells artificially. siRNA are included in a protein complex, “RISC” (RNA-
induced silencing complex), which breaks siRNA duplex  with formation of free 
single strand RNA fragments. RISC complex leads binding between siRNA and 
complementary mRNA, which is degradated and knocked-down. Result is post-
transcriptional silencing (Hannon and Rossi, 2004) (fig. 3.6). 
 
 
 
Fig. 3.6.  RNA interference mechanism (image from www. scbt.com). 
 
 FRTL-5 cells were transfected with siRNA to induce TMEM16A silencing, 
employing Lipofectamine 2000 (Invitrogen®), Superfect (Quiagen®), N-TER 
nanoparticle SiRNA transfection system (Sigma®), and with the following siRNA 
against rTMEM16A mRNA (all from Sigma Aldrich ®):  
 
  SASI_Rn02_00230075; 
  SASI_Rn02_00230076; 
  SASI_Rn02_00230077 ; 
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  universal negative control siRNA (Sigma Aldrich ®) (“scrambled” siRNA, 
which recognize no RNA sequence) 
 
 Lipofectamine was used at the ratio of 1μl (Lipofectamine): 20pmol (siRNA), with 
25/50 pmoles of siRNA, corresponding to concentrations of 50/100 nM. 
 Superfect was used at the ratio of 1.32 ul (Superfect, 3μg/μl): 20 pmoles (siRNA), 
with 25/50 pmoles of siRNA, corresponding to concentrations of 50/100 nM. 
 N-TER nanoparticle siRNA transfection system was used with recommended  
volumes, 8% v/v, and 50/100 nM siRNA were added.  Cells were exposed to 
constructs in +/-  serum medium, according to manufacturer’s instructions, for 24 h. 
 
Finally, after each kind of transfection experiment, cells expressing YFP-
H148Q/I152L were observed after 2-3 days with an inverted microscope (Zeiss 
Axiovert 200) equipped with a  XBO Xenon 75 W lamp, XF104-2 YFP filter set of  
YFP excitation wavelengths (500 ± 12,5 nm) and emission wavelengths (545 ± 17,5 
nm) (Omega Optical).  
Fluorescence signal was used as a index of successful DNA transfection or mRNA 
silencing, depending on effects produced by constructs delivered into cells. 
 
 
3.2.10 EXPRESSION CLONING 
 Expression cloning of hTMEM16A coding sequence was performed to study protein 
expression in a recombinant system (CHO K1), using a COOH-terminal-tag. 
 The original expression vector (pcDNA3.1) contained the coding sequence of human 
TMEM16A (kindly donated by Dr. J. Galietta, Laboratorio di Genetica Molecolare, 
Istituto Giannina Gaslini, and Centro di Biotecnologie Avanzate, Genova, Italy) 
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(empty vector in fig. 3.7, Invitrogen®). Dideoxy-nucleotide sequencing was 
performed in our laboratory previously. 
 
Fig. 3.7. pcDNA 3.1/V5-His-TOPO empty vector (Invitrogen®) with MCS region.         
 Human TMEM16A cDNA (NCBI Reference Sequence: NM_018043.5) was 
subcloned into pEYFP-N1 plasmid, containing EYFP (Enhanced Yellow Fluorescent 
Protein) coding sequence (kindly donated by Dr. Diego Alvarez De La Rosa, 
Departamentos de Fisiología y Farmacología, Instituto de Tecnologías Biomédicas, 
Facultad de Medicina, Universidad de La Laguna, La Laguna, Spain) (CLONTECH 
Laboratories, Inc.)(fig. 3.8). 
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Fig. 3.8. pEYFP-N1 empty vector (CLONTECH Laboratories, Inc.) with MCS region.         
  Enhanced Yellow Fluorescent Protein (EYFP) was in-frame fused to COOH-
terminus of hTMEM16A in pEYFP-N1 vector, to limit any possible functional 
alteration (more probable with EYFP-tagging at long hTMEM16A NH2-terminus).  
 First of all, a PCR reaction was performed  with primers specific for hTMEM16A, 
containing restriction sites for NheI and BamHI enzymes (in bold) using a 
proofreading DNA polymerase cocktail (Expand-High Fidelity PCR System kit, 
Roche-Applied Science®), according to manufacturer’s instructions. 
Forward primer: 5’-GCAGCTAGCGCCACCATGAGGGTCAACGAGAAGTAC-3’ 
Reverse primer: 5’-CGGTGGATCCCGCAGGACGCCCCCGTGGTA-3’ 
Reverse primer (sense sequence): 
5’-TACCACGGGGGCGTCCTGCGGGATCCACCG-3’ 
Amplicon: 2955 bp. 
 PCR product size and quality were assessed by agarose gel electrophoresis (1% 
agarose gel, ethidium bromide staining) and construct was extracted and purified with 
a commercially available kit (Illustra GFX PCR DNA & Gel Band Purification Kit - 
GE Healthcare), according to manufacturer’s instructions. 
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 After linearization with the appropriate restriction enzymes (Nhe1 and BamH1), 
constructs were dephosphorylated with APex™ Heat-Labile Alkaline Phosphatase 
(Epicentre®), to avoid vector recircularization, and finally purified. All purification 
steps were needed to remove salts, inhibitors of next treatments.  
 Ligation between the constructs was performed with Fast-Link ™ DNA Ligation Kits 
® (Epicentre) according to manufacturer’s instructions. Bacterial suspensions of 
DH5-α Escherichia coli strain (electrocompetent) were transformed with the resulting 
construct by heat-shock. As a comparison (negative control), another aliquot of 
bacterial suspension was transformed with linearized plasmid only. Transformed 
bacteria were plated into selection LB-BROTH medium with 10ug/ml kanamycin 
(proper antibiotic whose resistance is encoded by pEYP-N1 vector) and grown at 
incubator (37°C, 5% CO2). Plates seeded with both of the constructs or vector only 
were compared, counting number of grown colonies in each plate, as an estimate of 
relative probability to have successful transformation. Mini-preparations of constructs 
to be screened were made with DNA Mini-Prep kit ILLUSTRA Spin Kit ® (GE-
HEALTHCARE) and tested by agarose gel electrophoresis. Only one construct, with 
the most consistent molecular weight, according to theoretical of insert-containing 
vector (pEYFP-N1-hTMEM16A), was chosen to produce MIDI-preparations of 
plasmid DNA, from respective bacterial suspensions, using DNA Midi-Prep kit 
ILLUSTRA Spin Kit ® (GE-HEALTHCARE). Vectors were resuspended in water 
and quantified by absorption spectroscopy with a Nanodrop instrument (Thermo-
Scientific). 
 The chosen construct was employed for transfection of CHO K1 cell cultures, to 
confirm expression of fusion protein, through observation of fluorescence before next 
studies. Images were acquired with a FluoView 1000 confocal microscope (Olympus, 
Tokyo, Japan). Transfection details are described in section 3.2.8. 
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3.2.11 BIDIMENSIONAL SDS PAGE AND WESTERN BLOT 
 Proteomics is an approach recently established for large-scale study of protein 
structures and functions “Proteome" is fusion between "protein" and "genome" 
(Wilkins et al., 1996). Proteome is the whole set of protein products from an organism 
or system, variable depending on time, stimuli or stresses undergone by a cell or 
organism. 
 Among several techniques suitable for proteomic approach, we used 2-Dimensional 
SDS PAGE, capable of determining expression and post-translational modification of 
a complex mixture of proteins, by acrylamide gel electrophoresis in "two-
dimensions". Proteins are focused first in one direction, and then in another, to 
separate their modified and unmodified form.  
 Fusion protein hTMEM16A-EYFP was tested with 2-dimensional SDS Page, to 
determine the actual protein electrophoretic migration pattern, according its molecular 
weight and isoelectric point.  
 Before performing this experimental set, we calculated hTMEM16A protein (NCBI 
Reference Sequence: NP_060513.5) theoretical molecular weight and isoelectric point 
with prediction software provided by Massachusetts Institute of Technology 
(http://scansite.mit.edu/).  Particularly, we calculated values for hTMEM16A-EYFP 
fusion protein and hTMEM16A original protein to choose the suitable pH range for 
the first dimension and acrylamide concentration for the second gel electrophoresis. 
hTMEM16A predicted molecular weight was 114.1 kDa, isoelectric point 8.76 in the 
absence of phosphate groups (Tab. 3.1). hTMEM16A-EYFP predicted molecular 
weight was 125.4 kDa, isoelectric point 8.59, in absence of phosphate groups (Tab. 
3.2). 
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# Phosphates Molecular Weight Isoelectric Point 
0 114116,3352 8.76 
1 114194,2992 8.67 
2 114272,2632 8.57 
3 114350,2272 8.45 
4 114428,1912 8.31 
5 114506,1552 8.14 
6 114584,1192 7.92 
7 114662,0832 7.69 
8 114740,0472 7.48 
 
Tab. 3.1. Molecular weight (Da) and isoelectric point (pH values) prediction for hTMEM16A 
protein (NCBI Reference Sequence: NP_060513.5) +/- phosphate groups . Calculation performed 
with software on http://scansite.mit.edu/ webpage (Massachusetts Institute of Technology).   
 
# Phosphates Molecular Weight Isoelectric Point 
0 125,4359581 8.59 
1 125,5139221 8.48 
2 125,5918861 8.36 
3 125,6698501 8.20 
4 125,7478141 8.00 
5 125,8257781 7.76 
6 125,9037421 7.53 
7 125,9817061 7.34 
8 126,0596701 7.18 
 
Tab. 3.2. Molecular weight (Da) and isoelectric point (pH values) prediction for hTMEM16A-
EYFP fusion protein +/- phosphate groups. Calculation performed with software on 
http://scansite.mit.edu/ webpage (Massachusetts Institute of Technology).   
 
 
 
 EYP protein coding sequence in pEYFP-N1 vector (submission in progress on 
GenBank for corresponding cDNA): 
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K  L  E  Y  N  Y  N  S  H  N  V  Y  I  M  A  D  K  Q  K  N  G  I  K  V  N  F  K  I  R  H  N  I  E  D  G  S  V  Q  L  
A  D  H  Y  Q  Q  N  T  P  I  G  D  G  P  V  L  L  P  D  N  H  Y  L  S  Y  Q  S  A  L  S  K  D  P  N  E  K  R  D  H  
M  V  L  L  E  F  V  T  A  A  G  I  T  L  G  M  D  E  L  Y  K 
          
 CHO K1 cells were plated on 100mm Petri dishes (4,5 10
5
 cells/dish) and grown for 
2-3 days before transfection up to 95% confluence. hTMEM16A-EYFP cDNA was 
delivered to cells with lipofection (Lipofectamin2000 ®, INVITROGEN), at the ratio 
of 1:3 DNA-lipofectamine, or with PEI, (Polyethylene-imine, SIGMA®) at the ratio 
of 0,8/1,2ug: 3ul DNA:PEI (1 mg/ml).  
 One protein sample was tested on each 2-D gel. Membrane fractions from cell pellets 
were collected with a specific kit (Ready Prep Protein Extraction ®, BIORAD); 
complete cell lysis required sonication. Samples were then purified with Clean-up 
Ready Prep kit ® (BIORAD). Samples were resuspended in a specific buffer 
(Destreak ®, GE-HEALTHCARE) containing urea, carrier ampholytes and a reducing 
agent to solubilise proteins.  Samples were quantified using 2-D Quanti-IT kit ® (GE-
HEALTHCARE) kit, to control sufficient amounts of protein and not to overload gel.  
 Each sample (125 ul) was placed in contact with its own gel of the first dimension to 
be rehydrated. Gel consisted of a non linear gradient strip (ReadyStrip IPG Strip 
BIORAD), 7cm long, pH range 3-10.  
 Samples diffused passively during 1h incubation in an electrophoresis cell, then gels 
were placed in a tray (PROTEAN
®
  IEF System, BIORAD, fig. 3.9), covered by 
mineral oil (BIORAD) to avoid overwarming. Focusing was performed by applying a 
constant voltage, initially to allow active diffusion, then protein focusing, according to 
manufacturer’s instructions. 
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Fig. 3.9. Set-up of electrofocusing tray (PROTEAN
®
  IEF System, BIORAD).  
 After overnight isoelectrofocusing, the accumulated electric charge was greater than 
20,000 V. Strips were incubated in equilibration buffer I for 15’, to reduce sulphydryl 
groups, then in buffer II for 15’, to alkylate reduced sulphydryl groups, as described in 
Ready Strip IPG Instruction Manual (BIORAD), and finally in running buffer for gel 
electrophoresis.  
Each strip was placed on its own acrylamide gel to perform migration according 
molecular weight (dodecyl sulphate-polyacrylamide gel electrophoresis, SDS-PAGE). 
Resolving Gel: 8.5% Acrylamide, 1.5 M TRIS pH 8.8 at 25% v / v, SDS 0.1% w / v, 
APS 0.05% w / v, TEMED 5 * 10-4% v / v.  Gel Run:  160V  constant voltage.  
Gel transfer to polyvinylidene fluoride (PVDF) membrane was carried out at a 
constant current of 300 mA. System Mini-Protean ® III (BIORAD) was used for 
Western blot assay.  
 Non specific bindings to membranes were prevented with milk 5% solution in TBS 
(Tris-buffered saline) + Tween20 0,1% (Sigma). Membranes were then incubated 
with primary antibody anti-GFP 1:000 overnight (J-8 monoclonal, Living Colors® 
BD Biosciences), a mouse monoclonal (subclass IgG2a) that recognizes all GFP 
variants, including enhanced and destabilized proteins, fusions to these proteins, and 
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purified recombinant GFP. After appropriate washes to remove excess antibody, 
membranes were incubated with anti-mouse secondary antibody conjugated to Horse-
Radish-Peroxidase (HRP). At the end of  washings,  revelation was made with 
luminol-peroxide system (Immun-Star™ HRP Chemiluminescent Kit BIORAD), 
protein signal was detected with VersaDoc 4000 MP ® (BIO-RAD) imaging systems. 
 Detection of whole protein signals was performed also with Sypro-Ruby ® staining 
(BIO-RAD), a fluorescent probe that binds non-covalently to proteins with a detection 
limit of the order of 0.25- 1 ng. After 2-D electrophoresis, gels were fixed and 
incubated with probe and protein signals were checked under UV light. In this case, 
samples were membrane fractions from CHO K1 cells wild type (negative control) or 
CHO K1 cells transiently expressing hTMEM16A original protein (positive control).  
  
         
 
 
 
3.3 IN VIVO FUNCTIONAL EXPERIMENTS 
 
3.3.1 INSTRUMENTATION 
 In vivo functional experiments were performed with a perfusion system developed 
and used in our laboratory for several years (fig. 3.10). Round 25 mm diameter 
coversplips were used as cell growth substrate. When cells cultured reached 
confluence, coverslips were removed from 6well-plates and mounted on a perfusion 
chamber (oval-shaped, to allow a quick laminar flow). Chamber with coverslip was 
put on a thermo-regulated support (Warner Instrument Corporation™), to maintain 
temperature in chamber at 36°C-37°C steadily. Cells were observed with an inverted 
optical microscope Zeiss™ Axiovert 200, equipped  with xenon short arc lamp (75W 
XBO), through an oil immersion 40X objective.  
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Fig. 3.10. From left to right: inverted optical microscope Zeiss™ Axiovert 200 with perfusion  
system and CCD camera and shutter 10-C, thermo-regulated support and chamber for 
coverslips.  
 
 
 Experiments began with continuous perfusion of cells with PBS (10-12 ml/min), to 
stabilize temperature at 37°C, for at least 5’. Once the region of interest (ROI) had 
been selected, with software MetaFluor™ (Universal Imaging™, USA/Crisel 
Instrument™, Italy), image acquisition began. ROI contained at least 20-50 cells. Its 
average fluorescence was recorded, together with fluorescence of a background region 
(without cells), which was subtracted to ROI. Every experiment had its own ROI. If 
necessary, excitation light exposure duration and binning (number of image pixels, a 
resolution parameter) were modified to avoid an excessive effect of photobleaching 
and to obtain optimized fluorescence values. Photobleaching is YFP fluorescence 
decay due to excitation light exposure. 
 Observation of cells was made real-time. Every image was acquired with a CCD 
chamber (Coolsnap HQ CCD, Roper Scientific™) and the relative signals were 
recorded every 2”/5” with MetaFluor™ software. 
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YFP fluorescence was observed at these wavelength (λ):  excitation 500 ± 12.5 nm 
and emission 545 ± 17.5 nm; specific filters set used was XF104-2, OMEGA® 
optical.  
3.3.2 FUNCTIONAL DATA ANALYSIS 
 Raw data (absolute fluorescence) derived from experiments were saved with 
spreadsheet (Microsoft Office Excel). Afterwards data were analyzed with GraphPad 
Prism™ Software (GraphPad Software, Inc.). Data relative to resting fluorescence 
(F0) were analyzed to reduce photobleaching effects, which lead to fluorescence 
decay during experiments. Analysis method provided interpolation of values 
according to non linear regression with a one-phase exponential decay curve: result 
was a F0 theoretical curve for every instant. When cells were exposed to different 
compounds screened, the obtained fluorescence intensity (F) signals were normalized 
according to F0  to obtain  a relative fluorescence (RF) for every instant (F/F0).   
Average fluorescence variation and the associated SEM (Standard Error of the 
Mean)/n experiments were calculated for every experimental set.  
To determine the affinity of different purinergic receptor agonists or antagonists 
concentrations during influx and efflux phase  in stimulating iodide fluxes in FRTL-5 
cells, data obtained from experiments were analyzed using GraphPad software © and 
dose-response curve was obtained: 
(i). "fitting" of the data recorded was carried  in the last phase of  I
-
 influx and those 
obtained during I
-
 efflux, in particular since 30 cycles prior to the phase of efflux. 
"Fitting" of experimental data was done for each set of concentrations (0.1-100 uM) 
and was set or on a curve of association to an exponential phase (one-phase 
exponential association), or on a curve of association exponential two phases (two-
phase exponential association). According to obtained data, for each individual 
experiment, software choose the ideal curve approximation (Fig. 3.11 ). 
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Fig. 3.11. Representative graph of fitting between two single experiments. White dots: single 
experimental data from single acquisitions and the related best fitting curves.  
 
(ii). Derivative was calculated (Δy / Δx) for individual values on obtained curve. Data 
obtained from this function represent speed at which fluorescence is increased (Δf 
/Δt), the flow rate of I- at any single point, plotted as a function of time (t). Software 
selected the highest (max Δf /Δt) for each set and for each concentration (Fig. 3.12). 
  
Fig. 3.12. Representative graph. Fluorescence recovery maximum rate (Δf /Δt) (single data as a 
function of time) related to time  t (s
-1
). Data of two single experiments shown. 
 
(iii) Subsequently, it was set to a graph in which arises in connection with the 
recovery rate of fluorescence versus time (Δf /Δt) compared to the 3 agonists 
concentration (shown in logarithmic scale) (fig. 3.13). 
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Fig. 3.13. Representative graph (dose-response curve) to calculate agonist affinity with iodide 
efflux stimulation. Fluorescence recovery maximum rate (Δf /Δt) related to agonist concentration  
(uM), t (s
-1
). Logarithmic scale. 
 
 Statistical analysis of data relating to  maximum fluorescence recovery induced by 
different agonists/antagonists screened was performed with: T-test means of two 
groups, ANOVA more than two groups.. ANOVA one-way analysis and subsequently 
with Dunnett's multiple comparison test which compares each treatment compared to 
control.  
 
 
 
3.3.3 SOLUTIONS 
Cells were constantly perfused with a PBS (Phosphate-Buffered Saline) solution at 
7.4 pH. Components: 
 NaCl 137 mM; 
 KCl 2,7 mM; 
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 CaCl2 0,7 mM; 
 MgCl2 1,1 mM; 
 Na2HPO4 8,1 mM; 
 KH2PO4 1,5 mM; 
 Glucose 10 mM. 
Iodide flux experiments required addition of different compounds to PBS, putative 
agonists, antagonists or inhibitors of iodide efflux. Concentration range of agonists 
screened was 0.01-100uM. 
The effect of depolarization on iodide flux was analyzed perfusing FRTL-5 cells with 
K
+
-PBS solution: (tell substitution K instead of Na) influx clor and iodide substituted 
 NaCl 39,7 mM; 
 KCl 100 mM; 
 CaCl2 0,7 mM; 
 MgCl2 1,1 mM; 
 Na2HPO4 8,1 mM; 
 KH2PO4 1,5 mM; 
 Glucose 10mM. 
Intracellular Ca
2+
 and  BAPTA effect on iodide flux, stimulated by ATP and 
ionomycin, were performed using the following Ca
2+
-free PBS solution: 
 NaCl 137 mM; 
 KCl 2,7 mM; 
 MgCl2 1,1 mM; 
 Na2HPO4 8,1 mM; 
 KH2PO4 1,5 mM; 
 
82 
 
 Glucose 10 mM. 
 
Protocol used for iodide efflux experiments: 
 cells were perfused with PBS (pH 7.4) for 2’ (60 cycles), time usually 
required to observe a fluorescence stable baseline; 
 after, cells were perfused with  PBS+ NaI 100 µM to let iodide flow 
into them for 2’; 
 for 8’ image acquisition paused, keeping cells in PBS+ NaI 100 µM, 
to limit photobleaching effects; 
 cells were perfused with PBS/K-PBS+ stimulators or o PBS+ 
inhibitors (iodide efflux according to concentration gradient) for 2’. 
 In this kind of studies, images were acquired every 2” maintaining exposition time 
usually at 50 msec. 
 Before performing experiments, cells were incubated with BAPTA for some specific 
experiments, at 25 uM concentration, for 45’. BAPTA is a chelating agent for 
intracellular Ca
2+
. BAPTA-AM is acetoxymethyl ester form for BAPTA, is cell 
membrane permeable. Once inside cells, it is hydrolyzed by cell esterases. Result is 
active form (BAPTA), which chelates intracellular Ca
2+
 (fig. 3.14). 
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Fig. 3.14. BAPTA-AM action mechanism. Acetoxymethyl ester form for BAPTA (BAPTA-AM) is 
cell membrane permeable. Once inside cells, it is hydrolyzed by cell endogenous esterases into  
active form (BAPTA), which chelates intracellular Ca
2+
. 
 
3.3.4 INTRACELLULAR pH EXAMINATION WITH BCEF PROBE 
 FRTL-5 wild type were used to measure intracellular pH in functional in vivo 
experiments. Fluorescent BCECF (2,7,bis-carboxyethyl-5(6) carboxy-fluorescein) 
probe was employed. Also in this case the compound exists as membrane permeable  
acetoxymethyl ester (BCECF-AM), which enters whole cells and is converted into the 
acid form (BCECF) by cell esterases. This acid form is retained inside cells and shows 
a pH-dependent fluorescence response, because of its lateral chain bound to 
fluorescein, whose fluorescence intensity is progressively quenched by increasing 
acidity. Probe pKa is 6.98, suitable for cell analysis since their resting intracellular pH 
(pHi) is close (7.4).  
 BCECF is characterized by these wavelengths (λ): pH-independent excitation 440 nm 
and pH-dependent 490 nm (fig. 3.15). 
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Fig. 3.15. BCECF excitation spectrum at different wavelengths (λ). λ= 490 nm pH-dependent, λ= 
440 nm pH-independent. 
 
 
 
 
 Alterations in pH cause a shift in excitation wavelength, a fact that allows the use of 
the ratio between fluorescence signals (490/440) in order to normalize differences in 
probe loading among cells and photobleaching effects.  
 FRTL-5 were cultured on coverslips in 6well-plates as previously described. 5uM 
BCECF-AM, dissolved in 6H5 medium, was added to each coverslip fir 30’. Cells 
were washed with 6H5 medium twice and incubated in incubator 15’ again, to allow 
BCECF-AM hydrolysis. 
 BCECF fluorescence was observed with specific filters at these wavelength (λ): pH-
independent excitation 440 nm (XF1071) and pH-dependent 490 nm (XF1011) , 
emission 530 nm (XF3011). 
 Images were acquired every 5” with 10 ms exposition to avoid probe quick 
photobleaching effects. 
 For this kind of experiments, HBS (HEPES buffered saline)  was used, which 
consists of: 
 Hepes 10 mM 
 NaCl 140mM 
 KCl 5mM 
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 MgCl2 1,1mM 
 CaCl2 0,7mM 
 Finally pH was adjusted to 7.4 with 1M NaOH.  
 
 Calibration curve for pH was performed with 4 solutions characterized by different 
pH (6.5, 7, 7.5 e 8) and high K
+
 concentration (high K
+
-HBS), with the following 
components: 
 HEPES 10mM 
 NaCl 5mM 
 KCl 140mM 
 MgCl2 1,1mM 
 CaCl2 0,7mM  
 nigericin 7µM 
 Nigericin is a ionophore which allows a rapid equilibration of intra- and extracellular 
H
+
 and K
+
 ions. 
 Protocol used for experiments with BCECF probe: 
 cells were perfused with PBS (pH 7.4) for 2’ (12-24 cycles); 
 after, cells were perfused with HBS pH 7.4 for 2’; 
 cells were perfused with HBS pH 7.4+ 100 uM inhibitor for 2’; 
 cells were perfused with HBS pH 7.4 for 2’again; 
 after, for creation of calibration curve, cells were perfused with: 
 high K+-HBS pH 8  
 high K+-HBS pH 7.5 
 high K+-HBS pH 7 
 high K+-HBS pH 6.5 
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 Images were acquired every 5” with 10 ms exposition to avoid probe quick 
photobleaching effects. 
 
 
3.3.5 INTRACELLULAR Ca 
2+
 MEASUREMENT  WITH FURA-2 
 
 In vivo Ca
2+
i  measurement was performed using Fura-2 probe, in wild type FRTL-5. 
Fura-2 undergoes an absorption spectrum shift depending on free Ca
2+
i concentration. 
Without Ca
2+
i , Fura-2 has a peak at 380 nm in excitation spectrum, with a wide 
range. In a solution with Ca
2+
i , Fura-2 binds to it and its excitation peak shifts to 340 
nm. Bound to Ca
2+
i, Fura-2 emits an increased fluorescence (measured at 510 nm), 
without Ca
2+
i it is quenched (fig. 3.16). 
 
     
 
Fig. 3.16 Fura-2 absorbance spectrum at different wavelengths (λ) = 340, Ca 2+-dependent, λ= 380 
Ca 
2+
-dependent. 
 
 The protocol used was the same as BCECF. Cell-permeable AM-variant Fura-2 (1 
mM in DMSO), dissolved in 6H5, was added to each coverslip with cells (5 uM/ml 
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6H5) for 30’, then washes of cells with PBS twice and 15’ incubation again, to allow 
Fura-2 AM hydrolyzing by cell esterases.  
Fura-2 wavelength are: excitation 340 nm (detection filter XF1093) and 380 nm 
(detection filter XF1094), emission λ at 510 nm (detection filter XF3043). 
Images were acquired every 2” with an exposure of 10 ms. 
Solution used for this kind of experiment were PBS-based+ additives (compounds to 
test). 
  
 
 Protocol used for experiments with Fura-2 probe: 
 cells were perfused with PBS (pH 7.4) for 2’ (60 cycles); 
 after, cells were perfused with  PBS+ ATP 100uM+/-100 µM 
TA/FLUO/NFA or 25 uM BAPTA; 
 cells were perfused with PBS again 
 Images were acquired every 5” with exposition of 10 msec. 
 BCECF and Fura-2 are ratiometric probes: their shift based on pH/ Ca2+ fluctuations, 
allow correction of signal variations due to several parameters during experiments 
(i.e. probe accumulation, photobleaching, focalization plane shift, different optical 
pathway). Fluorescence signals were processed with excitation wavelength ratio 
(340/380 or 490/440) to evaluate the real intracellular [Ca
2
]/ pH. 
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3.3.6  YFP-H148Q/I152L PROTEIN PRODUCTION 
YFP-H148Q/I152L purified protein was used to detect direct interaction with 
screened compounds. To produce it, open reading frame (ORF) was cloned into a 
pGEX-4T-1 bacterial expression vector (GE Healthcare ©) (fig. 3.17), flanked by 
Glutathione S-transferase gene (GST). Fig. 3.18 shows YFP-H148Q/I152L sequence. 
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Fig. 3.17. pGEX-4T-1 bacterial expression empty vector (GE Healthcare ©). 
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Fig. 3.18 Coding sequence of YFP-H148Q/I152L (red: mutated aminoacids compared to original 
YFP protein) 
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Escherichia Coli (BL21 strain) bacteria were transformed with pGEX-4T-1-YFP-
H148Q/I152L vector with heat-shock. Protein production was induced with isopropyl-
β-D-tiogalatto-piranoside (IPTG, galattose-analogous inductor of genes under Lac 
operon control in E. Coli.). Bacterial lysis was performed with a lysis solution PBS 
50mM (pH 7.4) containing: 
 
 1% NP-40, 5mM EDTA; 
 0.4 mg/ml lysozyme and protein inhinbitors cocktail  (Roche®). 
 
 GST-YFP-H148Q/I152L fusion protein was purified with affinity chromatography 
using glutathione-agarose beads and eluted from column with a Cl
-
free buffer, which 
consisted of: 
 
 sodium phosphate buffer 50 mM (pH 8.8); 
 25mM reduced glutathione  
 200mM sodium gluconate. 
 
3.3.7  YFP AND CACC INHIBITORS DIRECT INTERACTION 
 
YFP purified protein extracts were employed to determine direct interaction among 
YFP and CaCC screened inhibitors (tannic acid, niflumic acid, fluoxetin). Solutions: 
 
 Sodium phosphate buffer pH 7.0 (SPB) 
 NaI 2 mM in SPB 
 NFA 300 µM in SPB 
 NFA 100 µM in SPB 
 NFA 300 µM + NaI 2mM in SPB 
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 NFA 100 µM + NaI 2mM in SPB 
 TA 100 µM in SPB 
 TA 100 µM + NaI 2mM  in SPB 
 FLUO 100 µM in SPB 
 FLUO 100 µM + NaI 2mM  in SPB 
 
Solutions prepared were diluted with YFP in SPB (1:1), put on coverslip and observed 
with a 20X objective. Three images were acquired every 3” and exposition time was 
500 msec. 
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CHAPTER   4 
 
RESULTS 
 
 
 
4.1 MOLECULAR CHARACTERIZATION OF TMEM16A IN 
THYROID GLAND 
 
4.1.1 TMEM16A mRNA EXPRESSION IN HUMAN NORMAL THYROID GLAND 
 
The molecular characterization of TMEM16A in human thyroid gland began  with 
assessment its transcriptional expression by RT-PCR. TMEM16A mRNA was 
detected in normal human thyroid tissue together with NIS, a specific marker for this 
tissue. Fig. 4.1  illustrates the results of a representative RT-PCR experiment on three 
independent human normal thyroid samples from different patients, showing specific 
bands for TMEM16A with the expected amplicon size (110 bp).  
 
 
Fig 4.1 Transcript expression in human thyroid gland (n=3). Left: signal of hGAPDH 
housekeeping gene mRNA (amplicon=69 bp), used as reaction positive control. Middle: 
hTMEM16A mRNA signal (amplicon=110 bp). Right: NIS mRNA gene signal used as thyroidal 
positive marker (amplicon=105 bp). RT- samples showed no signal (not shown).  
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4.1.2 TMEM16A mRNA EXPRESSION IN HUMAN THYROID GLAND: 
COMPARISON BETWEEN NORMAL AND TUMOUR 
 
 Since TMEM16A transcript was detected in human normal thyroid gland, the next 
step was to control its expression in tumor thyroid tissue. Fig. 4.2 shows TMEM16A 
expression in 3 independent normal and tumor thyroid samples. Every normal/tumour 
couple was from the same patient carrying thyroid papillary tumour (biopsy from 
healthy or tumor portion of the same sample). These result demonstrate that 
TMEM16A expression is maintained also in thyroid tumor tissue. (in contrast to NIS, 
decreased 2/3 samples). 
 
 
   
 
Fig. 4.2. Transcript expression in human thyroid gland (n=3 for coupled samples, + 3 normal 
samples). Upper image, left part: signal of h -actin housekeeping gene mRNA, used as technique 
positive control in 3 normal plus other 3 ,3 normal thyroid samples from different patients. 
Upper image, right part: NIS mRNA gene signal used as thyroid positive marker.  Bottom image: 
hTMEM16A mRNA signal in the same samples. RT- samples showed no signal (not shown). N: 
normal tissue; T: tumour tissue. 
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4.1.3 TMEM16A mRNA EXPRESSION IN FRTL-5 CELLS 
 
 Since positive results were obtained in thyroid tissue, research continued to verify if 
TMEM16A transcript were also expressed in FRTL-5 cells (from rat normal thyroid 
gland), used as an experimental model. TMEM16A mRNA was detected by RT-PCR 
with specific primers for rTMEM16A (fig. 4.3), indicating that this cell line could be 
employed as a model to study the channel functionally.  
 
 
 
Fig. 4.3. Transcript expression in FRTL-5 cells (representative experiment). From left to right: 
signal of h -actin housekeeping gene mRNA, used as reaction positive control, hTMEM16A 
mRNA signal, NIS mRNA gene signal used as thyroid positive marker.  RT- samples showed no 
signal (not shown).  
 
 
 
4.1.4 EFFECT OF TSH HORMONE ON TMEM16A mRNA IN FRTL-5 CELLS 
 
  TSH is the main physiologic/endogenous regulator of thyroid gland, therefore effect 
of TSH on TMEM16A mRNA expression was examined in FRTL-5 cells. (TSH is a 
component of cell culture medium..for differentiation etc) . Cells were grown to 50% 
confluence, followed by TSH deprivation and readdition. 
 The effect of TSH on TMEM16A mRNA levels was compared with the effect on NIS 
mRNA, since NIS is known to be regulated by TSH. Results are shown in fig. 4.4. 
Real Time PCR (Quantitative PCR) technique was used to detect and quantify 
rTMEM16A transcript levels. A “time course” analysis was performed: FRTL-5 cells, 
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deprived of TSH for one week, on 7
th
 day were treated differentially: some samples 
were maintained in TSH-free medium, other received TSH addition. Samples from 
both conditions (n=7) were collected after 6h, 12h, 24h to detect TSH-dependent 
changes in TMEM16A mRNA.  
 As expected, TSH deprivation led to a significant decrease of NIS transcript 
expression (100 fold less than control) and readdition of TSH partially restored NIS 
expression. In contrast, neither TSH deprivation nor readdition had any effect on 
TMEM16A mRNA expression levels (fig. 4.4). It remained high in both of 
conditions, suggesting that its expression is constitutive or at least TSH- independent.( 
p<0.0001.) 
 
 
 
 
 
Fig. 4.4.  Real Time PCR experiments with FRTL-5 cells (n=7). From left to right: NIS/ 
hTMEM16A mRNA signal on day 0, after 7 days +/-  TSH exposure : 0h, 6h,12h, 24h.   
h -actin housekeeping gene used as reaction  positive control. RT- samples showed no signal (not 
shown). NIS transcript decrease without TSH exposure in a statically significant manner 
p<0.0001. 
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4.1.5 EXPRESSION OF TMEM16A mRNA SPLICING ISOFORMS IN FRTL-5 
CELLS 
 
 Having confirmed TMEM16A mRNA expression in human thyroid gland samples 
and in FRTL-5 cells, the expression of TMEM16A alternative isoforms in FRTL-5 
cells was determined using primers specific for each isoform. Primers for segments b, 
c and d segments were designed for flanking regions, leading to two possible 
amplicon sizes representing the absence or presence or the corresponding segment: 
the lower band (175 bp for b, 118 for c, 230 for d) corresponds to the absence of 
segment in transcript, the upper to the presence of respective segment in transcript 
(amplicons: 241 for b, 130 for c, 305 for d). Primers for segment a were designed 
inside (amplicon: 267 bp). Fig. 4.6 shows results obtained. Amplicon specific for a 
segment was detected, thus it is contained in TMEM16 transcript expressed in 4 
independent samples of FRTL-5 cells. Both of amplicons specific for b segment were 
detected,  only the upper amplicon specific for c segment was detected, thus TMEM 
constitutively includes , only the lower amplicon specific for d segment was detected.  
Therefore, we concluded that TMEM16A/anoctamin-1alternative splicing isoforms 
expressed in FRTL-5 cells could include b segment, c segment was constitutively 
expressed but  d segment was not included.  
 TMEM16A mRNA alternative maturation isoforms are suggested to be TMEM16A 
“abc” and “ac” in FRTL-5 cells. 
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Fig. 4.5 Protein segments alternatively spliced in hTMEM16A. 
 
 
 
 
 
 
Fig.4.6. Upper line: TMEM16A transcript signal (305 bp) and b actin signal (hosekeeping gene). 
Lower line, from left to right: rTMEM16A mRNA signal related to a segment (amplicon 267 bp), 
b segment (amplicon 241/175 bp, b can be included or not in mature mRNA), c segment 
(amplicon 130/118 bp), d segment (amplicon 230 bp detected only, d segment not expressed), RT- 
samples showed no signal (not shown), (n=4 independent samples). 
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4.1.6 EXPRESSION OF ANOCTAMIN mRNA IN FRTL-5 CELLS. 
 
 In addition, (since TMEM16A belongs to family etc, containing conserved 
members,) the expression of these paralogs was also examined in FRTL-5 cells was 
checked with RT-PCR. Specific primers were used for every anoctamin to test 4 
independent FRTL-5 samples.   
 Clear expression in FRTL-5 cells was observed for: TMEM16A, TMEM16F, 
TMEM16K, TMEM16H (respective amplicons: 305 bp, 304 bp, 280 bp, 324 bp).   No 
signal was detected for either TMEM16B or TMEM16J (respective amplicons: 297 
bp, 327 bp). Variable signals for TMEM16C, TMEM16D, TMEM16E, TMEM16G 
were detected: TMEM16C and TMEM16G signals (respective amplicons : 290 bp, 
302 bp) were detected in ¾ samples, TMEM16D in ¼, TMEM16E (respective 
amplicons: 319 bp, 293 bp) in 2/4 samples faintly (fig. 4.7). 
 In conclusion, FRTL-5 showed a clear expression for TMEM16A, TMEM16F, 
TMEM16K, TMEM16H   anoctamin transcripts.  
 
 
 
 
 
Fig. 4.7. Expression of anoctamins in FRTL-5 cells. Up, from left to right: TMEM16A, 
TMEM16F, TMEM16K, TMEM16H, actin as housekeeping gene. Down, from left to right: 
TMEM16B, TMEM16C, TMEM16D, TMEM16E, TMEM16G, TMEM16J. RT- samples showed 
no signal (not shown), (n=4 independent samples). 
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4.2 FUNCTIONAL CHARACTERIZATION OF TMEM16A IN 
THYROID GLAND 
 
 Molecular characterization led to the conclusion that TMEM16A transcript is 
expressed in FRTL-5 cells. To determine whether TMEM16A is active in the thyroid 
gland as an anion channel, research continued by analyzing iodide transport in FRTL-
5 cells. Specifically anion transport in FRTL-5 cells was characterized to determine 
whether it is compatible with the known characteristics of CaCC/TMEM16A 
described in literature. 
 
4.2.1 IODIDE TRANSPORT IN THYROID CELLS: INFLUX ACTIVITY 
 
 Characterization experiments began with study of iodide influx in FRTL-5 cells, 
particularly selection clones that expressed YFP protein stably, as a halide biosensor 
(fig. 4.8, on the left). Galietta et al. (2001), measured I
-
 influx with YFP-
H148Q/I152L-based assay, as a model of Cl
-
 transport, because YFP-H148Q/I152L 
has higher affinity for I
-
 than Cl
-
. In this model, YFP-H148Q/I152L-expressing 
bronchial epithelium cells were perfused with solutions containing 100 mM, 
physiological concentration of Cl
-
. Partial substitution of extracellular Cl
-
 with the 
same amount of I
-
 allowed indirect analysis of Cl
-
  flux. We used this model to 
characterize I
- 
flux due to other halide transporters less specific than NIS in FRTL-5.
         
 
  
 
4.2.1.1 Characterization of  iodide flux in FRTL-5 cells 
 
Continuous perfusion system exposed cells first to a physiological buffer (PBS) to 
form and stabilize the baseline during initial stages of the observation. Then FRTL-5 
YFP-H148Q/I152L were exposed to PBS containing 100uM iodide, to study its influx 
specifically via NIS transporter, because NIS affinity constant is close to that value 
(Km ≈ 30uM). Cells showed a rapid decrease of fluorescence, indicator of iodide 
entry, of almost 50%  compared to baseline. (after removal of extracellular iodide led 
to recovery fluorescencelevel etc) . 
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Depriving cells of TSH from the culture medium for at least one week, absence of 
fluorescence decrease was noticed when perfused with PBS+100uM iodide. This 
indicated absence of iodide transport via NIS due to inhibition of its expression 
without TSH. In the same conditions, instead, perfusing cells with PBS+100mM, a 
conspicuous fluorescence decrease was observed anyway, although less than the 
previous condition (fig. 4.8, on the right). Such a decrease of fluorescence signal is 
due to iodide entry through other transporters or channels. 
 
 Described observations are compatible with NIS sensitivity at iodide concentrations 
of uM order, instead sensitivity of chloride channels is of  mM order.  
 
 In order to study TMEM16A function it is necessary to eliminate the contribution of 
NIS to iodide transport by maintaining FRTL-5 YFP-H148Q/I152L cells in a TSH-
free medium (5H5) for at least 1 week.  Under these conditions perfusion with a 
solution a 100mM external iodide concentration permitted the identification of iodide 
fluxes through pathways other than NIS. 
 
 
 
Fig.4.8 Left image: FRTL-5 Fischer rat thyroid cell line stably expressing YFP-H148Q/I152L, 
observed with inverted optical microscope at 40X objective (excitation 500 ± 12.5 nm and 
emission 545 ± 17.5 nm). Right image: iodide flow into FRTL-5 YFP-H148Q/I152L, absolute 
fluorescence is showed, exposed to 100uM/mM iodide, cultured with or without TSH for >1 wk). 
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4.2.1.2 Effect of nucleotides on iodide influx 
 
 Since TMEM16A is known to be stimulated by purinergic agonists, their effect on 
NIS-independent iodide influx in TSH deprived FRTL-5-YFP cells was examined. 
Cells were exposed to ATP UDP ADP added  to the  perfusion solution containing 
100mM K+I-. KI was used since TMEM16A is known to be activated by  
depolarization (Galietta et al., 2001). Particularly, exposure to nucleotides at different 
concentrations (0.1-100 uM) increasing the rate of decrease in fluorescence signal, All 
the three agonists let to a more rapid fluorescence decrease in response to iodide, 
suggesting that these agonists stimulated iodide influx. (fig.) This effect was 
concentration dependent for all three agonists, with the maximum effect occurring   at 
100uM. The affinity of each nucleotide was obtained from the concentration response 
curve obtained by plotting the maximum rate of fluorescence change against 
concentration (Fig. 4.9, bottom on the left, n=3-6 for ATP, n=4-6 for UTP, n= 4-6 for 
UTP).  Order of potency of agonists was  ATP > UTP > ADP . 
Since Depolarization activates (as previously mentioned) TMEM16A, stimulation of 
iodide influxes were examined in the presence of 100mM K (depolarization) or 
100mM Na (control). The result indicate that the affinity of ATP was increased , 
compatinble with known properties of TMEM16A.  (Fig. 4.9, bottom on the right).  
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Fig. 4.9 Upper images: fluorescence signals are shown as F/F0. FRTL-5 YFP-H148Q/I152L cells 
cultured in a TSH-free medium for at least 1 wk were exposed to 100mM K
+
I
-
 +/- ATP, UTP, 
ADP (0,1-100uM). Bottom images: fluorescence signals are showed as max rate (s-1) (influx), on 
the left nucleotide affinity curves are shown (fluorescence recovery rate versus time Δf /Δt for 
each nucleotide, compared to their concentration) on the right nucleotide affinity curves are 
shown in normal/depolarization conditions.(Logarithmic scale). 
 
 
4.2.1.3 Effect of calcium on iodide influx stimulated by ATP and ionomycin 
  
 Calcium effect on CaCC activity were characterized in FRTL-5 YFP-H148Q/I152L 
cells. Ionomycin was used as a ionophore, able to increase intracellular calcium 
concentration, rising permeability of cell and organelle membranes. Ionomycin is very 
powerful in stimulation of extracellular calcium entry and calcium release from 
intracellular stores through organelle membranes. It is active already at 1uM 
concentration. 
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 Exposition to ATP produced the same effect at 100uM concentration, thus it is 
revealed less powerful than ionomycin, already active at 1uM.  
 In fig. 4. 10 it can be seen a marked decrease of fluorescence signal due to calcium-
activated iodide entrance into FRTL-5 cells.  
 
 The next step was to establish if iodide influx were stimulated by calcium in PBS, so 
from extracellular compartment, or already present in cytoplasm, particularly from 
intracellular storage organelles. Therefore, FRTL-5 were exposed to PBS calcium-
free. Besides, a chelating of intracellular calcium, BAPTA, was used to remove 
calcium effect and to observe, intracellular calcium contribution on iodide entry 
mediated by CaCC. 
 
 In fig. 4.10 A control situation is shown. Perfusion solution (PBS) contains 
calcium (0,7 mM): expected iodide entry was observed into FRTL-5 in the 
presence of 1uM ionomycin and 100uM ATP compared to the baseline (n=6). 
 
 In fig. 4.10 B situation Ca2+-free is shown. With Ca2+-free PBS, iodide entry 
into FRTL-5 could still be observed, stimulated by ionomycin and ATP (n=5). 
 
 In fig. 4.10 C situation with BAPTA is shown. Cells were pre-incubated with 
25 uM BAPTA and perfused with Ca
2+
-free PBS. In this case a virtually 
complete inhibition of iodide influx could be observed. BAPTA, chelating 
intracellular calcium released from storage organelles, virtually removed every 
Ca
2+
 source from cells (n=3). 
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Fig. 4.10. Fluorescence signals are showed as F/F0. A, control situation: FRTL-5 YFP-
H148Q/I152L cells were perfused with KI PBS+calcium, then exposed to 1uM ionomycin and 
100uM ATP (n=6). B, situation Ca
2+
-free: Ca
2+
-free PBS perfused FRTL-5 (n=5). C, situation 
with BAPTA: cells were pre-incubated with 25 uM BAPTA and perfused with Ca
2+
-free PBS 
(n=3). 
 
  
In conclusion, results showed in FRTL-5 cells that calcium-activated iodide influx 
depended on intracellular calcium only, released from stores of intracellular 
organelles (as the endoplasmic reticulum). Ca
2+
-activated iodide flow properties, 
included activation by nucleotides and intracellular calcium, were coherent with 
known properties of TMEM16A calcium-activated channel. 
 
 
4.2.2 IODIDE TRANSPORT IN THYROID CELLS: EFFLUX ACTIVITY 
 
 NIS-independent iodide influx into FRTL-5, was revealed to have properties coherent 
to CaCC. Attention was focused on  activity of iodide efflux. 
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4.2.2.1 Use of a experimental model for iodide efflux studies: CHOK-1 cells 
 
To begin characterization of iodide efflux, the same experimental conditions were 
reproduced as described before: presence or absence of extracellular calcium in PBS,  
presence or absence of intracellular calcium released by storage organelles, chelated 
by BAPTA. Before undertaking a depth study about FRTL-5 thyroid cells, iodide 
transport was characterized in a model cell system, CHOK-1 cell lines, to find and 
optimize the best experimental conditions, and to confirm functional properties of 
currents due to TMEM16A. CHO K1 cells were chosen because of their good 
adhesion to substrate, feature suitable for functional experiments, and lack of known 
endogenous CaCC expression.  
 
4.2.2.2 Expression of TMEM16A mRNA in CHOK-1 wild type / NIS/ YFP-
hTMEM16A cells 
 First of all, the chosen experimental model CHOK-1 cells were considered about the 
endogenous TMEM16A expression. This study was carried out by RT-PCR, on wild 
type cells previously. Neither TMEM16A transcript expression was observed, nor 
evidence was found in literature so far, thus CHOK-1 cell lines were chosen as a 
model definitively.  
 Stable clones of CHOK-1, selected and established previously in our lab, expressing 
hNIS and YFP-H148Q/I152L were employed. Absence of endogenous TMEM16A 
mRNA expression was confirmed. Besides, maintenance of hNIS and YFP-
H148Q/I152L expression, after long culture and cryopreservation periods,  was 
verified before employing them in the next characterization functional studies. 
 
 Fig. 4.11 shows that CHOK-1- hNIS/YFP-H148Q/I152L stable clones do not express 
TMEM16A endogenously, thus they can be used as a cell model for negative control 
in functional experiments. Besides, cells preserve intact exogenous hNIS and YFP-
H148Q/I152L expression, and are adequate for functional characterization of iodide 
transport. Transfection with hTMEM16A cDNA led to transient exogenous 
expression of hTMEM16A by CHOK-1- hNIS/YFP-H148Q/I152L, detectable by RT-
PCR (fig. 4.11): amplicon specific for hTMEM16A (305 bp) was detected.  
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Fig. 4.11. From left to right, in duplicate samples of CHOK-1 YFP-H148Q/I152L/hNIS cells 
(control, C), transfected with pcDNA3.1 (mock, M), transfected (T) with pcDNA3.1hTMEM16A 
(expressing hTMEM16A transiently). Amplicon specific for hTMEM16A is detected (305 bp). 
 
 
 Since mRNA signal were detected in CHOK-1 expressing hTMEM16A transiently, 
this model cell was tested to know effects of exogenous hTMEM16 expression on 
iodide efflux, to be compared with putative endogenous CaCC/rTMEM16A 
functional activity expressed in FRTL-5 cell lines.  
 
4.2.2.3 Effect of ionomycin on iodide efflux in CHOK-1 wild type / NIS-YFP-
hTMEM16A cells 
 Calcium-activated iodide conductance in efflux, due to hTMEM16A transporter, 
expressed in stable clones CHOK-1-hNIS/YFP-H148Q/I152L transiently was 
evaluated. Aim was observation of efflux properties, to have a model of functional 
response and, going on with studies on FRTL-5, making a comparison between 
expected and obtained results observed in this model system.   
 Analogous experiments were performed, similar to experiments made to study iodide 
influx, adapting protocol to efflux situation. Perfusion solution (PBS as usual) 
contained 1uM ionomycin, to stimulate intracellular calcium concentration. First of 
all, clones without TMEM16A exogenous expression were used to detect any iodide 
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transport due to other endogenous transporters or to other isoforms belonging to 
anoctamin family.  
 Fig. 4.14 A shows CHOK-1-hNIS/YFP-H148Q/I152L cells perfused with 
PBS (control). 
 
  Fig. 4.14 E shows cells, pre-loaded with iodide, exposed to 1uM ionomycin 
for 2’. A small fluorescence decrease can be observed, likely due to pH 
variation provoked by ionomycin. 
 
 Fig. 4.14 B shows CHOK-1-hNIS/YFP-H148Q/I152L-pcDNA3.1 cells 
(mock), perfused with PBS in efflux stage (control) (n = 210 cells). 
 
  Fig. 4.14 F shows absence of iodide efflux in mock cells exposed to 1uM 
ionomycin, compared to control conditions. Cell clones are adequate negative 
controls, without detectable functional expression of transporters involved in 
calcium-activated iodide efflux (n =234 cells). 
 
 Finally, fig. 4.14 C shows CHOK-hNIS/YFP-H148Q/I152L stable clones with 
transient hTMEM16A expression perfused with PBS in efflux stage 
(control)(n =214 cells). 
 
 Fig. 4.14 G shows actual fluorescence increase in efflux stage with 1uM 
ionomycin in CHOK-hNIS/YFP-H148Q/I152L stable clones with transient 
hTMEM16A expression. After initial fluorescence decrease, due to 
extracellular iodide entry (10’ exposition to iodide 100uM as usual), 
exposition to PBS only let the “wash-out” of intracellular iodide slowly (20’ 
for a basal levels complete recovery), not detectable  during the short time 
interval considered. Instead, addition of ionomycin to cells provoked a rapid 
fluorescence decrease, due to iodide efflux out of cells. Particularly, 79/488 
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cells responded to ionomycin, depending on tranfection efficiency (qualitative 
and quantitative) (n=488 cells).  
 Observed properties of calcium-activated iodide efflux are compatible with known 
properties of TMEM16A calcium-activated channel. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.14. Fluorescence signals are showed as F/F0 . A: CHOK-1-hNIS/YFP-H148Q/I152L cells 
perfused with PBS (control).  E: cells exposed to 1uM ionomycin. B: CHOK-1-hNIS/YFP-
H148Q/I152L-pcDNA3.1 cells (mock)(PBS in efflux stage, control). F: mock cells exposed to 1uM 
ionomycin, compared to control conditions. C: CHOK-hNIS/YFP-H148Q/I152L stable clones 
with transient hTMEM16A expression (control), exposed to PBS in efflux stage. G: CHOK-
hNIS/YFP-H148Q/I152L-hTMEM16A cells exposed to 1uM ionomycin.  
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 In conclusion, it can be asserted that transient exogenous hTMEM16A expression, in 
CHOK-1-hNIS/YFP-H148Q/I152L stable cell clones, led to functional expression of 
a Ca
2+
-activated iodide transport in efflux, whose properties are coherent with 
characteristics of TMEM16A endogenously expressed, described in literature.  
 
 Then, characterization of Ca
2+
--activated iodide transport in efflux in FRTL-5 cell 
lines was started, to understand if it could take place via CaCC/TMEM16A 
endogenously expressed in FRTL-5 cells. The same experimental model was used, as 
previously: exposition of cells to PBS with 1uM ionomycin after verifying iodide 
influx into the cells.  
 
4.2.2.4 Effect of ionomycin and ATP on iodide efflux in FRTL-5 cells: calcium-
dependence  
 
 Analysis continued testing effect of calcium on iodide efflux in FRTL-5 cells. The 
same system was employed as described for iodide influx experiments: ionomycin or 
ATP to stimulate CaCC activity and intracellular calcium chelation with BAPTA.  
 Fig. 4.16 shows all performed conditions. Fig. 4.16 A, B, C show relative 
fluorescence due to iodide flow; fig. 4.16 D shows maximum rate of iodide flow 
(n=4). 
 
 A, control condition: FRTL-5 cells perfused with PBS+100uM iodide (10’as 
usual). Cells uptook iodide; during pause of image acquisition, iodide uptake 
reached the steady state. Following perfusion with PBS+100uM ATP or 
PBS+1uM ionomycin (2’ as usual) stimulated iodide efflux, with a maximum 
peak reached instantaneously. Cells perfused only with PBS showed a slow 
iodide efflux. 
 
 B, calcium-free condition: when iodide uptake reached the steady state,  
FRTL-5 cells were perfused with calcium-free PBS+100uM iodide. Calcium-
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free PBS+100uM ATP or calcium-free PBS+1uM ionomycin stimulated 
instantaneous iodide efflux, also in absence of extracellular calcium.  
 
 C, calcium-free condition+ BAPTA: FRTL-5 cells pre-incubated with BAPTA 
(45’ as usual) and perfused with calcium-free PBS+100uM iodide, when 
iodide uptake reached the steady state. PBS+100uM ATP or PBS+1uM 
ionomycin did not stimulate instantaneous iodide efflux in absence of 
intracellular calcium.  
 
 D, graph shows comparison among maximum rate of iodide efflux. 
Particularly, as it can be seen on the right, deprivation of intracellular calcium 
did not allow iodide efflux activation. 
 
 Also in iodide efflux stage, results suggested a fundamental role of intracellular 
calcium in activation of iodide efflux, which is extracellular calcium-independent. 
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Fig. 4.16. fluorescence signals are showed as F/F0. A, control condition: FRTL-5 cells perfused 
with PBS+100uM iodide, +/- 100uM ATP or 1uM ionomycin. B, calcium-free condition: FRTL-5 
cells were perfused with calcium-free PBS+100uM iodide +/- 100uM ATP or 1uM ionomycin. C, 
calcium-free condition+ BAPTA: FRTL-5 cells pre-incubated with BAPTA and perfused with 
calcium-free PBS+100uM iodide (n=4). D, comparison among maximum rate of iodide efflux. 
Data points or bars represent means ± standard errors of 4 measurements. 
 
 
 
 
4.2.2.5 Effect of receptor agonists on iodide efflux in FRTL-5 cells  
 Receptor agonists effect on iodide transport in efflux in FRTL-5 cells was 
characterized. Cells were exposed to increasing extracellular agonist concentration, to 
verify which agonists were the most effective. In general potency was revealed bigger 
at 100uM concentration. Agonists screened were ATP, epinephrine, dopamine, 
acetylcholine, histamine, serotonin (5HT), TSH. 
 
 Fig. 4.17 A: among tested agonists, only two produced iodide efflux responses, 
ATP and epinephrine (100uM)(2’ as usual). ATP-dependence and response 
entity were coherent with calcium-activated iodide current provoked by 
TMEM16A in CHOK-1-hNIS/YFP-H148Q/I152L-hTMEM16A, observed 
during previous experiments. With  the other agonists fluorescence recovery 
was similar to control. Dopamine and acetylcholine produced not reproducible 
responses.(n=6-11 for ATP and epinephrine, n=5-7 for dopamine, and 
acetylcholine, n=4-8 for histamine, TSH, 5-HT).   
 
 Fig. 4.17 B, only epinephrine and ATP produce a statistically significant 
response compared to control situation (p<0,01). 
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Fig. 4.17. Fluorescence signals are showed as F/F0. A: Tested agonists, ATP, epinephrine, 
dopamine, acetylcholine, histamine, serotonin, TSH. B, maximum rate in iodide efflux stimulated 
by screened agonists. Statistical analysis performed with ANOVA one way method (p< 0.0001), 
and  Dunnett’s multiple comparison post test to compare every treatment with control. (* : p< 
0,01). 
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4.2.2.6 Effect of ATP/UTP/ADP nucleotides on iodide efflux in FRTL-5 
 
 Sensitivity of iodide transporters, involved in observed efflux response, to 
nucleotides was analyzed. 
 
 Fig. 4.18 A: FRTL-5 cells exposed to different ATP nucleotide concentration 
(2’ as usual). Response of efflux caused by ATP was dose-dependent. Tested 
concentration in PBS were 1, 10, 100 uM: at increasing used concentration, 
response of efflux was more intense and showed the highest slope for every 
effective concentration, virtually instantly (n=6-11). 
 
 Fig. 4.18 B: same experiment was performed, using UTP nucleotide. Observed 
efflux responses had the same properties of those detected exposing FRTL-5 
cells to ATP. Responses were concentration-dependent and maximum at 
100uM concentration.    However,  entity of  induced response was less than 
the entity due to exposition to ATP, for every employed concentration (n=5-
7). 
 
 Fig. 4.18 C: exposition of FRTL-5 to increasing nucleotide concentrations, 
ADP in this case. Effect on efflux response was active but in a more modest 
manner compared to that detected with previous nucleotides, at 100uM ADP 
only (n=4-8). 
 
 Fig. 4.18 D: exposition to nucleotides let iodide efflux increase in a 
concentration-dependent manner with a potency order ATP > UTP > ADP 
(maximum rate graph that represents affinity curve for each agonist) (ATP 
Ec50=4,9 uM , UTP Ec50 =>10 uM, ADP Ec50=>100uM). 
 
 Fig. 4.18 E: depolarization conditions (100mM K+PBS) did not alter ATP 
affinity on its own receptors in FRTL-5 cells (curve slope not modified). 
 
 Fig. 4.18 F: chloride-free PBS conditions (100mM K+PBS) did not alter 
iodide efflux response in FRTL-5 cells. This activity was chloride-
independent. 
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 Hence, it can be asserted that response of iodide efflux is evoked in FRTL-5 in a 
concentration-dependent manner, with a maximum peak at 100uM, characterized by 
potency order of nucleotides on involved receptors below: ATP >UTP> ADP,  
compatible with P2Y receptor properties. Neither cell membrane depolarization nor 
chloride provoked effect on iodide efflux response in FRTL-5 cells. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.18. Fluorescence signals are showed as F/F0. A: FRTL-5 cells exposed to different ATP 
concentration (1, 10, 100 uM) (n=6-11).  B: same experiment was performed, using UTP 
nucleotide (n=5-7). C: exposition of FRTL-5 to increasing ADP nucleotide concentrations (n=4-8). 
D: fluorescence signals are showed as max rate (s-1) (influx), nucleotide affinity curves are shown 
for nucleotides ATP, UTP, ADP (fluorescence recovery rate versus time Δf /Δt for each 
nucleotide, compared to their concentration) (logarithmic scale) ) (ATP Ec50=4,9 uM , UTP Ec50 
=>10 uM, ADP Ec50=>100uM) . E: ATP affinity curves are shown in normal/depolarization 
conditions (100mM K+PBS). F: comparison between control and  chloride-free PBS conditions 
under ATP exposure. Data points or bars represent means ± standard errors. 
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4.2.2.7 Properties of ATP and calcium-mediated iodide efflux response in FRTL-5: 
duration 
 
 Iodide efflux stimulated by nucleotides, ATP particularly, and by cytoplasmic ATP 
increase, was characterized further to analyze its duration as well as its intensity. 
FRTL-5 cells were exposed to PBS containing 100uM iodide, 100uM ATP or 1uM 
ionomycin, as previously. 
 
 Fig. 4.19 A, exposition to PBS with 100uM iodide (10’) caused high iodide 
influx into cells, also up to 50% compared to baseline, as expected in FRTL-5 
cells cultured at usual conditions, with TSH. Afterwards cells were perfused 
with PBS, conditions which provoked iodide efflux as expected, through non-
specific transporters (n=1). 
 
 Fig. 4.19 B shows situation of perfusion with PBS, without 100uM iodide, 
with 100 uM ATP (20’), to check nucleotide effects in control conditions. No 
ATP-dependent effect was detected on baseline, except to a small fluorescence 
increase, likely caused by pH increase after exposition of the cells to ATP. 
 
 Fig. 4.19 C shows situation of perfusion with PBS, without 100uM iodide, 
with 1uM ionomycin (10’), to check effects of cytoplasmic calcium increase in 
control conditions. In this case, baseline was slightly increased, likely caused 
by pH increase after exposition of  cells to ionomycin. 
 
 Fig. 4.19 D shows situation of perfusion with PBS+100uM iodide (10’), then 
with PBS containing 100uM ATP (20’). A rapid response of efflux, developed 
virtually instantaneously, could be seen.  
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 Fig. 4.19 E, shows a different situation: in the efflux stage, FRTL-5 cells kept 
on being perfused with PBS+100uM iodide. Iodide efflux evoked by 
exposition with PBS+iodide+ATP100uM (20’) took place, response was rapid, 
instantaneous and intense but temporary: in few less than 10’, baseline was 
increased with a peak, as seen in control conditions + ATP100uM  but without 
iodide. However, the interesting result is that, immediately after, iodide began 
to enter the cells again, as it could be detected by fluorescence signal decrease. 
Thus, response of efflux is transient, with iodide perfused continuously, 
involved transporters and channels did not keep on responding to ATP.  
 
 Fig. 4.19 F: FRTL-5 cells were perfused before with PBS + 100uM iodide 
(10’), then with PBS + ionomycin 1uM (10’). A rapid response of efflux could 
be detected, developed virtually instantly. Contemporary presence of 
ionomycin allowed iodide efflux out of FRTL-5 cells anyway. 
 
 Fig. 4.19 G: during the efflux stage, FRTL-5 cells kept on perfusing with PBS 
containing 100uM iodide. Iodide efflux evoked by exposition with PBS and 
iodide+ionomycin (10’) took place, but contemporary presence of ionomycin 
and iodide did not allow complete iodide flow out of cells. A rapid and intense 
response of efflux was observed but, in 10’, baseline was increased with a well 
pronounced peak, as seen in control conditions with ionomycin but without 
iodide. However also in this case, immediately after, iodide began to enter the 
cells with bigger quickness compared to condition with ATP, as it could be 
detected by fluorescence signal decrease. Also in this case efflux response was 
transient, with iodide continuously, involved transporters and channels did not 
keep on responding to ionomycin. 
 
In conclusion, in the light of the obtained results, transporters and channels 
responsible of calcium-activated iodide efflux showed a rapid activation, virtually 
immediate but transient. This suggested that CaCC began insensitive with iodide 
perfused continuously after the first activation.  
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Fig. 4.19. Fluorescence signals are showed as F/F0. A: exposition of FRTL-5 to PBS with 100uM 
iodide (10’) and PBS on efflux stage. B: perfusion with PBS, without 100uM iodide, + 100 uM 
ATP (20’). C: perfusion with PBS, without 100uM iodide, + 1uM ionomycin (10’). D: perfusion 
with PBS+100uM iodide (10’), then with PBS + 100uM ATP (20’). E:during efflux stage, FRTL-5 
cells continuously perfused with PBS+100uM iodide.  F: FRTL-5 cells were perfused before with 
PBS + 100uM iodide (10’), then with PBS + ionomycin 1uM (10’).  G: during the efflux stage, 
FRTL-5 cells continuously perfused with PBS+100uM iodide , then with PBS and 
iodide+ionomycin (10’) (n=1). 
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4.2.2.8 Effect of catecholamines on iodide efflux  
 
Calcium-activated iodide efflux was characterized further, also considering receptor 
agonists of catecholaminergic system. FRTL-5 cells were perfused with PBS at 
increasing concentrations of epinephrine or norepinephrine to examine their effects 
and compare them with those detected during iodide influx studies in FRTL-5. Finally 
were compared effects of adrenergic antagonists to noepinephrine-induced iodide 
efflux. 
 
Effect of endogenous receptor agonists 
 
 Fig. 4.20 (upper, on the left): fluorescence signals are related to iodide efflux 
experiments, carried out exposing iodide-preloaded FRTL-5 cells to PBS+ 
epinephrine (epi) at concentration range of 0,01-10uM (2’). Response of 
calcium-activated iodide efflux was detected and resulted characterized by 
concentration-dependent intensity, with a maximum at 10uM. It showed a 
virtually immediate activation (a few seconds) (n=7-8) 
 
 Fig. 4.20 (bottom, on the right): the same kind of experiment can be seen, but 
exposing FRTL-5 cells to PBS+ norepinephrine (NE) at concentration range of 
0,01-10uM (2’). Response signals produced are similar for entity and 
properties, also in this case maximum at 10uM (n=5-6). 
 
Effect of endogenous and exogenous receptor agonists: comparison among affinities 
 
 Fig. 4.20 (bottom, on the left): comparison among affinities of different 
receptor agonists of catecholaminergic system, maximum rate affinity curve. 
Iodide-preloaded FRTL-5 were exposed to PBS+/- thyroid endogen/synthetic 
agonists (0.01-100uM, 2’).  Epinephrine and norepinephrine (selective α 
receptors more than β) were shown the most active on receptors involved in 
response, compared to other screened agonists, phenylephrine (PE) (selective 
for α1 receptors) and isoproterenol (iso) (selective for β receptors), at the same 
concentration range (synthetic agonists) (epinephrine Ec50=4.1uM, 
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norepinephrine Ec50= 5.1uM, phenylnephrine Ec50=3.7 uM). Isoproterenol did 
not induce any response. 
 
 Fig. 4.20 (bottom, on the right) shows comparison among effects of 
norepinephrine (NE, agonist) and prazosin (PRAZ), phentolamine (PHE), 
propranolol (PROP) (antagonists of catecholaminergic system, respectively 
selective for α1 receptors, α1/ α2, β) on norepinephrine-induced iodide efflux 
response. Graph shows maximum rate levels (affinity curves). Iodide-
preloaded FRTL-5 were exposed to PBS+/- thyroid antagonists (100uM, 2’).   
Prazosin and phentolamine showed to inhibit norepinephrine-activated iodide 
efflux response, propranolol showed to be inactive. 
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Fig. 4.20. Fluorescence signals are showed as F/F0. Upper images: FRTL-5 cells perfused with 
PBS+/- epinephrine (epi) (left,n=7-8) or PBS+/-norepinephrine (NE) (right, n=5-6) (0,01-10uM). 
Bottom images: fluorescence signals are showed as max rate (s-1) (influx), nucleotide affinity 
curves are shown for epinephrine, norepinephrine, phenylephrine (PE), isoproterenol (iso) 
(fluorescence recovery rate versus time Δf /Δt for each agonist, compared to their concentration) 
(logarithmic scale) ) (epinephrine Ec50=4.1 uM , norepinephrine Ec50 =5.1 uM, phenylephrine 
Ec50=3.7 uM ) at increasing concentrations (left); comparison among  affinities at 100 uM for 
antagonists (prazosin PRAZ, phentolamine PHE, propranolol PROP) +/- NE induced-iodide 
efflux response (right). Data points or bars represent means ± standard errors. 
 
 
4.2.2.9 Catecholaminergic receptorial agonists: effect of isoproterenol/isoprenaline on 
intracellular calcium.  
 
 
 As a cell model FRTL-5 cells not expressing YFP were employed. To measure 
intracellular calcium levels FURA-2 probe was used. 
 Cells were incubated 30’ membrane permeable FURA-2-AM form, hydrolysed by 
cell esterases to obtain FURA-2 active form. 
 Exposure of cells to various agonists tested (ATP, epinephrine or adrenaline, 
norepinephrine, or noradrenaline, isoprenaline and dopamine) increased intracellular 
levels of calcium. 
 In particular, ATP caused the highest increase in intracellular calcium levels among 
all the agonists screened (fig. 4.21), consistent with the most active stimulation of 
CaCC produced by ATP, as seen in fig. 4.18.  
 Interestingly, isoprenaline induces increase in intracellular calcium levels, although 
lower than the other agonists (fig. 4.21). Previously, it was seen that this agonist was 
not able to stimulate iodide efflux. These data suggested the existence of a threshold 
level of intracellular calcium, above which activates the channel. 
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Fig. 4.21. Fluorescence signals are showed as F340/F380 of fura-2 probe. Adrenaline/epinephrine, 
noradrealine/norepinephrine, isoprenaline/isoproterenol, dopamine agonists tested on FRTL-5 
cells. Single representative experiment. 
 
4.2.2.10 Effect of Ca 
2+
 on iodide efflux stimulated by epinephrine  
 
 Similarly, effect of epinephrine was tested, to confirm if it could stimulate CaCC 
activity also in efflux stage, checking also its dependence on calcium.  
 Fig. 4.22 shows all performed conditions. Fig. 4.22 A, B, C show relative 
fluorescence due to iodide flow; fig. 4.22 D shows maximum rate of iodide flow 
(n=3-5). 
 
 A: control condition. FRTL-5 cells perfused with PBS+100uM iodide (10’). 
Cells uptook iodide; during pause of image acquisition, iodide uptake reached 
the steady state. Following perfusion with PBS+100uM epinephrine (1’) 
stimulated iodide efflux, with a maximum peak reached instantaneously. Cells 
perfused only with PBS show a slow iodide efflux (recovery in almost 20’). 
 B: calcium-free condition. When iodide uptake reached the steady state,  
FRTL-5 cells were perfused with calcium-free PBS+100uM iodide (2’). 
Calcium-free PBS+100uM epinephrine (1’)  stimulated instantaneous iodide 
efflux, also in absence of extracellular calcium, but less than control condition 
(PBS).  
 Calcium-free condition+ BAPTA: FRTL-5 cells pre-incubated with BAPTA 
(45’), preloaded with PBS+100uM iodide (10’)  and perfused with calcium-
free PBS+100uM iodide (1’). Calcium-free PBS+100uM epinephrine (1’) did 
not stimulate iodide efflux.  
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 Graph shows comparison among maximum rate of iodide efflux in all the 
conditions. In the middle condition B is showed: absence of extracellular 
calcium activated iodide efflux but with a rate smaller than control situation.      
On the right condition C is showed: deprivation of intracellular calcium did 
not allow iodide efflux activation. 
 
Effect of extracellular calcium on epinephrine-activated iodide efflux appears more 
marked than ATP or ionomycin. Lack of extracellular calcium did not allow the same 
instantaneous iodide efflux as seen in control condition. Lack of extracellular calcium 
and total depletion of intracellular calcium with BAPTA blocked every iodide efflux 
response.  
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Fig. 4.22. Fluorescence signals are showed as F/F0. A: FRTL-5 cells perfused with PBS+/- 
epinephrine (100uM) (control). B: FRTL-5 cells perfused with PBS+/- epinephrine (100uM) (in 
Ca
2+
 free PBS). C: FRTL-5 cells, pre-incubated with BAPTA,  perfused with PBS+/- epinephrine 
(100uM) (in Ca
2+
 free PBS) (n=3-5). D: maximum rate graph of the three conditions described: 
effects of perfusion with PBS, Ca
2+
 free PBS, Ca
2+
 free PBS + BAPTA on epi stimulated iodide 
efflux. Data points or bars represent means ± standard errors of  3-5 measurements. 
 
 
 
 
 
 
 
 
 
 
 
4.2.2.11 Effect of CaCC/TMEM16A inhibitors on iodide efflux stimulated by ATP 
 
 Specific CaCC inhibitors described in literature: niflumic acid (NFA), tannic acid 
(TA), were screened to detect any effect on iodide efflux stimulated by ATP (n=6-7). 
 
 Fig. 4.23 A (left): control condition: FRTL-5 cells pre-loaded with 
PBS+100uM iodide (10’). Perfusion with NFA/TA 100uM showed no effect 
on iodide basal efflux. Interestingly, TA produced a increased basal iodide 
level, as shown with fluorescence baseline lowering after acquisition pause, 
compared to control. 
 
 Fig. 4.23 A (right): ATP effect (100uM). FRTL-5 cells pre-loaded with 
PBS+100uM iodide (10’). Perfusion with NFA/TA 100uM  inhibited rapid 
ATP-stimulated iodide efflux: NFA partly, TA completely, producing, also in 
this case, a increased basal iodide level, as shown with fluorescence baseline 
lowering after acquisition pause, compared to control. 
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 Fig. 4.23 B (left): maximum rate graph for conditions described below with 
comparison between influx and efflux stages. TA inhibited iodide efflux and 
increased basal iodide level in a statistically significant manner. 
 
 Fig. 4.23 B (right): steady state graph for conditions described below. TA and 
NFA inhibited iodide efflux a statistically significant manner (p< 0,01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
   
Fig. 4.23. Fluorescence signals are showed as F/F0. A (left): FRTL-5 cells perfused with PBS+/- 
NFA/TA (100uM) (control). A (right): FRTL-5 cells perfused with PBS+/- NFA/TA (100uM) 
(+ATP 100uM) (n=6-7). B (left): maximum rate graph for conditions described below. B (right): 
steady state graph for conditions described below. Statistical analysis performed with ANOVA 
one way method (p< 0.0001), and  Dunnett’s multiple comparison post test to compare every 
treatment with control. (* : p< 0,01). 
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4.2.2.12 Effect of CaCC/TMEM16A inhibitors on iodide efflux stimulated by 
epinephrine and comparison with iodide efflux stimulated by ATP  
 
Specific CaCC inhibitors described in literature: niflumic acid (NFA), tannic acid 
(TA), were screened to detect any effect on iodide efflux stimulated by epinephrine. 
 
 Fig. 4.24 A: control condition: FRTL-5 cells pre-loaded with PBS+100uM 
iodide (10’). Perfusion with NFA/TA 100uM (100uM)  showed no effect on 
iodide basal efflux. Also in this condition, TA produced a increased basal 
iodide level, as shown with fluorescence baseline lowering after acquisition 
pause, compared to control. 
 
 Fig. 4.24 B: epinephrine effect (100uM). FRTL-5 cells pre-loaded with 
PBS+100uM iodide (10’). Perfusion with NFA/TA 100uM inhibited rapid 
epinephrine-stimulated iodide efflux: NFA partly, TA completely, producing, 
also in this case, a increased basal iodide level, as shown with fluorescence 
baseline lowering after acquisition pause, compared to control. 
 
 Fig. 4.24 C: maximum rate graph for conditions described below with 
comparison between influx and efflux stages. TA inhibited iodide efflux and 
increased basal iodide level in a statistically significant manner, presumilbly 
for increased iodide retention inside cells (p< 0.01). 
 
 Fig 4.24 (bottom): comparison between maximum rate graphs of  ATP and 
epinephrine-stimulated iodide efflux response. TA and NFA blocked iodide 
efflux response in both cases (ATP and epinephrine). 
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Fig. 4.24. Fluorescence signals are showed as F/F0. A: FRTL-5 cells perfused with PBS+/- 
NFA/TA (100uM) (control). B: FRTL-5 cells perfused with PBS+/- NFA/TA (100uM) 
(+epinephrine 100uM). C: maximum rate graph for conditions described below. Statistical 
analysis performed with ANOVA one way method (p< 0.0001), and Dunnett’s multiple 
comparison post test to compare every treatment with control. (* : p< 0,01). Bottom: comparison 
between maximum rate graphs of  ATP and epinephrine-stimulated iodide efflux response. Data 
points or bars represent means ± standard errors of  measurements. 
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4.2.2.13 YFP protein binding assay with iodide efflux inhibitors 
 
 
Detected effect of iodide efflux inhibition was tested, to understand possible non 
specific effects of inhibitors rather than an actual effect on CaCC in FRTL-5 cells 
during iodide efflux stage. Niflumic acid (NFA) and tannic acid (TA) were tested. 
 
 Fig. 4.25 A: Fluorescence signals are showed as F/F0; FRTL-5 cells were 
perfused with PBS+/- NFA/TA (100uM) (5’) (control). TA produced  
quenching of YFP resting fluorescence  (10%) , while NFA quenched resting 
YFP fluorescence more (25%), plateaux reached after 5’ and complete 
fluorescence recovery after other 5’. 
 
To detect mechanism which altered YFP fluorescence by inhibitors, possible 
intracellular pH variations and binding with YFP were considered in different buffers 
(SPB and HEPES). 
 
 Fig. 4.25 B: detection of inhibitors-dependent intracellular pH variations. 
FRTL-5 cells were perfused with PBS+/- NFA/TA (100uM) (5’). pH signal 
was detected with BCECF probe and resulted decreased (>10%) during 
exposition with NFA. TA showed no effect on intracellular pH. 
 
 Fig. 4.25 C: YFP protein-binding assays with TA/NFA (0-100uM) (relative 
fluorescence, control fluorescence: 100%). NFA showed no effect on YFP 
purified protein fluorescence, while TA produced more quenching of YFP 
fluorescence at increasing TA concentrations employed (10-30-100 uM), up to 
80% with 100uM TA.. 
 
 Fig. 4.25 D:   affinity curve for iodide of TA(10uM)  and NFA. Both of 
inhibitors produced no effect on YFP affinity for iodide.  
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 Taken together, these results suggested that NFA effect on iodide efflux was due 
partially to its acidification effect inside cells but not to direct binding to YFP protein 
expressed exogenously by FRTL-5 cells. Different buffers used (SPB and HEPES) 
did not alter fluorescence YFP, which is only dose-dependent.  
 TA showed to have a effect on intracellular acidification and, interestingly, seemed to 
have a direct binding with YFP protein, since interaction between TA and YFP 
purified protein led to fluorescence quenching. 
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Fig. 4.25. A: Fluorescence signals are showed as F/F0; FRTL-5 cells perfused with PBS+/- 
NFA/TA (100uM) (control). B: detection of inhibitors-dependent intracellular pH variations. C: 
YFP protein-binding assays with TA/NFA (relative fluorescence, control fluorescence: 100%). 
Data points or bars represent means ± standard errors of 3 measurements. D:   affinity curve for 
iodide of TA and NFA. TA IC50 1.4 mM (TA 10uM), Control IC50 0.98 mM. (IC: intracellular 
concentration). 
 
 
4.2.2.14 Effect of RNA interference on rTMEM16A transcript in FRTL-5 
 
 Endogenous rTMEM16A transcriptional expression knock-down was performed with 
three different siRNAs specifically designed against TMEM16A (#75, #76, #77, 
Sigma) and three different constructs for delivery into cells.  
FRTL-5 YFP-H148Q/I152L cells were treated to siRNA constructs for 2 or 5 days 
with three delivery systems: 
 
 Fig. 4.26 A: FRTL-5 were exposed to N-TER nanoparticles™ and 100nM 
siRNAs against TMEM16A (#75, #76, #77, Sigma) for 2 days. The first 
experiment seemed to show a knock-down of rTMEM16A transcript, whose 
levels were almost 2 fold less than control samples, while the other 
experiments showed decreased rTMEM16A transcript also without specific 
siRNA (with buffer blank, universal negative control siRNA, no treatment). 
Low knock-down signals probably resulted by low transfection efficiency in 
FRTL-5 cells. This evidence suggested that system could be used but with 
optimized experimental conditions (n=3-4). 
 
 Fig. 4.26 B: FRTL-5 were exposed to N-TER nanoparticles™ and 100nM 
siRNAs against TMEM16A (#75, #76, #77, Sigma) for 5 days. Not marked 
knock-down effect, observed after 2 days, was lost after 5 days of treatment, 
suggesting a short-term effect of mRNA silencing.  
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 Fig. 4.26 C: FRTL-5 were exposed to Lipofectamine 2000® (lipo) and  to 
Superfect®  (SF) and 50/100nM siRNAs against TMEM16A (#75, #76, #77, 
Sigma) for 2 days. No evidence of knock-down could be detected with this 
construct. 
 
 Fig. 4.26 D: Mean + SEM graph for 2 days N-TER reagent treatment, for n=3 
independent experiments. Exposure  to specific siRNA against rTMEM16A 
produce a two-fold decrease in rTMEM16A expression compared to control. 
 
 
 
Results appeared difficult to interpret so far, acid nucleic delivery conditions have to 
be improved to obtain reproducible and significant effects. 
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Fig. 4.26. RNA interference of rTMEM16A in FRTL-5 cells with different techniques. A: 2 days-
treatment with N-TER™ nanoparticle and three different siRNA (100 nM) against TMEM16A 
(n=3-4). B: 5 days-treatment with N-TER reagent.. C: 2 days-treatment with Superfect®, 
Lipofectamine 2000® and three different siRNA (50/100 nM) against rTMEM16A (n=1). D: 
Mean+SEM for siRNA treatment against rTMEM16A with N-TER reagent (2 days, n=3). 
 
 
Effect of RNA interference of TMEM16A transcript on ATP-induced iodide efflux 
response in FRTL-5 
 
 After TMEM16A transcriptional expression knock-down and functional 
characterization of calcium-activated iodide efflux in FRTL-5, effects of TMEM16A 
mRNA interference was checked also at functional level, to detect any consequent 
variations in iodide efflux response . 
 FRTL-5 cells were treated to siRNA constructs for 2 days with three different 
siRNAs specifically designed against TMEM16A (100nM) SASI_Rn02_00230075, 
SASI_Rn02_00230076, SASI_Rn02_00230077 (Sigma), using N-TER 
nanoparticles™ (Sigma). (Single representative experiments, n=19-24 cells). 
 
 
 Fig. 4.27 up: FRTL-5 cells, treated with  specific siRNA#76 (100uM) against 
TMEM16A mRNA for 2 days, perfused with PBS+ATP 100uM in efflux 
stage, responding/not responsing to ATP.  
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 Fig. 4.27 bottom: FRTL-5 cells, treated with universal negative control 
(100uM) for siRNA for 2 days, perfused with PBS+ATP 100uM in efflux 
stage, responding/ not responding to ATP. 
 
 Among the tested cells were excluded those that were unable to load iodide, probably 
because of toxicity effect of buffer or silencing-induced cellular stress, with resulting 
depriovation of a a gene product necessary for normal function, as putatively 
TMEM16A is for thyroid cells. 
 An effective suppression of the activation of efflux of iodide induced by ATP 
following treatment with the siRNA 76 (4.27). Considering, however, the toxic effects 
of treatment and the low transfection efficiency data are difficult to interpret. 
 Several cells treated with siRNA against TMEM16A showed blockade in ATP-
induced iodide efflux. Response induced in the other cells probably was due to little 
efficacy of treatment, since FRTL-5 cells are characterized by low transfection 
efficiency. This evidence suggested that system could be used but with optimized 
experimental conditions. 
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Fig. 4.27. Fluorescence signals are showed as F/F0  . FRTL-5 cells preloaded with PBS+I- 100uM 
and perfused with PBS+/- ATP 100uM. Up: FRTL-5 cells, treated with  specific siRNA#76 against 
TMEM16A mRNA, perfused with PBS+ATP 100uM in efflux stage, responding (16) or not 
responding (3) to ATP. Bottom: FRTL-5  cells, treated with universal negative control for siRNA, 
perfused with PBS+ATP 100uM in efflux stage, responding (12) to ATP. Single representative 
experiment for each figure. Black lines: mean signal from single cell in one experiment. 
 
 
 
4.3 ONGOING EXPERIMENTS 
 
 Recently, molecular analysis of TMEM16A was enriched with study of protein 
expression. This aspect was developed at Dr. Diego Alvarez De La Rosa Rodríguez’s 
laboratory, Pharmacology Unit, Canary University Hospital, La Laguna University, 
Tenerife.  
4.3.1 DETECTION OF hTMEM16A-EYFP PROTEIN IN CHO K1 hTMEM16A 
CELLS 
 
 First of all, hTMEM16A was expressed in CHO K1 cells transiently. Membrane 
proteins were obtained from CHO K1-hTMEM16A cell samples and tested with 2-D 
electrophoresis. Before performing proteomic experimental set, prediction of 
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hTMEM16A isoelectric point and molecular weight was calculated with specific 
software found on http://scansite.mit.edu/. Check of human TMEM16A protein  
NCBI Reference Sequence, NP_060513.5,  and EYFP  sequence showed predicted 
molecular weight of 114,1 kDa  and 11,3 kDa respectively, and an isoelectric point                
of 8,76 and 5,90 respectively, in absence of phosphates groups. Addiction of more  
phosphate groups should make proteins more acid, as showed in section 3.2.11.     
According to these predictions, first dimension was tested with a 3-10 pH range, 
second dimension with 8,5% acrylamide concentration in electrophoresis gel. More 
than 100ug membrane proteins were loaded for each sample. Gel stained was made 
with Sypro Ruby® (Sigma), a fluorescent probe, and detected under UV light. 
Fig. 4.28 shows two gels. The initial approach to detect the right spot pattern, 
coherent with hTMEM16A predicted parameters, was comparison between wild type 
CHO K1 and CHO K1 expressing  hTMEM16A transiently.  
 Left fig.: membrane fractions from wild type  CHOK-1 (negative control) do 
showed no spot in 8-10 pH range. A group of spots could be detected, as 
expected, at 6-7 pH range. 
 Right fig.:  membrane fractions from CHOK-1-hTMEM16A showed a group 
of close spots: interestingly, after electrophoretic migration, this spot group, 
not detected in control samples, was localized in a region coherent with 
hTMEM16A predicted molecular weight and isoelectric point (114,1 kDa and 
8,76 pH). Also here, as found in control samples, a group of spots could be 
detected at 6-7 pH range, with a shift on the right compared to control, maybe 
due to a sample artefact.  
 Comparing the two gels (control/exogenous hTMEM16A) some protein spots 
detected in recombinant system were absent in negative control. Their location 
was actually compatible with predicted isoelectric point and molecular weight. 
 
 This preliminary result (n=1) suggested that proteomic approach could be used to 
detect proteins with migration pattern compatible with hTMEM16A. One or more 
spots could be hTMEM16A protein signals, suitable for next sequencing with 
MALDI-TOF technique.   
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Fig. 4.28. Sypro Ruby® staining of 2-D electrophoresis gel. First dimension: 3-10 pH range; 
second dimension: gel with 8,5% acrylamide. Left image: >100 ug membrane protein loaded 
(n=1) from wild type CHO K1. Right image: >100 ug membrane protein loaded (n=1) from CHO 
K1 expressing  hTMEM16A transiently.  
 
 
 
 
4.3.2 DETECTION OF hTMEM16A-EYFP PROTEIN IN CHO K1 hTMEM16A-EYFP 
CELLS  
 
 After the first preliminary result, detection system was performed: membrane protein 
samples from CHO K1 expressing hTMEM16A-EYFP fusion protein transiently were 
tested with Western Blot technique, detecting protein signal with monoclonal 
antibody against pan-FP, to have a specific spot to compare with the previous 
approach. 
Fig. 4.29 shows two different acrylamide gels, to compare protein signal obtained 
with staining and antibody recognition and to identify putative hTMEM16A protein 
signal more precisely.  
  Left: the same gel showed in lower fig. 4.29, membrane fractions from 
CHOK-1-hTMEM16A showed a group of close protein spots in 8-10 pH 
range.  
 
 Right: 2-D electrophoresis of membrane fractions from CHOK-1-
hTMEM16A-EYFP revealed two spots in 100-150 kDa range. Predicted 
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molecular weight of fusion protein was 125,4 kDa, coherent with detected 
signals, and isoelectric point 8,6 pH or less depending on phosphate groups 
added to TMEM16A during post-translational modification processes.  
Probably the lowest signal detected post-translational modification-free 
hTMEM16A-EYFP form, the highest detected a protein form with two 
putative post-translational modifications: one phosphorylation, which 
decreases pI, and one glycosylation, which increases molecular weight.  
 
 Taken together, these preliminary results suggested that proteomic approach could be 
employed to characterize hTMEM16A protein in several aspects, such as post-
translational modifications, and represent another useful  protein detection system to 
be compared with specific antibodies recognition, once available.  
 
 
 
 
 
Fig. 4.29. Left image: Sypro Ruby® staining of a 2-D electrophoresis gel. First dimension: 3-10 
pH range; second dimension: gel with 8,5% acrylamide. >100 ug membrane protein loaded (n=1) 
from CHO K1 expressing  hTMEM16A transiently. Right image: Western Blot of a 2-D 
electrophoresis gel. >100 ug membrane protein loaded (n=1) from CHO K1 expressing  
hTMEM16A-EYFP transiently.  
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CHAPTER   5 
 
DISCUSSION 
 
 Topic of our research is iodide transport in thyroid follicular cells. Iodide influx into 
thyrocytes through their basolateral membrane is well known, but less is known about 
iodide efflux through apical membrane, towards the follicular lumen. Among the 
feasible involved proteins, a novel calcium-activated chloride channel, 
TMEM16A/ANO1 (Galietta et al., 2008, Yang et al., 2008, Schroeder et al, 2008), 
seems to have adequate properties to exert a role in this activity. This channel belongs 
to a family of protein, “anoctamins”, with specific structural and functional features: 
eight transmembrane domains and involvement in anion transport.  So far, known 
members of this family are ten in humans, called TMEM16A/ANO1, 
TMEM16B/ANO2 up to TMEM16K/ANO10) (Schreiber et al., 2010). 
 
 Published results on mouse tissues (Schreiber et al., 2010) showed that ANO1, 6, 7, 
8, 9, 10 were mostly expressed in epithelial tissues, while ANO2, 3, 4, 5 were 
common in neuronal and muscle tissues. When expressed in Fisher Rat Thyroid 
(FTR) cells (polarized but not differentiated cell line), all anoctamins localized to 
plasma membrane but only ANO1, 2, 6, and 7 produced CaCC. ANO1, ANO6 and 10 
produced chloride currents, very different on to each other. It seemed that each tissue 
was characterized by its own anoctamin expression pattern, a tissue-specific set, to 
produce tissue specific CaCC (Ca 
2+
 activated chloride conductance) (Schreiber et al., 
2010). 
 
 Gene expression profiles, available on BioGPS portal (http://biogps. gnf.org),  
suggested that TMEM16A was expressed in tissues (human, mouse, rat) with different 
levels and, particularly, up-regulated in some tumours (i.e. human colon carcinoma).   
In human thyroid gland TMEM16A seemed to be expressed more than background 
expression levels. 
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 According to this, TMEM16A was chosen  as a object of study, putative responsible 
of CaCC in thyroid gland, among other anoctamins with a known CaCC function:  
TMEM16A/ANO1, TMEM16B/ANO2, TMEM16B/ANO2, TMEM16F/ANO6, 
TMEM16H/ANO8, TMEM16K/ANO10 (Schreiber,2010, Suzuki, 2004). Activity of 
TMEM16A and TMEM16B was more marked than the other, but TMEM16B seemed 
to be not expressed in thyroid gland (Schreiber, 2010). Finally, research focused on 
TMEM16A. Besides, cells expressing TMEM16A show channels with the following 
permeability sequence to anions: NO3− > I− > Br− > Cl− > F− (Yang, 2008): 
evidence of permeability to iodide higher than chloride, supported our hypothesis 
about involvement of TMEM16A in iodide flow in thyroid follicular cells. 
 
 The first important result was TMEM16A mRNA expression in human normal 
thyroid gland.  
 Then, also its expression in human tumour thyroid gland was considered. Screening 
was performed on coupled samples (normal and tumour portion from the same patient 
with thyroid papillary tumour). It revealed that TMEM16A mRNA was maintained in 
thyroid cancer.  
 Besides, it was investigated if TMEM16A transcript expression could undergo 
regulation by TSH. TSH is the main regulator hormone of thyroid gland. To study 
TSH effect on TMEM16A transcript in thyroid gland, FRTL-5 cell lines (Fisher rat 
normal thyroid gland follicular cells) were used as a model, suitable for functional 
experiments and established for a long time and employed in many studies on thyroid. 
 We found that FRTL-5 expressed TMEM16A transcript with RT-PCR experiments, 
so resulted to be suitable as a model also for next studies. Moreover, QRT-PCR 
experiments showed that TSH did not regulate TMEM16A in FRTL-5, suggesting 
that apical iodide efflux was constitutive. FRTL-5 not exposed to TSH did not express 
NIS mRNA, confirming actual TSH effect.  
 
 Characterization of TMEM16A continued with detection of its alternative splicing 
isoforms mRNA in FRTL-5 cells. TMEM16A protein has got four segments subject 
to alternative splicing of their codified mRNA, each isoform contains or not a specific 
segment (“a”, “b”, “c”, “d”). Particularly some works (Ferrera et al., 2011), showed 
correlation between splicing isoforms and functional properties. Every transcript, in 
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fact, produces a protein isoform containing or not codified peptide segments. 
Alternative splicing of TMEM16A transcript could be a system for channel tissue-
specificity, based on functional properties as voltage-dependence as calcium 
sensitivity (Ferrera et al., 2011). “B” and “c” segments seemed to be inside a region 
important for calcium sensitivity and membrane potential dependence. Primers for b, 
c and d segments were designed outside of each segment to distinguish segments 
expressed in TMEM16A mRNA (Manoury, 2010). Therefore, we observed that 
TMEM16A/anoctamin-1 alternative splicing mRNA isoforms expressed in FRTL-5 
cells did not contain  d segment, instead c segment was constitutively expressed.  
 
 Next step was investigation of expression profile of other members belonging to  
anoctamin family as well as TMEM16A/ANO1 in FRTL-5 cells, to discover if some 
members could be suitable targets of further functional studies on iodide transport in 
thyroid gland. All anoctamin expression was detected with RT-PCR experiments. 
Results showed that TMEM16A/ANO1, TMEM16F/ANO6, TMEM16H/ANO8, 
TMEM16K/ANO10 mRNA were expressed in FRTL-5 cells. The other members, 
TMEM16C/ANO3, TMEM16D/ANO4, TMEM16E/ANO5, TMEM16G/ANO7, 
resulted to be expressed weakly and in a variable manner.  Instead, TMEM16B/ANO2 
and TMEM16J/ANO9, showed no signal but their specific primers were designed on 
mouse sequences instead of rat, because rat TMEM16A coding sequences were still 
not registered.  
 
 To confirm TMEM16A mRNA expression with an alternative approach, 
transcriptional expression knock-down was performed with three different siRNAs 
(100nM) specifically designed against TMEM16A. Best results were obtained with a 
peptide-based transfecting agent, N-TER nanoparticles™, after 2 days treatment. 
Experiments showed knock-down of rTMEM16A transcript. Low knock-down signals 
probably resulted by low transfection efficiency in FRTL-5 cells. The same approach 
was performed in FRTL-5 cells tested with functional assay. Several cells treated with 
siRNA against TMEM16A showed blockade in ATP-induced iodide efflux. 
This evidence suggested that system could be used, optimizing experimental 
conditions, and in previous studies it revealed successful (i.e. on bronchial epithelium 
cell lines, Galietta, 2008).  
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 FRTL-5 cells are from Fisher rat normal thyroid gland and express all thyroid 
markers. After previous selection of stable clones in our laboratory (Rhoden et al., 
2007) FRTL-5 cells expressed stably an exogenous protein, YFP-H148Q/I152L. YFP-
H148Q/I152L is a fluorescent protein that results very useful as a halide biosensor, 
particularly it has got high affinity for iodide. Its fluorescence signal is quenched 
when iodide enters the cells, compared to baseline, but recovers when iodide flows 
out of the cells. 
 
  To begin the characterization of calcium-activated iodide conductance in FRTL-5, 
putatively mediated by TMEM16A in our hypothesis, experiments were performed to 
study iodide influx as a model of chloride, with a partial substitution of chloride with 
iodide. Iodide flows into thyrocytes through NIS, so it was necessary deletion of its 
contribute to iodide transport to analyze only iodide flow via other channels, such as 
putative TMEM16A. Therefore, FRTL-5 cells were cultured for at least one week 
without TSH hormone, to inhibit NIS expression. TSH is the most relevant regulator 
of growth and differentiation of thyroid gland. Among TSH fundamental functions 
there are induction of NIS transcriptional and protein expression, NIS transport to cell 
membrane (Carrasco et al, 2003).  
 
 Iodide influx, in FRTL-5 not exposed to TSH, took place only at high iodide 
concentrations (mM), via channels (i.e. chloride channels) less specific for iodide than 
NIS, not expressed in this condition. Response of iodide influx, by cells cultured with 
TSH, was evoked by both chloride channels and NIS, if exposed to 100mM iodide. 
 Calcium-activated chloride conductance was stimulated by purine nucleotides, such 
as UTP (Galietta et al., 2008). Then, nucleotides were tested to characterize it, 
particularly in FRTL-5 cell lines model, to verify if they stimulated chloride influx via 
TMEM16A CaCC channel. CaCC are activated by intracellular calcium concentration  
increase, event provoked also by nucleotides. 
 
 Two mechanisms for intracellular calcium  increase can be theorized: (i) nucleotides 
bind to P2X purinergic receptors, which stimulate sodium influx and, accordingly, 
 
144 
 
membrane action potential variation that provokes voltage-dependent calcium 
channels opening; (ii) nucleotides bind to P2Y purinergic receptors, Gq-coupled, with 
consequent activation of PLC, which causes IP3 increase and, accordingly, calcium 
release from intracellular stores. 
 
 At the end, result is intracellular calcium-activated influx of calcium again, via store-
operated channels (SOC). Our experiments confirm this mechanism and indicate that 
P2Y purinergic receptors could be involved, because observed order of nucleotide 
potency on receptors was ATP > UTP > ADP in FRTL-5, as it happens on P2Y 
receptors. Differences on fluorescence reflected differences on iodide entry into 
FRTL-5, due to different potency of nucleotides on their own receptors. Indirectly 
such a difference suggested a different affinity of nucleotides on studied channels 
activity. Order of nucleotide potency is compatible with P2Y purinergic receptors.  
 
 Another aspect analyzed was behaviour of CaCC when cell membrane was 
depolarized in FRTL-5 cells. Perfusion with K-PBS provoked depolarization in cell 
membrane of FRTL-5. Also with less than 1uM ATP, iodide influx was higher, 
confirming a property of TMEM16A already described: increased activation in 
depolarization conditions. Since CaCC are active with membrane potential  
depolarization condition (Galietta et al., 2001), used PBS contained 100mM K
+
Cl
-
 
instead of 100mM Na
+
Cl
-
. 
 
 Taken together, these evidences suggested presence of a thyroid CaCC, TMEM16A, 
as a putative molecular target. 
 
 Calcium can active and open channels directly or through calcium-calmodulin 
complex, with activation of calmodulin-dependent kinase II, that phosphorylates 
channels. Intracellular calcium increase, stimulated by ionomycin, a ionophore 
selective for calcium, was actually responsible for iodide influx in our cell model. 
Lack of extracellular calcium in perfusion solution (PBS) allowed iodide influx. Next 
step was to establish origin of calcium capable to activate channels. Perfusing cells 
with Ca
2+
 free PBS, but chelating also intracellular calcium with BAPTA compound, 
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iodide influx could not take place into FRTL-5 cells. This evidence suggested 
activation of channels by calcium released from intracellular store organelles only.  
 
 Our results were compatible with the expression of a CaCC (Ca 
2+
 activated chloride 
conductance/ channel) such as TMEM16A in FRTL-5. 
 
 After, since channels responsible of iodide apical efflux are not all known, our work 
focused on a potential role of TMEM16A in iodide transport, as well as chloride, in 
thyroid, for iodide accumulation in the follicular lumen.  
 
To begin characterization of iodide efflux, the same previous experimental conditions 
were reproduced, such as presence of absence of extracellular calcium in PBS,  
presence of absence of intracellular calcium released by storage organelles, chelated 
by BAPTA compound. Before undertaking a depth study about FRTL-5 thyroid cells, 
iodide transport was characterized in a model cell system, CHOK-1 cell lines, to find 
and optimize the best experimental conditions and to confirm functional properties of 
currents due to TMEM16A.  
 
 First of all, the chosen experimental model CHOK-1 cells, were considered about the 
endogenous TMEM16A mRNA expression. No TMEM16A transcript expression was 
observed, thus CHOK-1 cell lines were chosen as a model definitively, since wild type 
cells were a good negative control. Clones of CHOK-1 stably expressing hNIS and 
YFP-H148Q/I152L were selected and established previously in our laboratory. 
Absence of endogenous TMEM16A mRNA expression was confirmed.  Besides, 
maintenance of hNIS and YFP-H148Q/I152L expression after long culture and 
cryopreservation periods,  was verified. 
 
 Characterization continued on calcium-activated iodide conductance in efflux, due to 
hTMEM16A transporter, expressed in stable clones CHOK-1-hNIS/YFP-
H148Q/I152L transiently. Aim was observation efflux properties, to have a model of 
functional response and, going on with studies on FRTL-5, making a comparison 
between obtained results and expected observed in the model system.   
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 Thus, analogous experiments were performed, similar to experiments made to study 
iodide influx. PBS contained ionomycin, to stimulate intracellular calcium 
concentration increase, at 1uM concentration. First of all, clones without TMEM16A 
exogenous expression showed no iodide transport due to other endogenous 
transporters such as members of anoctamin family. Then,  CHOK-hNIS/YFP-
H148Q/I152L stable clones, with transient hTMEM16A expression, were checked. 
After initial fluorescence decrease, due to extracellular iodide entry, exposition to PBS 
only let the “wash-out” of intracellular iodide but slowly (20’), not detectable  during 
the short time interval considered (usually 5’). Instead, exposure of cells to PBS+1uM 
ionomycin provoked a rapid fluorescence decrease, due to iodide efflux out of cells.  
 Observed properties of calcium-activated iodide efflux were compatible with known 
properties of TMEM16A calcium-activated channel. 
 Thus, FRTL-5 expressing NIS were employed. They were subjected to iodide pre-
loading, mediated by NIS, responsible only for iodide influx. Experiments similar to 
influx were performed, but on the iodide efflux stage, testing nucleotides (ATP, UTP, 
ADP 100uM) and ionomycin-activated intracellular calcium increase.  
Our results showed actual iodide efflux increase due to ionomycin exposition, as 
detected by starting fluorescence recovery, in a few seconds, instead of 20 minutes 
requested usually.  
 
 Screening with receptor agonists was performed to detect their effect on iodide 
efflux. 
 First of all TSH, histamine, acetilcholin, serotonin, dopamin were tested. TSH was 
found to generate a I-/Cl- current in FRTL-5 cells (electrophysiological studies , 
Yoshida et al. of 1999) but in our system produced no effect, likely because of 
different sensitivity of technique.  
 Histamine is present in mast cells residing in thyroid gland (Melander et al., 1973), 
seretonin is able to activate intracellular pathways that culminate in increased 
cytoplasmic calcium in cells FRTL-5 (Tamir et al., 1992), and stimulates iodide 
organification and thyroid hormones synthesis (Melander, 1970), but no effect was 
detected our experiments. 
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 Thyroid gland is innervated by cholinergic nerves (Van Sande et al., 1980) and 
acetylcholine is able to stimulate the efflux of radioiodide in FRTL-5, interacting with  
muscarinic receptor (Di Girolamo et al. 1991), but in our system produced no effect. 
 
 Dopamine was found to induce organification of iodide and is present in mast cells 
residing in thyroid gland and in parafollicular cells (Melander et al., 1973). No effect 
on iodide efflux was detected in our experimental system. 
 
 Since thyroid gland is innervated by sympathetic nervous system (Tice and 
Creveling, 1975) and catecholamines (including epinephrine and norepinephrine) 
stimulate the synthesis of thyroid hormones (Melander, 1970), we wanted to test some 
endogenous catecholaminergic receptor agonists epinephrine and norepinephrine. 
 Epinephrine and norepinephrine, can interact with all the adrenergic receptors (α1, 
α2, β1, β2, β3), thus, to identify receptor that mediates effect of these agonists on 
iodide efflux in FRTL-5 B5 cells, were tested two more selective exogenous 
adrenergic agonists: phenylephrine, which binds α1 receptors, and isoprenaline, which 
interacts with β receptors.  
Epinephrine and norepinephrine were able to stimulate iodide efflux strongly, also at 
1uM. It was demonstrated that phenylephrine, unlike isoprenaline, was able to 
stimulate iodide efflux, even though it is much less potent endogenous agonists. From 
this result, it can be concluded that adrenergic agonists act in FRTL-5 cells through α1 
receptor.  
 
 Since ATP is able to stimulate calcium-activated channels interacting with purinergic 
receptors (Verkman and Galietta, 2009), was evaluated its effect on iodide efflux in 
FRTL-5 cells.  
ATP, epinephrine and norepinephrine were found to stimulate iodide efflux more than 
other tested previously. ATP was more effective than epinephrine and norepinephrine 
in channel activation, because fluorescence recovers more rapidly (1’-2’), anyway 
epinephrine and norepinephrine very potent in iodide efflux stimulation also at low 
concentrations (uM). Channel activity is dose-dependent. 
 Iodide efflux increased stimulated also with exposition to purine nucleotides, as 
detected by starting fluorescence recovery, virtually instantly, instead of 20 minutes 
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requested usually.  Also in efflux we found the same nucleotide potency order ATP > 
UTP > ADP on involved receptors. 
 
 Another property compatible with TMEM16A is its transient activation, 
characteristic we found in iodide efflux activity in FRTL-5 cells. Iodide efflux was 
stimulated by ATP and ionomycin in FRTL-5; afterwards (in 10’) with contemporary 
presence of iodide and ATP/ionomycin, they accumulated iodide again. Hence, 
activation of channels involved in iodide efflux seems to be transient, fact that 
suggested CaCC are characterized by a refractory period, in which their status is 
inactive. 
 
 To distinguish the precise class of adrenergic receptors involved in iodide efflux, we 
needed more selective exogenous agonists, because epinephrine and norepinephrine 
are not so specific (they can bind to all of kinds, α1,α2, β1, β2, β3). Phenylephrine, 
which binds α1 receptors, and isoproterenol, which binds all β receptors, were used for 
this aim. Only phenylephrine could stimulate iodide efflux in FRTL-5 cells. 
Isoproterenol could not stimulate iodide efflux, but it was observed also that 
intracellular calcium increase was lower than phenylephrine-induced. This is coherent 
with existence of a threshold level of calcium for activation of channel involved in 
iodide efflux. 
 
 Also in experiments on iodide efflux, origin of calcium capable to activate channels 
was established. Chelation of intracellular calcium with BAPTA compound, in FRTL-
5 cells perfused with Ca
2+
 free PBS, did not allow iodide efflux in FRTL-5 cells.  This 
evidence suggested activation of channels by calcium released from intracellular store 
organelles only. Not only calcium-dependent iodide efflux response, but also ATP and 
epinephrine –dependent response were tested to know source of calcium responsible 
for iodide efflux. BAPTA pre-incubation /calcium-free perfusion solution revealed 
also in this case that, in FRTL-5 cells, response depended on increase of calcium from 
intracellular store organelles only. 
 
According to recent studies (Caputo et al., 2008; Hartzell et al., 2009), niflumic acid 
(NFA) is a CaCC inhibitor. Use of NFA could identify mediator of iodide efflux. 
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NFA was used to check if it could inhibit stimulation of iodide efflux due to ATP. 
Tannic acid is a compound present in several natural products, i.e. green tea and red 
wine. TA seems to be a highly selective TMEM16A inhibitor (Namkung et al., 2010), 
putative responsible of iodide efflux in thyrocytes according to working hypothesis.  
Experiments on I
- 
efflux demonstrated their effectiveness in inhibiting effect of ATP 
stimulation, but, these compounds have been shown to be highly specific for 
TMEM16A channel and being characterized by certain properties that can influence 
the evaluation of data obtained. Niflumic acid and tannic acid inhibitors were showed 
to change basal fluorescence in FRTL-5 YFP used in our experiments. To detect any 
non specific effect, pH changes (with BCECF probe-based functional assay) and 
direct interaction with YFP protein was checked. 
Niflumic acid led to intracellular pH decrease, tannic acid was shown to have a direct 
binding of YFP purified protein without changing in iodide affinity. Interestingly, 
tannic acid increased basal iodide levels.  
  
 Finally, through cloning expression, a fusion protein between hTMEM16A and 
EYFP (Enhanced YFP) (C-term tag), was expressed transiently in a exogenous 
system,  CHOK-1 cells. CHOK-1-hTMEM16A-EYFP cell samples (membrane 
fractions), were tested with 2-dimensional (2-D) electrophoresis gel. Detection was 
performed with Western Blot, using a specific antibody against GFP and all its 
variant. Isoelectric point and molecular weight of recombinant protein were predicted 
with software found on  http://scansite.mit.edu/ webpage (respectively, 8.6 and 125,43 
kDa).  2-D gel electrophoresis pointed out two protein signals compatible with 
theoretical values of hTMEM16A-EYFP fusion protein, located beyond pH 7 and 
between 100 and 150 kDa (preliminary result). Moreover,  presence of two signals is 
compatible with some post-translational modifications undergone by proteins, such as 
glycosylations (higher molecular weight), phosphorylations (isoelectric point lower), 
acetylations (isoelectric point lower). Actually TMEM16A has a conserved N-linked 
glycosylation site between seventh and eighth transmembrane domain (Hartzell, 
2009). 
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Our working hypothesis is based on a putative role of TMEM16A channel in iodide 
efflux in thyroid. Iodide flows into thyrocyte through basal membrane via NIS, that 
lets its intracellular accumulation and concentration up to 100 times more, compared 
to cytoplasm. Then, iodide diffuses into follicular lumen through apical membrane via 
other channels, such as pendrin. ATP and other less specific nucleotides active 
TMEM16A (or other CaCC), iodide flows out of thyrocyte into follicular lumen in a 
rapid and transient manner. Inactivated channel cannot transport iodide out, so high 
intracellular iodide concentration can be recovered via NIS. 
Thyroid shows expression of purinergic receptors and is innerved by ANS nervous 
fibers. Nucleotides as ATP may be involved as cotransmitters. Their functional role 
could be thyroid hormone synthesis increase, and our experiments confirm this 
putative function, since iodide can be more available (more influx and efflux). 
ATP is necessary for homeostasis and energy production for body  metabolism and is 
produced ubiquitously. In nervous system districts and inflammatory tissues higher 
ATP levels were found, also released by inflammatory cells (Pellegatti et al., 2008). 
Inflammatory responses and high metabolic activities take place around and inside 
tumour cells, events which would explain high extracellular ATP levels around 
tumour cells.  
Activation of calcium-activated iodide conductance in efflux, mediated by 
TMEM16A, could be one reason of poor results of radioiodide-therapy applied to 
some patients. Some classes of thyroid cancer with poor prognosis, as metastatic and 
anaplastic, do not response to therapy because not able to load radioiodide anymore. 
NIS transporter is little or not expressed, with consequent less iodide influx, factor 
that makes more difficult their treatment. Besides, efficacy of radioiodide-therapy 
depends upon not only iodide influx via NIS, but also iodide retention inside thyroid 
tumour cells and iodide lost, caused by its efflux. Tumour cells are little or not 
polarized, so they lack normal follicular architecture that allows iodide accumulation. 
The more extracellular ATP is produced there, the more would be iodide efflux and 
lost from tumour cells. Pharmacological characterization of inhibitors of channel 
involved in this activity, such as TMEM16A, could lead to improve the current 
therapy. 
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CHAPTER   6 
 
CONCLUSIONS 
 
Our working hypothesis asserted that  molecular responsible of iodide efflux in 
FRTL-5 cells was TMEM16A protein. This channel transports Cl
-
/I
-
 in a Ca2
+
 -
dependent manner, properties of CaCC activity. Research was performed to 
characterize iodide efflux activity and discover if could have properties coherent with 
TMEM16A. 
  Molecular evidences: 
 TMEM16A mRNA wss expressed in human normal and tumour thyroid gland 
and in FRTL-5 cell lines; 
 
 TMEM16A mRNA was not dependent on TSH hormone in FRTL-5 cells;  
 
 TMEM16A mRNA alternative splicing isoforms expressed in FRTL-5 cells 
were “abc” and “ac”; 
 
 anoctamins expressed in FRTL-5 cells were: TMEM16A, F, K, H; 
 
 
  Functional evidences (iodide influx): 
 
 iodide transport is coherent with TMEM16A functional properties: 
 
 activation due to ATP, UTP, ADP had potency order ATP> UTP> ADP, 
typical of P2Y purinergic receptors, probably involved in this transduction 
pathway in FRTL-5 cells; 
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 affinity of nucleotides on their own receptors increased in depolarization 
conditions in FRTL-5 cells;  
 
 activation of iodide influx was  due to calcium released from intracellular 
stores in FRTL-5 cells, and is extracellular calcium-independent 
 
Molecular evidences: 
 
 CHO K1-NIS/ YFP- expressing cells showed no endogenous mRNA 
expression of hTMEM16A; 
 
Functional evidences (iodide efflux): 
 
   CHO K1-NIS/ YFP- hTMEM16A expressing cells showed calcium-activated 
iodide efflux; 
 
  activation of calcium-induced iodide efflux was  due to calcium released from 
intracellular stores in FRTL-5 cells, and is extracellular calcium-independent; 
 
 ATP and epinephrine stimulated iodide efflux in FRTL-5 cells; 
 
 activation due to ATP, UTP, ADP had potency order ATP> UTP> ADP, 
typical of P2Y purinergic receptors, probably involved in this transduction 
pathway in FRTL-5 cells; 
 
 iodide efflux calcium-dependent activation was transient in FRTL-5 cells; 
 
 epinephrine and norepinephrine agonists activated iodide efflux at uM 
concentrations in FRTL-5 cells; 
 
 prazosin and phentolamine antagonists blocked epinephrine-activated iodide 
efflux in FRTL-5 cells; 
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 epinephrine, norepinephrine and isoproterenol increased intracellular calcium 
levels in FRTL-5, but isoproterenol with not marked entity,  not  enough to 
elicit a calcium-activated iodide efflux response; 
 
  activation of epinephrine-induced iodide efflux was  due  to calcium released 
from intracellular stores in FRTL-5 cells, and is extracellular calcium-
independent; 
 
 ATP/epinephrine-dependent Ca2+-activated iodide efflux was inhibited by 
specific inhibitors such as niflumic acid and tannic acid in FRTL-5 cells; 
 
 tannic acid blocked iodide efflux but also increased basal intracellular iodide 
levels in FRTL-5 cells; 
 
 niflumic acid led to decrease in intracellular pH in FRTL-5 cells; 
 
 tannic acid seemed to have a direct binding with YFP protein in FRTL-5 cells; 
 
 specific siRNA against TMEM16A knocked-down its transcriptional 
expression in FRTL-5 cells but result has to be confirmed; 
 
 RNA interference treatment against TMEM16A provoked inhibition of ATP-
dependent iodide efflux response in FRTL-5 cells which sufficiently received 
interfering construct.  
 
 
Novel approaches for characterization of anoctamins: 
 2-D electrophoresis on CHO K1 expressing hTMEM16A-YFP fusion protein 
revealed two spots, recognized by specific antibodies against YFP, with 
isoelectric point and molecular weight compatible with hTMEM16A protein, 
suggesting its post-translational modifications such as glycosylation and 
phosphorylation. 
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  In conclusion, we demonstrated a calcium-activated iodide conductance in efflux, 
with properties compatible with CaCC/TMEM16A activity. These results suggest that 
TMEM16A does play a role in mediation of iodide efflux in thyroid gland.  
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CHAPTER   7 
 
PERSPECTIVES 
 
 Sequencing of anoctamins transcripts expressed in FRTL-5 cells 
 
 Western Blot and immunocytochemistry to detect TMEM16A protein in 
FRTL-5 cells with specific antibodies 
 
 Optimization of RNA interference assay on TMEM16A transcript in FRTL-5 
cells 
 
 
 Complete functional characterization of iodide efflux in FRTL-5 cells with 
CaCC inhibitors, receptor agonists/antagonists  
 
 New experiments with 2-D SDS-PAGE and sequencing of TMEM16A protein 
with gas-mass spectrometry (MALDI-TOF, time-of-flight  mass spectrometer) 
to detect splicing isoforms expressed in FRTL-5 cells 
 
 
 Detection of post-translational modification of TMEM16A protein in FRTL-5 
cells with proper enzymatic treatments 
 
 Application of these technique to rat and human thyroid tissues to investigate 
TMEM16A and the other anoctamins expression 
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 Study of interaction between TMEM16A splicing isoforms one to each other 
and with other anoctamins, to detect involvement in CaCC activity in thyroid, 
specifically of iodide efflux. 
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